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Abstract 
The FDA approval of molecularly-targeted drugs that specifically targeted 
aberrant signaling proteins has brought about new hope for the treatment of 
advanced melanoma. Historically, metastatic melanoma has been an untreatable 
devastating disease. Two BRAF inhibitors (vemurafenib and dabrafenib), a MEK 
inhibitor (trametinib), and a combination of dabrafenib and trametinib are 
currently in use and several other drugs are in clinical development. Melanoma is 
known to metastasize to distant organs such as the lung, liver and brain.  
 A critical challenge in the successful treatment of metastatic melanoma is the 
effective treatment of brain metastases. A significant proportion of melanoma 
patients have brain metastases at autopsy. It is also known that once patients 
develop clinical signs of CNS disease, they have an abysmally poor survival (less 
than 6 months).  This brings about an important question about the efficacy of 
current drugs in treating brain metastases. The blood-brain barrier is comprised 
of a tight network of endothelial cells that are sealed together by tight-junction 
(TJ) protein complexes. The BBB also expresses several efflux transport proteins 
that utilize ATP to pump drug molecules against a concentration gradient. 
Together, the TJ proteins and ATP-dependent efflux transport proteins are 
known to effectively limit the permeability of several chemotherapeutics across 
the blood-brain barrier.  
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Of particular interest are two efflux transporters, P-glycoprotein (P-gp) and 
breast-cancer resistance protein (BCRP) that are known to be highly expressed 
at the BBB. One of the aims of this thesis project was to understand the factors 
that potentially limit the efficacy of molecularly-targeted drugs in treating deadly 
melanoma brain metastases. Through this work, we have shown that several 
molecularly-targeted agents are substrates for active efflux by P-gp and BCRP. 
Through a series of carefully planned in vitro experiments and elegant 
pharmacokinetic studies in mice we conclude that the limited brain distribution of 
vemurafenib, dabrafenib, trametinib, and GSK2126458 (a Pi3K/mTOR inhibitor) 
is due to their interaction with P-gp and BCRP.  We also investigated potential 
differences in pharmacokinetics and pharmacodynamics of vemurafenib when 
administered as pharmacy grade Zelboraf versus non-pharmacy grade 
vemurafenib. We observed that formulation differences that affect the solubility of 
a drug are extremely critical to designing and interpreting meaningful pre-clinical 
studies.  Currently, we are conducting studies in a novel melanoma mouse model 
in order to understand the efficacy of molecularly- targeted drugs in treating brain 
metastases (single agent or in-combination). The findings of this thesis provide 
significant insight into the selection of rational drug combinations and are highly 
relevant to improving the treatment of melanoma brain metastases.  
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CHAPTER 1: IMPROVING THE DELIVERY OF MOLECULARLY-
TARGETED AGENTS TO EFFECTIVELY TREAT MELANOMA 
BRAIN METASTASES  
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1. 1 Introduction 
 
Metastases of melanoma into the central nervous system (CNS) are a common 
occurrence in the progression of metastatic melanoma.  Brain metastases are a 
untreatable and lethal condition in most patients with advanced stages of 
melanoma.  Surgery, stereotactic radiotherapy, and whole brain radiation have 
been the main treatment methods for brain metastases. More recently, 
understanding of the genetic drivers of melanoma has led to the development of 
molecularly targeted agents such as vemurafenib, dabrafenib, and trametinib 
have been approved by the FDA for use in patients with metastatic melanoma. 
 
BRAF inhibitors that block the MAPK signaling pathway have certainly emerged 
as a new hope for this previously untreatable deadly disease. Vemurafenib and 
dabrafenib, the two BRAF inhibitors have shown remarkable results in reducing 
extra-cranial melanoma metastases (Chapman et al., 2011; Falchook et al., 
2012; Hauschild et al., 2012), however, their efficacy in the treatment of brain 
metastases is questionable.  
The success of these therapeutic agents in treating melanoma brain metastases 
greatly depends upon their delivery across the blood-brain barrier (BBB). The 
BBB is a physiological barrier that prevents the distribution of chemotherapeutic 
agents to the central nervous system. P-gp and BCRP are two important drug 
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efflux transporters that are highly expressed at the human BBB and are known to 
play an influential role in distribution of drugs to the brain (Uchida et al., 2011). 
Several chemotherapeutic agents do not cross the BBB due to their interaction 
with efflux transporters, thus making the brain a sanctuary site for metastatic 
tumor cells. Another significant concern is the development of resistance to 
molecularly targeted agents. Several other novel agents are currently in clinical 
development to be used in combination with BRAF inhibitors. One success story 
is that of the trametinib, a MEK inhibitor in combination with dabrafenib that 
significantly improved overall survival as compared to single agent dabrafenib 
(Flaherty et al., 2012a). Combination therapies that block alternate signaling 
pathways such as PI3K/mTOR is also a promising option for delaying resistance. 
In this chapter, current treatment options for melanoma brain metastases, the 
mechanisms that limit the brain delivery of these agents, and possible methods 
to overcome resistance and delivery challenges have been discussed.  
1. 2 Melanoma 
Melanoma is a neoplasm that originates in the pigment producing cells of the 
skin. Of the 3 million skin cancers that are diagnosed each year, basal and 
squamous cell carcinoma account for about 90% of the cases. Melanoma is the 
third most common skin cancer and has the highest mortality rate. It is estimated 
that 1 in 50 Americans will be diagnosed with melanoma at some point in their 
life-time (Siegel et al., 2014).  
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In the early stages of melanoma, localized disease is curable with a 5-year 
survival of greater than 90% while disseminated disease (metastatic melanoma) 
has an extremely poor prognosis with an overall survival of less than 1-year and 
5-year survival of less than 15% (Balch et al., 2009). The incidence of melanoma 
has been steadily escalating and it is predicted that approximately 74,000 new 
cases and ~ 10,000 deaths from the disease are expected in 2015 (Siegel et al., 
2015). After lung and breast cancer, melanoma is the third most common 
neoplasm to metastasize to the brain (Johnson and Young, 1996).  Most 
melanomas arise from the skin and are called cutaneous melanomas. UV 
radiations are thought to play a significant causative role in cutaneous lesions. 
However, the exact role of UV radiations for acral lentiginous, mucosal and 
nodular type lesions is not well understood. Some of the risk factors for the 
development of CNS metastasis in melanoma patients include male sex, 
thickness or ulceration of primary lesion, site in the head and neck, mucosal or 
acral lentiginous tumors, and nodular primary lesions (Sampson et al., 1998). 
1. 3 Melanoma brain metastases 
More than 90% of melanoma patients develop brain metastases within three 
years of diagnosis of primary melanoma, and most of these patients die from 
progressive disease (Fife et al., 2004). Patients with one to three brain 
metastases are often treated with surgical resection or stereotactic radiosurgery, 
while those with several brain metastases typically receive whole brain radiation 
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(Gibney et al., 2012). Unfortunately, melanomas are highly resistant to radiation 
and chemotherapy, and patients with brain metastases have a dismal survival of 
the order of 4 months from first detection despite aggressive therapy (Sampson 
et al., 1998; Fife et al., 2004). Melanoma brain metastases are the cause of 
death in nearly 95 % of patients (Sampson et al., 1998). Patients with multiple 
brain metastases and extensive peripheral disease can have particularly poor 
survival, which can be as short as 1-2 months (Gupta et al., 1997; Fife et al., 
2004). Incidentally, 50 to 70% of melanoma patients have brain metastases at 
autopsy (Fife et al., 2004).  
After lung and breast cancer, melanoma is the third most common cancer to 
metastasize to the brain (Amer et al., 1978; Johnson and Young, 1996; Schouten 
et al., 2002). The presence of brain metastases in 50-70% of melanoma patients 
at autopsy is suggestive of a unmet medical need.  
Drug delivery across the blood-brain barrier (BBB) is a crucial factor that has 
been severely overlooked for the success of novel targeted therapies in treating 
melanoma brain metastases.  The success  of many small molecule drugs in the 
effective treatment of central nervous system tumors is limited by their 
penetration across the blood-brain barrier, in particular by their interaction with 
efflux transporter proteins, including P-glycoprotein, and breast cancer resistance 
protein (BCRP) (Agarwal et al., 2011b). 
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The last decade has seen tremendous progress in the treatment of melanoma 
without much improvement in outcomes for patients with melanoma brain 
metastases. One important reason for this is the fact that patients with melanoma 
brain metastases have been systematically excluded from several clinical trials 
(Fife et al., 2004). 
1. 4 Mechanism of Melanoma brain metastasis 
 
The influence of the BBB and the natural tropism of melanoma to the brain are 
key factors that need to be well understood to improve the treatment of 
melanoma brain metastases.  The “seed and soil” hypothesis proposed by 
Stephen Paget tried to explain the dissemination of tumor cells (“seed”) from the 
primary site via the blood stream to distant organs based on an inherent 
biochemical affinity of cancer cells for a certain distant site (“soil”) which further 
leads to the development of metastases (Fidler, 2003).  
Metastasis is a multistage process where the cancer cells from the primary site 
disseminate to distant organs. The metastatic cascade in the formation of brain 
metastases is comprised of a series of sequential processes where tumor cells 
escape from the primary tumor, enter the blood circulation, attach to blood 
vessels, and extravasate along the BBB into the brain parenchyma. This is 
followed by invasion and interaction with the brain microenvironment leading to 
survival and proliferation of tumor cells (Fig.1.1). Based on the characteristics of 
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the tumor cells, they can grow either by forming new blood vessels 
(angiogenesis), or develop by growing along pre-existing blood vessels (vascular 
co-option) (Joyce and Pollard, 2009; Fidler et al., 2010; Fidler, 2011).  The 
invasion and growth of tumor cells in the brain parenchyma is facilitated by the 
interaction of tumor cells with endothelial cells. 
1. 5 Recent improvements in the treatment of peripheral melanoma 
metastases 
Recent discovery of activating mutations in the MAPK signaling pathway has led 
to the development of molecularly targeted agents that inhibit specific signaling 
proteins. The FDA approved BRAF inhibitors, vemurafenib and dabrafenib and a 
mitogen-activated protein kinase inhibitor, trametinib, have shown remarkable 
efficacy against peripheral melanoma tumors (Chapman et al., 2011; Falchook et 
al., 2012; Flaherty et al., 2012a; Hauschild et al., 2012) (Fig.1.2).  Vemurafenib 
and dabrafenib were approved after showing significant improvement in 
progression-free survival and overall survival (PFS) compared to dacarbazine. 
Dacarbazine (alkylating agent), an ineffective drug, was the standard of care for 
the treatment of advanced melanoma before the approval of vemurafenib 
(Serrone et al., 2000). Similarly, trametinib also showed a significant 
improvement in PFS leading to its approval. However, the emergence of 
resistance to BRAF inhibitors is a major hurdle in the long-term success of BRAF 
inhibitors. Resistance to BRAF inhibitors leading to eventual relapse is found to 
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usually occur within one year of single-agent therapy (Sullivan and Flaherty, 
2013; Trunzer et al., 2013). Combination therapy with multiple molecularly 
targeted agents is a promising approach that has been pursued to overcome 
resistance and prolong survival. However, the efficacy of these agents in the 
treatment of melanoma brain metastases is poorly understood.  
Effective combination therapy for melanoma brain metastases with targeted 
agents requires the sufficient delivery of all agents in the combination across the 
BBB to target sites in melanoma brain metastases that may reside behind an 
intact BBB.   
1. 6 Failure of treatments for melanoma brain metastasis 
1. 6. 1 Blood-brain barrier as a significant barrier to drug delivery 
The BBB is comprised of endothelial cells that are joined together by tight-
junctions, surrounded by extracellular matrix components, pericytes and 
astrocyte foot processes which together form the neurovascular unit. These tight 
junctions (zonula occludens) between endothelial cells make the BBB relatively 
impermeable to a large variety of drug molecules (Loscher and Potschka, 2005). 
In addition to the tight-junction proteins, the BBB also expressed a wide variety of 
transport proteins of the ATP Binding Cassette (ABC) family of proteins. These 
proteins are expressed on the basolateral and apical surface of the endothelial 
cells and play a critical role in efflux of several drugs that are used to treat brain 
diseases (Loscher and Potschka, 2005).  
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P-glycoprotein (P-gp, ABCB1, MDR1) , a 170 kDa phosphorylated glycoprotein 
and a 72 kDa half-transporter protein -BCRP (breast cancer resistance protein) 
are two important efflux transporters that are highly expressed at the human 
BBB, and are known to influence the CNS distribution of several drugs(Agarwal 
et al., 2011a; Uchida et al., 2011). The influence of these two efflux transporter 
proteins is known to play an important role in the treatment of CNS diseases 
such as HIV and glioma (Ohtsuki and Terasaki, 2007; Shaik et al., 2007; Agarwal 
et al., 2011b).   
The presence of the BBB significantly impairs the delivery of several 
chemotherapeutic agents to brain metastases (Agarwal et al., 2011b). The BBB 
serves as a physical barrier and the ABC transporter proteins contribute to 
maintaining brain homeostasis by excluding potentially harmful endogenous and 
exogenous chemicals. 
In successful treatment of melanoma brain metastases with rational 
combinations, it is important to ensure that all drugs in the combination achieve 
efficacious concentrations in all micrometastatic target sites in the brain. 
Microscopic subclinical brain metastases likely have a relatively intact BBB and 
also express functional efflux transporters (Fig. 1.10). Melanoma cells that have 
been previously treated with chemotherapeutic agents have been known to 
express the ATP-dependent efflux transporter ABCB5, while a side-population of 
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stem cells from melanoma tumors are known to express ABCB1 and ABCB5 
(Chartrain et al., 2012; Luo et al., 2012).  
The lack of efficacy of chemotherapy in treating brain tumors can be attributed to 
this reason. In the context of melanoma brain metastases treatment, with the 
more recent molecularly-targeted agents regard, not much is known about the 
interaction of vemurafenib, dabrafenib, trametinib and GSK2126458  with P-gp 
and BCRP.  
1. 6. 2 Current therapeutic options for melanoma 
Until recently, the standard therapy for metastatic melanoma was the alkylating 
agent, dacarbazine which had a modest survival of 5-6 months, and an almost 
insignificant survival advantage with severe side effects and toxicities (Serrone et 
al., 2000). Also, high dose interleukin-2 (IL-2) has a poor survival of about a year 
with significant toxicities which include arrhythmias, hypotension, capillary leak 
syndrome and severe neurological changes, thus making it an extremely difficult 
treatment for patients. The toxicities of high-dose IL-2  requires ICU (intensive-
care units)-level monitoring that still resulted in treatment related deaths in 
approximately 2% of patients in clinical trials (Atkins et al., 1999; Atkins et al., 
2000). It is important to note here that high dose IL-2 has a really poor response 
rate of less than 5% in patients with melanoma brain metastases (Guirguis et al., 
2002). Temozolomide, the alkylating agent which crosses the blood-brain barrier 
(BBB) has a dismally poor survival rate of 7% and a progression free survival of 
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1.2 months in patients with brain metastases with no prior treatment (Agarwala et 
al., 2004). 
1. 6. 3 Molecularly-targeted agents 
More recently, research effort has led to rapid progress in the development of 
molecularly targeted agents for the treatment of melanoma. The discovery and 
understanding of oncogenic driver mutations in melanoma has been crucial in the 
development of specific drugs that target the disease.  In melanoma, oncogenic 
driver mutations in BRAF and NRAS in the MAPK (mitogen-activated protein 
kinase) signaling pathway, p53 mutations, and PTEN mutations have been 
identified to play an important role in the progression of the disease (Hodis et al., 
2012). 
The discovery of activating mutations in the mitogen-activated protein kinase 
(MAPK) pathway, particularly in melanoma has led to significant advanced in 
therapeutic strategies for metastatic melanoma. Novel therapies that target 
specific molecular drivers of cancer progression such as the MAPK and 
PI3K/mTOR (phosphoinositide 3-kinase) signaling pathways have brought new 
hope for improved treatment of metastatic melanoma in recent years.  
The MAPK signaling pathway is known to be highly deregulated in about 80% of 
melanomas as well as in a wide range of other human cancers (Davies et al., 
2002). BRAF is a serine-threonine kinase in the RAS-RAF-MEK-ERK signaling 
cascade. An important sequencing effort in 2001 identified important point-
  12 
mutations in the BRAF gene in melanoma; these mutations were also prevalent 
at differing frequencies in other human cancers such as colon, thyroid and 
ovarian cancer (Davies et al., 2002). Further genetic analysis led to the finding 
that point mutations in BRAF are the most commonly found somatic mutation in 
melanoma and its prevalence is about 50% (Hocker and Tsao, 2007). Also, it is 
known that ~ 90% of all identified BRAF mutations that occur in human cancers 
result in a V600 E/D/K amino acid substitution (Wellbrock et al., 2004). This 
mutation increases BRAF protein catalytic activity by approximately 50-200 fold 
as compared to wild-type resulting in constitutive activation of the MEK and ERK 
downstream proteins (Davies et al., 2002; Karasarides et al., 2004; Wan et al., 
2004). The frequency of this activating mutation and the addiction of melanomas 
to this pathway make mutated BRAF an extremely important therapeutic target 
(Wan et al., 2004). 
Normally, signaling via the MAPK pathway requires the binding of a growth 
factor, cytokine or hormone to a receptor tyrosine kinase which leads to the 
activation of RAS (Fig. 1.3). RAS is upstream of BRAF, and upon activation 
recruits BRAF to the cell membrane which further signals via MEK and ERK 
kinases leading to cell proliferation and growth.    Activating mutations lead to 
constitutive signaling  via the MAPK (mitogen-activated protein kinase) signaling 
pathway that stimulates nuclear translocation of phosphorylated extracellular 
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signal-regulated kinases, subsequent gene transcription, leading to uncontrolled 
tumor growth and proliferation (McCubrey et al., 2008).  
1. 6. 3. 1 BRAF targeted therapy – Vemurafenib and Dabrafenib 
A majority of melanoma patients with BRAF (v-raf murine sarcoma viral 
oncogene homolog B) mutations exhibit a valine to glutamic acid substitution at 
amino acid 600 (V600E; BRAF V600E).  The prevalence of this mutation 
provided a new exiting target for therapy and led to the development of specific 
BRAF inhibitors. Over the last few years, the clinical development and FDA 
approval of two BRAF inhibitors, vemurafenib and dabrafenib has changed the 
landscape of melanoma treatment. Previously, sorafenib, a nonspecific RAF 
inhibitor, which was able to inhibit both, wild-type and mutant BRAF, yielded 
extremely poor clinical response when used as a single agent (Eisen et al., 
2006).  
Vemurafenib is a highly selective, potent and well-characterized small-molecule 
BRAF V600E inhibitor that was developed using a structure-guided drug 
discovery approach (Tsai et al., 2008). It was approved by the Food and Drug 
Administration in August 2011 for patients with late-stage melanoma harboring 
the V600E mutation. Vemurafenib showed a remarkable improvement in overall 
and progression free survival in a significant percentage of BRAF V600E positive 
melanoma patients (Chapman et al., 2011; Ribas et al., 2011).  
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An important factor that leads to near 100% mortality in patients with melanoma 
brain metastases is likely to be the limited brain permeability of therapeutic 
agents across the blood-brain barrier (BBB). In this context, it is important to 
understand the role of BRAF inhibitors for the treatment of melanoma brain 
metastases in addition to surgery and radiation therapy. In the case of 
vemurafenib, prior evidence through case studies in the literature suggest that 
there has been a potential lack of efficacy in the treatment of melanoma brain 
metastases (Rochet et al., 2012).  
Dabrafenib (GSK2118436) is a potent ATP-competitive inhibitor of the BRAF 
kinase, the second BRAF inhibitor to be approved by the FDA after it showed 
comparable clinical response to that of vemurafenib (Chapman et al., 2011; 
Hauschild et al., 2012). The safety and clinical response of dabrafenib against 
peripheral melanoma metastases was greater than 50% (Hauschild et al., 2012). 
Interestingly, dabrafenib showed promising reduction in tumor size in ~90% of 
the patients with melanoma brain metastases (Falchook et al., 2012).  
However, it is still not clear whether dabrafenib is effectively delivered to all 
micrometastatic sites, particularly those that a situated beyond an intact BBB. 
Given the potential lack of efficacy of vemurafenib in treating melanoma brain 
metastases and the insufficient information about dabrafenib in its potential 
survival benefit in patients with melanoma brain metastases, it is imperative to 
study the brain distribution of both these molecules in greater detail. 
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1. 6. 4 Resistance Mechanisms 
Much of the current clinical data suggests that patients on BRAF inhibitors slowly 
stop responding to therapy due to the eventual development of resistance and 
relapse of disease (Puzanov et al., 2011). Several mechanisms may be 
responsible for this resistance. Mutations in upstream signaling proteins such as 
RAS or compensatory signaling from other growth factor receptors such as 
PI3K/mTOR may be driving the reactivation of the MAPK signaling pathway and 
strengthening the resistance to BRAF therapy (Flaherty et al., 2012a). Currently, 
several mechanisms have been suggested for the development of resistance to 
BRAF therapy, activating mutations in NRAS, upregulation of upstream RAS 
protein, platelet-derived growth factor receptor, phosphatidylinositol signaling 
(PI3K/mTOR), and loss of PTEN, upregulation of cyclinD1 and downregulation of 
p27Kip1 (Aplin et al., 2011). Activating mutations in NRAS could potentially lead to 
signaling via CRAF, despite inhibition of BRAF using vemurafenib or dabrafenib. 
Also, the loss of PTEN is commonly found in melanoma which results in the 
increased signaling via the PI3K pathway (Villanueva et al., 2010).The 
occurrence of PTEN mutations with the concomitant maintenance of BRAF 
suggests that the PI3K pathway may be a potential driver of resistance (Fig.1.4).  
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1. 7 Overcoming resistance 
1. 7. 1 Targeting multiple signaling pathways 
A rational combination of drugs that target multiple signaling pathways will 
eventually be the standard of care for the successful treatment of melanoma. 
However, in the context of treating melanoma brain metastases effectively, the 
challenge is the sufficient delivery of all agents in the combination across the 
BBB to the target sites in the brain that may reside behind an intact BBB.   
Several new drug molecules are currently in development in combination with 
BRAF inhibitors, these include RAS, MEK, and PI3K/mTOR inhibitors (Fig.1.5) 
(Nikolaou et al., 2012).  
In the context of delaying resistance, a recent success story is that of orally 
bioavailable MEK (MAPK kinase) inhibitor, trametinib, which was FDA approved 
as a single agents after it showed a 4.3 months progression free survival as 
compared to 1.5 months in the chemotherapy arm in phase 3 clinical trial in 
patients with BRAF V600E mutation (Flaherty et al., 2012b). MEK is a signaling 
protein that is downstream of BRAF in the MAPK signaling cascade. MEK on 
phosphorylation causes the phosphorylation of ERK which leads to gene 
transcription, cell division and growth. 
Also, the combination of BRAF inhibitor dabrafenib and MEK inhibitor trametinib 
has shown significant improvement in progression-free survival in melanoma 
patients (9.4 months in the combination arm as compared to 5.8 months on 
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monotherapy) (Flaherty et al., 2012a) which led to the FDA approval of the 
combination.  
 However, acquired resistance to combinations is a significant problem that 
needs to be addressed as a top priority (Wagle et al., 2011). In the case of the 
dabrafenib and trametinib combination, a case study looking at the whole-exome 
sequencing (WES) and whole-transcriptome sequencing (RNA-seq) in 5 patients 
who had acquired resistance to the combination led to the identification of 
activating mutations in MEK2 in 3 of the 5 patients (Wagle et al., 2011; Wagle et 
al., 2014). This mutation was found to confer a profound resistance to the 
combination of dabrafenib and trametinib (Wagle et al., 2014).  
In overcoming resistance to the combination of dabrafenib and trametinib, is the 
possibility of blocking downstream signaling proteins such as ERK or the addition 
of an inhibitor of other alternate signaling pathways that may be concomitantly 
deregulated (Fig.1.6). In the case of melanoma, it is observed that the 
PI3K/AKT/mTOR inhibitor is frequently altered by a functional loss of PTEN or 
the amplification of AKT (Goel et al., 2006). 
Simultaneously targeting of both the MAPK and the PI3K signaling pathways is 
an approach that has been proposed and actively being pursued in a subset of 
NRAS mutant melanomas (Fig.1.7) (Smalley et al., 2006). 
The PI3K (phosphoinositide 3-kinase (PI3K) signaling pathway is found to be 
activated in several human cancers.  The PI3K signaling pathway is a 
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downstream effector signaling molecule of the RAS pathway. PI3K 
phosphorylates a second messenger, phosphatidylinositol-4, 5-biphosphate, 
thereby generating phosphatidylinositol-3, 4, 5-triphosphate, which activates 
AKT. Activated AKT has several cellular and enzymatic substrates, which 
promote cellular proliferation, growth and survival (Fig.1.8). In this context, 
GSK2126458, a highly potent and selective inhibitor of PI3Ks and the 
mammalian target of rapamycin (mTOR) may be a possible option to be 
considered for combination therapy. However, it is crucial to remember that the 
true success of combination therapy for treating melanoma brain metastases will 
depend on whether all drugs in the combination will be delivered across the BBB 
to all metastatic sites. Other signaling pathways driven by Akt and cyclin D-cyclin 
dependent kinases (4/6) complexes are being investigated intensely to identify 
novel targets that can improve combination therapy and delay resistance (Miller 
and Flaherty, 2014)(Fig. 1.9.).  
1. 7. 2 Immunotherapy: Targeting inhibitory immune receptors 
Immune checkpoint blockade with antibodies has also been an important 
strategy that has been pursued to obtain durable response in the treatment of 
metastatic melanoma. Antibodies against inhibitory immune receptors, CTLA-4, 
PD-1 and PD-L1 have shown promising response in a subset of melanoma 
patients.  
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Normally, T-cell activation leads to an upregulation of CTLA-4 which in-turn 
causes the downregulation of T-cell function.  The rationale for ipilimumab was 
the observation that blocking CTLA-4 could result in anti-tumor immunity in 
preclinical models. 
Ipilimumab was the first approved anti-CTLA-4 antibody which showed an 
improvement in overall survival in two phase III clinical trials in melanoma 
patients (Hodi et al., 2010; Robert et al., 2011). Tremelimumab, a second anti-
CTLA- 4 antibody did not show a statistically significant improvement in overall 
survival (Ribas et al., 2013).  
The success with targeting CTLA-4 led to other approaches targeting 
immunological checkpoints. PD-1 and its ligand PD-L1 are negative regulators of 
T-cell based immune response. When engaged by its ligand, PD-1 leads to an 
inhibition of kinase activity, which further leads to the inhibition of T-cell 
activation.  Broadly, there are two categories of anti-bodies that target the PD-
1/PD-L1 axis; antibodies that inhibit PD-1 and those that target and inhibit PD-L1. 
Nivolumab and Pembrolizumab are PD-1 targeting anti-bodies that have shown 
durable response in a phase-I clinical trials in patients with solid tumors (Topalian 
et al., 2012; Topalian et al., 2014). The ability of the immune system to readily 
adapt to the changing tumor microenvironment is thought to be a reason for the 
durable response seen with immunotherapy as compared to the acquired 
mutations to molecularly targeted agents which make them ineffective. A 
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promising approach is to combine CTLA-4 and PD-1/PD-L1 antibodies for 
patients who benefit from immunotherapy. A combination of ipilimumab and 
nivolumab has shown durable response in melanoma patients (Wolchok et al., 
2013). It remains to be seen whether immunotherapy can be effectively 
combined with molecularly-targeted agents to improve patient outcomes while 
keeping side effects under control.  
1. 8 Statement of the problem 
Melanoma brain metastases are a major cause of mortality in patients with 
advanced melanoma. The successful treatment of melanoma brain metastases 
has been extremely challenging and it is unclear whether the more recent and 
promising molecularly-targeted agents will be able to make an impact on 
improving the treatment of brain metastases. From previous experience with 
brain tumors, in particular glioblastoma, it is known that several 
chemotherapeutic agents that are known to be substrates of P-gp and BCRP are 
mostly ineffective due to their inability to cross the BBB.  
In the case of the newer molecularly-targeted agents for melanoma, 
(vemurafenib, dabrafenib, trametinib, and GSK2126458) there is sparse clinical 
data about their efficacy treatment of melanoma brain metastases. It is critical to 
examine the brain distribution of these drugs in mouse models, with the hope that 
the preclinical evidence gained will help in choosing drugs and rational 
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combinations that can eventually provide a durable response for this devastating 
disease.   
Also, the development of resistance is a significant problem which needs to be 
addressed for the rational selection of efficacious combination therapies. 
Effective combination therapy for melanoma brain metastases with targeted 
agents requires the sufficient delivery of all agents in the combination across the 
BBB.  It is likely that brain metastases differ from peripheral mets in mechanisms 
and time course of development of resistance to different drug concentrations in 
brain versus peripheral mets. The problem in selection of drugs or rational 
combinations to obtain durable response in treating melanoma brain metastases 
requires that we have substantial information about the pharmacokinetics and 
brain distribution of these agents. Also, it is crucial to pursue strategies to 
improve their brain distribution. 
1. 9 Research Objective 
The objectives of this research program were: 
1) To investigate and elucidate the crucial mechanisms affecting the brain 
distribution of several currently used molecularly-targeted anti-melanoma drugs. 
Of particular interest was to understand the influence of active efflux by P-
glycoprotein (P-gp) and Breast cancer resistance protein (BCRP) on the 
pharmacokinetics of three classes of molecularly- targeted drugs (BRAF, MEK 
and Pi3K/mTOR inhibitors). 
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2) Based on the understanding gained in (1), to devise strategies to improve the 
brain distribution of these agents by inhibition of P-gp and Bcrp using known 
inhibitors in combination with these agents.  
1. 9. 1 Research Plan 
Vemurafenib and dabrafenib are potent FDA- approved BRAF inhibitors that are 
currently used for the treatment of metastatic melanoma, including patients with 
melanoma brain metastases. In order to understand the influence of active 
transport mechanisms on the brain distribution of these two agents, we 
quantitatively assessed the role of P-gp and BCRP mediated transport via 
elegant pharmacokinetic studies in chapter II (vemurafenib) and chapter III 
(dabrafenib).  
Several clinical studies have observed that patients on BRAF inhibitors 
eventually stop responding to therapy. The development of resistance to BRAF 
inhibitors is a huge challenge that needs to be overcome in order to prolong 
treatment response. Blocking downstream signaling proteins or alternate 
signaling pathways is a strategy to delay resistance to therapy. MEK is 
downstream of BRAF in the MAPK signaling pathway and trametinib is a potent 
MEK inhibitor that is FDA-approved to be used as a single agent and in 
combination with dabrafenib for the treatment of advanced melanoma. In chapter 
IV, we pharmacokinetically assess the influence of active transport on the brain 
distribution of trametinib and a combination of dabrafenib and trametinib. 
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As a second strategy to overcome resistance, it is known that the Pi3K/mTOR 
signaling pathway play an important role in the progression of melanoma. The 
combined inhibition of the Pi3K/mTOR signaling besides BRAF and MEK 
inhibition is a strategy that is being investigated. Chapter V examines the 
influence of efflux transport proteins on the brain distribution of GSK2126458 (a 
potent Pi3K/mTOR inhibitor). We also attempt to improve the brain distribution of 
GSK212658 using elacridar (a dual inhibitor of P-gp and Bcrp). 
The reformulation of crystalline vemurafenib into an amorphous solid dispersion 
led to a huge improvement in oral bioavailability. This formulation change was 
critical to enable the clinical use of vemurafenib. In chapter VI, we study the 
difference in pharmacokinetics and oral bioavailability of pharmacy grade 
vemurafenib versus non-pharmacy grade (crystalline powder) vemurafenib and 
its impact on vemurafenib brain distribution in a mouse model. 
In summary, this dissertation attempts to provide a substantial understanding of 
the influence of active transport on the brain distribution and pharmacokinetics of 
important anti-melanoma drugs. From our findings, we will be able to make 
important recommendations regarding the rational use of these drugs as single 
agent and in combination for the treatment of melanoma brain metastases.  
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Figures 
 
Figure 1.1: Various steps in the formation of melanoma brain metastasis 
(Fokas et al., 2013) 
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Figure 1.2: BRAF inhibitors (vemurafenib and dabrafenib) and MEK 
inhibitor (trametinib) block the MAPK signaling pathway 
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Figure 1.3: The RAF signaling pathway 
 
Binding of growth factor to receptor tyrosine kinases (RTK) leads to downstream 
signaling via RAS, RAF, MEK (mitogen-activated protein kinase (MAPK)/ERK 
kinase) and ERK (extracellular signal-regulated kinase) (Bollag et al., 2012) 
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Figure 1.4: Mechanism of acquired resistance to BRAF inhibitors 
 
BRAF V600E melanoma tumors may acquire resistance via RAS mutation, RTK 
activation, COT activation (Poulikakos and Rosen, 2011). 
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Figure 1.5: Molecularly-targeted agents that inhibit the MAPK and PI3K 
signaling pathway  
 
RAF and PI3K are downstream of RAS and are potential therapeutic targets that 
have to be rationally selected for single or combination treatment of melanoma 
brain metastases. 
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Activation of RTKs, lead to signaling via MAPK, PI3K. GNAQ and GNA11 mutations are mutated in ocular melanoma. In 
the nucleus, epigenetic silencing of tumor suppressor genes occurs through DNA methylation and histone acetylation by 
DNA methyltransferase (DNMT) and histone deactylase (HDAC), respectively(Nikolaou et al., 2012) 
Figure 1.6: Important signaling pathways and therapeutic targets in melanoma 
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Figure 1.7: Schematic of the MAPK and PI3K pathways in melanoma and the clinical compounds available for 
their inhibition (Vultur et al., 2011) 
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Figure 1.8: The PI3K signaling pathway  
 
PI3K phosphorylates a second messenger, phosphatidylinositol-4, 5-
biphosphate, thereby generating phosphatidylinositol-3, 4, 5-triphosphate, which 
activates AKT. Activated AKT has several cellular and enzymatic substrates, 
which promote cellular proliferation, growth and survival.
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Figure 1.9: Currently targeted signaling pathways in melanoma therapy. 
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Figure 1.10: Barriers to drug delivery in treatment of melanoma brain metastases: 
Shows the expression of efflux transporters, P-gp, Bcrp and MRPs at the BBB, ABCB5 known to be expressed by melanoma 
cells, and ABCB1 and ABCB5 expressed by the stem cell like side population of cells in melanoma tumors. 
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CHAPTER 2: IMPACT OF P-GLYCOPROTEIN (ABCB1) AND 
BREAST CANCER RESISTANCE PROTEIN (ABCG2) ON THE 
BRAIN DISTRIBUTION OF A NOVEL B-RAF INHIBITOR: 
VEMURAFENIB (PLX4032) 
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Vemurafenib (PLX4032) is a novel small molecule BRAF inhibitor, recently 
approved by US Food and Drug Administration (FDA) for the treatment of 
patients with metastatic melanoma with a BRAFV600E mutation. The objective of 
this study was to investigate the role of P-glycoprotein (P-gp) and breast cancer 
resistance protein (BCRP) on the distribution of vemurafenib to the central 
nervous system.  In vitro studies conducted in transfected Madin-Darby canine 
kidney-II cells show that the intracellular accumulation of vemurafenib is 
significantly restricted due to active efflux by P-gp and BCRP. Bidirectional flux 
studies indicated greater transport in basolateral-to-apical direction than apical-
to-basolateral direction due to active efflux by P-gp and BCRP. Selective P-gp 
and BCRP inhibitors zosuquidar and Ko143 were able to restore the intracellular 
accumulation and bidirectional net flux of vemurafenib. The in vivo studies 
revealed that the brain distribution coefficient (area under the concentration time 
profile of brain / area under the concentration time profile of plasma) of 
vemurafenib was 0.004 in wild-type mice. The steady-state brain-to-plasma ratio 
of vemurafenib was 0.035 ± 0.009 in Mdr1a/b-/- mice, 0.009 ± 0.006 in Bcrp1-/- 
mice, 1.00 ± 0.19 in Mdr1a/b-/-Bcrp1-/- mice, compared to 0.012 ± 0.004 in wild 
type mice.  These data indicate that the brain distribution of vemurafenib is 
severely restricted at the blood-brain barrier due to active efflux by both P-gp and 
BCRP. This finding has important clinical significance given the ongoing trials 
examining the efficacy of vemurafenib in brain metastases of melanoma. 
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2. 1 Introduction 
Melanoma is a neoplasm that originates in the pigment producing cells of 
the skin. The incidence of melanoma is escalating. For example, in 2011, 
approximately 70,000 individuals were expected to be diagnosed with melanoma 
in the United States, and ~8800 were predicted to die from melanoma (Siegel et 
al., 2011). After lung and breast cancers, malignant melanoma is the third most 
common neoplasm that metastasizes to the brain (Johnson and Young, 1996). 
Approximately 50-75% of melanoma patients are found to have brain metastases 
at autopsy (Fife et al., 2004). Once the lesions have become established in the 
central nervous system (CNS), the median survival is less than 6 months (Fife et 
al., 2004; Raizer et al., 2008).  
 The current therapeutic options for melanoma patients include surgery, 
radiotherapy, and chemo or immunotherapy. The standard therapy using high 
dose interleukin-2 and dacarbazine proves to be unsuccessful in metastatic 
melanoma, with response rates of only 10 to 20% (Comis, 1976; Atkins et al., 
1999; Garbe et al., 2011). The gene encoding the serine-threonine protein kinase 
B-RAF (BRAF) was found to be mutated in ~40-60% of melanomas (Wan et al., 
2004).  BRAF is an important component of RAF/MEK/ERK signaling pathway 
which regulates cell proliferation and growth (McCubrey et al., 2008). The 
mutated BRAF gene results in signaling pathways that promote tumor cell 
proliferation, invasion, and resistance. Among the BRAF mutations approximately 
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80% exhibit a valine to glutamic acid substitution (V600E; BRAFV600E) resulting in 
constitutive expression of kinase activity (Davies et al., 2002). A recent study 
indicated that BRAFV600E is associated with poor patient survival (Long et al., 
2011), and further studies show that the incidence of BRAFV600E mutation in brain 
metastases of melanoma is similar to that found in peripheral sites (Capper et al., 
2011). Given the prevalence of BRAFV600E mutations in a large number of 
melanomas, BRAF has been an attractive treatment target for melanoma 
patients with V600E mutation, and as such many small-molecule inhibitors of 
BRAF have been developed. 
Vemurafenib (previously known as PLX4032) is a small molecule 
BRAFV600E inhibitor that was developed using a structure-guided drug discovery 
approach (Tsai et al., 2008). It was approved by U.S. Food and Drug 
Administration (FDA) in August 2011 for late-stage melanoma patients with 
BRAFV600E mutation. Clinical trials with vemurafenib have shown remarkable 
responses in a high percentage of BRAF mutant melanoma cases (Ribas et al., 
2011), with improved overall and progression-free survival (Chapman et al., 
2011). A clinical trial evaluating the efficacy of vemurafenib in brain metastases 
of melanoma is currently recruiting patients (ClinicalTrials.gov identifier: 
NCT01378975). Whether or not vemurafenib will show clinical activity in brain 
metastases of melanoma is an important question that remains to be answered. 
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In this context, it is crucial to determine the mechanisms influencing the brain 
distribution of vemurafenib to further support the clinical investigations.  
A major factor contributing to the rapid and near 100% mortality in 
melanoma patients with brain metastases has been the presumed limited 
permeability of chemotherapeutics across the blood-brain barrier (BBB).  The 
BBB is a highly evolved vasculature structure which limits most molecules from 
distributing into the brain from the blood compartment. Anatomically, the 
vasculature of the BBB is unique in that it is comprised of endothelial cells, that 
are circumferentially sealed together by tight-junction protein complexes, that 
form the lumen of the vessel. Further, active efflux transporters that are present 
on the luminal side of capillary endothelium efficiently pump out the drugs from 
the brain to the blood circulation. Adenosine triphosphate-binding cassette 
proteins (ABC) such as P-glycoprotein (P-gp) and breast cancer resistance 
protein (BCRP) are major members of the efflux transporters present on the 
luminal membrane of the brain capillary endothelial cells (Schinkel and Jonker, 
2003).  Studies have shown that many therapeutic agents are substrates of these 
transporters and as a result have very limited brain distribution (Loscher and 
Potschka, 2005).  
Vemurafenib can be considered a “sea-change” in the treatment of melanoma 
patients. However, important questions still remain regarding resistance and 
effective delivery to all sites of melanoma metastases, particularly in brain. In this 
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regard, there is a paucity of data regarding the delivery of anti-melanoma agents 
to brain metastases. Given the remarkable activity of the novel targeted 
BRAFV600E inhibitors in peripheral disease, it becomes critical to examine the 
mechanisms that may limit their delivery to brain metastases. Whether 
vemurafenib can cross the BBB to achieve therapeutic levels in the CNS remains 
unknown. This has motivated us to examine the interaction of vemurafenib with 
the two main BBB efflux transporters, namely P-gp and BCRP. Herein, using in 
vitro models, we show that vemurafenib is an avid substrate for both P-gp and 
BCRP. In vivo studies using genetic knockout mice indicate both transporters 
play a significant role in limiting the CNS distribution of vemurafenib. 
2. 2 Materials and Methods 
2. 2. 1 Chemicals 
Vemurafenib (PLX4032) was purchased from Chemietek (Indianapolis, IN). [3H]-
Vinblastine was purchased from Moravek Biochemicals (La Brea, CA). [3H]-
Prazosin was purchased from Perkin Elmer Life and Analytical Sciences 
(Waltham, MA). KO143 was a generous gift from Dr. Alfred Schinkel (The 
Netherlands Cancer Institute, Amsterdam, The Netherlands) and zosuquidar 
[LY335979, (R)-4-((1aR, 6R,10bS)-1,2-difluoro-1,1a,6,10b-tetrahydrodibenzo-
(a,e) cyclopropa( c)cycloheptan-6-yl)-((5-quinoloyloxy) methyl)-1-piperazine 
ethanol, trihydrochloride] was kindly provided Eli Lilly and Co.(Indianapolis, IN). 
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All other chemicals used were of high performance liquid chromatography or 
reagent grade and were obtained from Sigma-Aldrich (St. Louis, MO).  
2. 2. 2 In vitro studies 
All the in vitro studies were performed using polarized Madin-Darby canine 
kidney-II (MDCKII) cells. MDCKII-wild type (WT) and MDR1-transfected 
(MDCKII-MDR1) cell lines were kindly provided by Dr. Piet Borst (The 
Netherlands Cancer Institute). MDCKII-WT and Bcrp1-transfected (MDCKII-
Bcrp1) cells were a kind gift from Dr. Alfred Schinkel (The Netherlands Cancer 
Institute). Cells were cultured in Dulbecco’s modified Eagle’s medium 
supplemented with 10% (v/v) fetal bovine serum and antibiotics (penicillin, 100 
U/mL; streptomycin, 100 µg/mL; and amphotericin B, 250 ng/mL). Cells were 
grown in 25 mL tissue culture treated flasks before seeding for the experiments 
and were maintained at 37º C in a humidified incubator with 5% CO2.   
2. 2. 2. 1 In vitro accumulation studies 
The intracellular accumulation of vemurafenib was performed in 12-well 
polystyrene plates (Corning Inc. Corning, NY) as described previously (Agarwal 
et al., 2010; Agarwal et al., 2011). Briefly, cells were seeded at a density of 2 x 
105 cells and were grown until the cells were ~80% confluent. On the day of 
experiment the culture media was aspirated and the cells were washed two times 
with cell assay buffer (122 mM NaCl, 25 mM NaHCO3, 10 mM glucose, 10 mM 
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HEPES, 3 mM KCl, 2.5 mM MgSO4, 1.8 mM CaCl2, and 0.4 mM K2HPO4). Then 
the cells were preincubated with assay buffer for 30 min, after which the buffer 
was aspirated and the experiment was initiated by adding 1 mL of vemurafenib (2 
µM) to each well and further incubated for 60 min. The assay plates were 
incubated at 37º C on an orbital shaker (60 rpm) for the entire duration of the 
experiment. After the incubation period, the drug solution was aspirated and the 
cells were washed twice with ice cold PBS. Then the cells were lysed by adding 
500 µL of 1% Triton X to each well. A 400 µL of solubilized cell fraction was 
sampled from each well and the concentration of vemurafenib was determined 
using LC-MS/MS as described below.  
 
2. 2. 2. 2 Directional transport across MDKCII monolayers 
The bidirectional flux studies were performed using 6-well Transwell® plates 
(Cornings Inc. Lowell, MA). The cells were seeded at a density of 2 x105 cells per 
well and the media was changed every other day until confluent monolayers 
were formed.  On the day of experiment, the culture medium was aspirated and 
the cells were washed twice with assay buffer and after 30 min preincubation, the 
experiment was initiated by adding the vemurafenib solution (2 µM) in assay 
buffer to the donor compartment. Samples (200 µL) were collected from the 
receiver compartment at 0, 30, 60, 90, 120, and 180 minutes and replaced with 
drug-free assay buffer. Similarly, at the beginning of the experiment a 200 µL 
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sample was drawn from the donor compartment and replaced with 200 µL of 
drug solution. The Transwell® plates were incubated at 37 ºC on an orbital shaker 
for the duration of experiment except for the brief sampling times. When an 
inhibitor was used, the inhibitor was present in the both compartments during the 
pre and post incubation period.  
The apparent permeability (Papp) for the directional transport was 
calculated as previously described (Agarwal et al., 2011). The permeabilities 
were calculated using the following equation 
 
 
(1) 
 
Where, (dQ/dt) is the slope obtained from the initial linear range from the amount 
transported versus time plot, A is the area of the Transwell® membrane, and C0 is 
the initial donor concentration. The efflux ratio and corrected efflux ratio were 
calculated using eqs. 2 and 3, respectively,  
 
 
(2) 
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(3) 
where A→B represents permeability in apical to basolateral and B→A represents 
permeability in basolateral to apical direction. 
2. 2. 2. 3 Competition assays using P-gp and Bcrp probes 
Competition assays were performed using the prototypical probe substrates 
prazosin for BCRP and vinblastine for P-gp. Intracellular accumulation of these 
substrates at 60 min was determined in MDCKII-Bcrp1 or MDCKII-MDR1 cells in 
the presence of different concentrations of vemurafenib ranging from 1 µM to 25 
µM. The increase in probe accumulation relative to control (i.e., no vemurafenib 
treatment) was reported as a function of vemurafenib concentration. 
2. 2. 3 In vivo Studies 
2. 2. 3. 1 Animals 
All of the in vivo studies were performed in FVB (wild type), Mdr1a/b-/- (P-gp 
knockout), Bcrp1-/- (BCRP knockout), and Mdr1a/b-/-Bcrp1-/- (triple knockout) mice 
of a FVB genetic background (Taconic Farms, Germantown, NY). All animals 
were 8 to 10 weeks old at the time of experiment. Animals were maintained in a 
12 hr light/dark cycle with an unlimited access to food and water. All studies were 
carried out in accordance with the guidelines set by the Principles of Laboratory 
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Animal Care (National Institutes of Health, Bethesda, MD) and approved by the 
Institutional Animal Care and Use Committee of the University of Minnesota. 
2. 2. 3. 2 Brain Distribution of vemurafenib in FVB mice 
The dosing formulation of vemurafenib was prepared either in a vehicle 
containing 1% Tween 20 and 1% HPMC (for oral dosing) or in a vehicle 
containing 40% DMSO, 40% propylene glycol, and 20% saline (for i.v. studies). 
All vemurafenib formulations were freshly prepared on the day of experiment. In 
the first study, wild type, Mdr1a/b-/- , Bcrp1-/- , and Mdr1a/b-/-Bcrp1-/- mice received 
an oral dose of 25 mg/kg and blood and brain samples were collected 1 and 4 hr 
post dose. At the end of the desired time point, the animals were euthanized 
using a CO2 chamber. Blood was collected via cardiac puncture and collected in 
heparinized tubes. Plasma was obtained by centrifuging the blood at 7500 rpm 
for 10 min. Brains were rapidly removed from the skull, rinsed with ice cold PBS 
followed by a flash freeze in liquid nitrogen. Brain and plasma samples were 
stored at -80º C until further analysis.  
In the i.v. dosing study, wild type and Mdr1a/b-/-Bcrp1-/- mice were 
administered vemurafenib via the tail vein at a dose of 2.5 mg/kg. Blood and 
brain samples were processed after 5, 30, 90, 180, 300, and 480 minutes (n=4 
for each time point) as mentioned above.  
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2. 2. 3. 3 Steady state brain distribution of vemurafenib 
To determine the steady state brain and plasma concentrations of vemurafenib, 
Alzet osmotic mini pumps (Durect Corporation, Cupertino, CA) were loaded with 
vemurafenib (25 mg/mL dissolved in DMSO) to be released for 48 hrs at a rate of 
1µL/hr. After vemurafenib loading, mini pumps were primed overnight in sterile 
saline at 37 º C. Pumps were implanted in the peritoneal cavity of wild type, 
Mdr1a/b-/- , Bcrp1-/- , and Mdr1a/b-/-Bcrp1-/- mice as previously described (Agarwal 
et al., 2010; Agarwal et al., 2011). Briefly, mice were anesthetized using 
isofluorane and the abdominal cavity was shaved. A small midline incision was 
made in the lower abdomen under the rib cage. Then a small incision was made 
directly in the peritoneal membrane and the primed pump was inserted in the 
cavity. The incision was sutured and the skin was closed using surgical clips. The 
animals were allowed to recover on a heating pad and, once recovered, moved 
to their original cages. The animals were sacrificed 48 hrs after the implantation 
of the pumps, and brain and plasma samples were processed as described 
above.  
2. 2. 3. 4 Analysis of vemurafenib using LC-MS/MS 
The concentrations of vemurafenib in cell lysates, assay buffer, plasma and brain 
homogenate were determined using a sensitive and specific liquid 
chromatography coupled with tandem mass spectrometry (LC-MS/MS) assay. 
For brains, 3 volumes of 5% bovine serum albumin was added and homogenized 
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to get a uniform homogenate. For analysis of unknowns, an aliquot of cell lysate, 
cell assay buffer, brain homogenate or plasma was spiked with 50 ng of 
PLX4720 as an internal standard and alkalinized by addition of 2 volumes of pH 
11 buffer (1 mM sodium hydroxide, 0.5mM sodium bicarbonate). The samples 
were then extracted by addition of 10 volumes of ethyl acetate followed by 
vigorous shaking for 5 min and centrifuged at 7500 rpm for 5 min at 4ºC to 
separate the organic layer. The organic layer was transferred to microcentrifuge 
tubes and dried under nitrogen. Samples were reconstituted in 100 µL of mobile 
phase and transferred into HPLC glass vials. Chromatographic analysis was 
performed using an AQUITY UPLC® system (Milford, MA, USA). The 
chromatographic separation was achieved using an Agilent Technologies Eclipse 
XDB-C18 column (4.6 x 50 mm) with 1.8 µm Zobrax Rx-SIL as the stationary 
phase. The mobile phase consisted of 20 mM ammonium formate with 0.1% 
formic acid and acetonitrile (30:70 v/v), and was delivered at a flow rate of 0.25 
mL/min.  
The column effluent was monitored using a Waters/Micromass QuattroTM 
Ultima mass spectrometer (Waters, Milford, MA). The instrument was equipped 
with an electrospray interface, and controlled by the Masslynx (Version 4.1) data 
system. The samples were analyzed using an electrospray probe in the negative 
ionization mode operating at a spray voltage of 2.96 kV for both vemurafenib and 
PLX4720 (internal standard). Samples were introduced into the interface through 
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a heated nebulized probe where the source and desolvation temperatures were 
set at 100 ºC and 275 ºC, respectively. The spectrometer was programmed to 
allow the [MH]- ion of vemurafenib at m/z 488.23 and that of internal standard at 
m/z  412.26 to pass through the first quadrupole (Q1) and into the collision cell 
(Q2). The collision energy was set at 27V for vemurafenib and 25V for PLX4720. 
The product ions for vemurafenib (m/z 380.89) and the internal standard 
PLX4720 (m/z 304.82) were monitored through the third quadrupole (Q3). The 
retention time for vemurafenib and the internal standard PLX4720 was 4.2 and 
2.9 min, respectively. The assay was sensitive and linear over a range of 1.2 
ng/mL to 1.2 µg/mL, with the coefficient of variation being less than 15% over the 
entire range. 
2. 2. 4 Pharmacokinetic Calculations 
Pharmacokinetic parameters and metrics were calculated by noncompartmental 
methods using Phoenix WinNonlin (Version 6.1) (Pharsight, Mountain View, CA). 
The area under the concentration time curve in both plasma and brain was 
calculated using the trapezoidal rule, and the area under the curve was 
determined up to the last measured time point (AUC 0-tlast). AUC 0-tlast was used in 
determining brain to plasma distribution ratio. The area under the curve from time 
zero to infinity was also determined and the area extrapolated was less than 20% 
of the total area under the concentration curve. The terminal rate constants were 
determined using all the data points in the brain and the last three data points in 
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the plasma. In plasma, the concentration at zero time was extrapolated using the 
terminal rate constant to measure the area under the curve at time zero to the 
first measured time point.  
2. 2. 5 Statistical Analysis:  
Data in all experiments represent mean ± SD unless otherwise indicated. 
Comparisons between two groups were made using an unpaired t-test. One way 
ANOVA, followed by Bonferonni’s multiple comparisons test, was utilized to 
compare multiple groups.  A significance level of p <0.05 was used for all 
experiments. (GraphPad Prism 5.01 software, San Diego, CA, USA).  . 
2. 3 Results: 
2. 3. 1 Intracellular accumulation of vemurafenib: 
 The intracellular accumulation of vemurafenib was studied in MDCKII WT and P-
gp or Bcrp overexpressing cell lines. [3H]-prazosin and  [3H]-vinblastine were 
used as positive controls for Bcrp and P-gp, respectively. As expected, the 
accumulation of [3H]-prazosin (Fig. 2.1A) was significantly lower in Bcrp 
overexpressing cell lines (WT: 100.0 ± 8.7; Bcrp: 8.0 ± 2.4, p<0.0001). Similarly, 
the accumulation of [3H]-vinblastine (Fig. 2.1B) in P-gp overexpressing cells was 
~80% lower compared to its WT line (WT: 110.0 ± 16.4; MDR1: 13.8 ± 4.1, p = 
0.0004). Vemurafenib accumulation was ~ 77% lower in Bcrp overexpressing cell 
line compared to its WT line (WT: 100.0 ± 5.0; Bcrp: 12.9 ± 0.3, P<0.0001). The 
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difference in accumulation was abolished when a specific Bcrp inhibitor Ko143 
was added (Bcrp: 8.0 ± 2.4; Bcrp with Ko143: 69.8 ± 3.0, p<0.05). Similarly, the 
accumulation of vemurafenib was ~20% lower in P-gp overexpressing line 
compared to its WT control (WT: 100.0 ± 2.6; MDR1: 73.6 ± 5.5, p<0.05), and the 
difference in accumulation was abolished (Fig. 2.1B) when a specific P-gp 
inhibitor LY335979 was added (MDR1: 73.6 ± 5.5; MDR1 with LY: 110.8 ± 2.9).  
The aggregate of these data indicates that vemurafenib is a substrate for both P-
gp and Bcrp in vitro. 
2. 3. 2 Competition assays:  
The in vitro competition assays for vemurafenib were performed in MDCKII cells 
using vinblastine and prazosin as P-gp and Bcrp prototype probe substrates, 
respectively. The addition of increasing concentrations of vemurafenib resulted in 
a gradual increase in accumulation of prazosin and vinblastine in MDCKII-Bcrp1 
cells and MDCKII-MDR1 cells, respectively. The fold increase in prazosin 
accumulation in MDCKII-Bcrp1 cells at 10 µM of vemurafenib was no different 
than the effect seen with 0.2 µM Ko143, a potent Bcrp inhibitor (Fig. 2.2A). 
Similarly, at 25 µM of vemurafenib, the fold increase in vinblastine accumulation 
was no different than the effect seen with the potent P-gp inhibitor LY335959 
(Fig. 2.2B) in MDCKII-MDR1 cells. These data suggest that vemurafenib may 
share the same binding sites on the transporter proteins as these prototypical 
probe substrates.  
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2. 3. 3 Bidirectional flux across MDCKII monolayers:  
The in vitro transport (apical to basolateral, A to B; and basolateral to apical, B to 
A) of vemurafenib was studied in MDCKII wild type, and P-gp or Bcrp 
overexpressing cell lines. Fig. 2.3A and 2.3B demonstrate the transport of 
vemurafenib in the A to B and B to A direction in Bcrp1 and corresponding wild-
type cell monolayers. In the wild type cells, there was minimal transport (less 
than 2.3% in 1.5 hrs) of vemurafenib in either direction (Fig. 2.3A). In case of the 
MDCKII-Bcrp1 cells, the permeability of vemurafenib in the B to A direction was 
significantly higher than the permeability in the A to B direction [A to B: (0.02 ± 
0.003 × 10-6 cm/s); B to A: (9.9 ± 6.8 × 10-6 cm/s); p <0.05; Fig. 2.3C]. The 
addition of 0.2 µM Ko143, a specific Bcrp inhibitor, resulted in partial inhibition of 
Bcrp mediated vemurafenib transport in these cells (Fig. 2.3C). 
The transport of vemurafenib in the A to B and B to A direction in MDR1 
and corresponding wild-type cell monolayers is depicted in Fig. 2.3D and 2.3E. In 
the case of the MDCKII-MDR1 transfected line, the permeability of vemurafenib 
in B to A direction was significantly greater compared with permeability in A to B 
direction [A to B: (0.21 ± 0.16 × 10-6 cm/s); B to A: (16.7 ± 2.1 × 10-6 cm/s); p 
<0.05; Fig. 2.3F] resulting in an efflux ratio of ~80. The addition of 1 µM 
LY335979, a potent inhibitor of P-gp, resulted in partial inhibition of P-gp 
mediated vemurafenib transport in these cell lines (Fig. 2.3F). The B to A 
permeability of vemurafenib was not significantly different from the A to B 
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permeability in the corresponding wild-type cells. The corrected flux ratio was 
found to be approximately 34 in control and 2 in cells treated with the P-gp 
inhibitor LY335979. 
2. 3. 4 Brain distribution of vemurafenib in FVB wild type and Mdr1a/b-/-
Bcrp1-/- mice after intravenous administration:  
The brain distribution of vemurafenib was studied in FVB wild type mice after an 
i.v. dose of 2.5 mg/kg via the tail vein. Fig. 2.4 shows the concentration time 
profile of vemurafenib in both plasma and brain at 5, 30, 90, 180, 300, and 480 
minutes of post i.v dose. The plasma concentrations of vemurafenib were 
significantly higher (~3 log units) at all-time points compared to its brain 
concentrations, indicating the severely restricted brain distribution of 
vemurafenib. The brain to plasma partitioning (AUCbrain / AUCplasma) was found to 
be ~0.004 in FVB wild type mice. The pharmacokinetic parameters are depicted 
in Table 2.1. 
 In a separate study, the brain distribution of vemurafenib in Mdr1a/b-/-
Bcrp1-/- mice was examined after an i.v. dose of 2.5 mg/kg. As shown in Fig. 
2.5B, the brain concentrations of vemurafenib in Mdr1a/b-/-Bcrp1-/- mice were 
significantly higher than in wild type mice. The plasma concentrations were not 
different between the two types of mice (Fig. 2.5A). The brain to plasma (B/P) 
ratio of vemurafenib in wild-type mice was ~0.4%, significantly lower than the B/P 
ratio in Mdr1a/b-/-Bcrp1-/- mice (Fig. 2.5C).  
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2. 3. 5 Brain distribution of vemurafenib after oral administration:  
The brain distribution of vemurafenib was examined 1 and 4 hr post oral dose (25 
mg/kg) of vemurafenib  in FVB wild type, Mdr1a/b-/- , Bcrp1-/- , and Mdr1a/b-/-
Bcrp1-/- mice. As shown in Fig. 2.6A, the brain concentrations of vemurafenib 
were significantly lower than plasma after 1 hr post dose in wild type, Mdr1a/b-/- , 
and Bcrp1-/- mice with a B/P ratio of < 0.02. It should be noted that the brain 
concentrations were not corrected for the vascular content as the total brain 
distribution of vemurafenib was approximately equal to the vascular volume 
indicating the very limited brain distribution of vemurafenib. However, the B/P 
ratio of vemurafenib was significantly (p <0.0001) higher in Mdr1a/b-/-Bcrp1-/- mice 
[Fig. 2.6A and 2.6B, B/P ratio at 1hr: 0.090 ± 0.036; at 4hr: 0.36 ± 0.07] than the 
wild type and single knockout mice at both 1 and 4 hr post dose. Importantly, the 
B/P ratio of Mdr1a/b-/-Bcrp1-/- mice was 8-fold higher than wild type at 1 hr and 
30-fold higher than wild type at 4hrs. These data show the important roles of both 
P-gp and Bcrp in restricting the delivery of vemurafenib across the BBB. 
 
2. 3. 6 Steady state brain distribution of vemurafenib:  
The steady state brain distribution of vemurafenib was studied after a constant 
intraperitoneal infusion using the Alzet osmotic pumps for 48 hrs. As shown in 
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Fig. 2.7A, the steady state brain concentrations of vemurafenib were significantly 
lower in wild type, Mdr1a/b-/- , and  Bcrp1-/- mice compared to their respective 
steady state plasma concentrations. The steady state B/P plasma ratio of 
vemurafenib in Mdr1a/b-/-Bcrp1-/- mice equaled approximately 1(Fig. 2.7B), which 
is 80 fold (p< 0.0001) greater than the wild type and single knockout mice. [Wild 
type: 0.012 ± 0.004; Mdr1a/b-/- : 0.035 ± 0.009; Bcrp1-/- : 0.009 ± 0.006; Mdr1a/b-/-
Bcrp1-/- : 1.00 ± 0.19].  
2. 4 Discussion: 
 The development of vemurafenib, a potent BRAFV600E inhibitor, yields new 
hope for the melanoma patients who harbor this mutational status. However, the 
durable efficacy of vemurafenib depends on overcoming resistance (Wagle et al., 
2011) and ensuring adequate delivery to all sites of metastases in melanoma 
patients, particularly the brain. Given the remarkable success in the early clinical 
trials (Chapman et al., 2011; Ribas et al., 2011), it is of particular interest to 
examine mechanisms that may limit the CNS distribution of vemurafenib to 
support further clinical trials. In the current study, we have evaluated how BBB 
efflux transporters influence the CNS distribution of vemurafenib using both in 
vitro cell culture models and in vivo using genetic knockout mice. We 
demonstrate that vemurafenib is a substrate for the ABC transporters P-gp and 
BCRP, and that active efflux by these two transporters at the BBB severely 
restricts the CNS distribution of vemurafenib.  
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Studies performed in vitro using MDCKII cells that overexpress human P-
gp or murine BCRP revealed that vemurafenib is an avid substrate for the two 
efflux transporters. Using prototypical probe substrates (prazosin for BCRP and 
vinblastine for P-gp), we have seen a concentration-dependent increase in 
cellular accumulation of the probe with increasing concentrations of vemurafenib. 
We have examined the vectorial transport of vemurafenib across monolayers 
formed from MDCKII wild-type, MDCKII-MDR1 transfected cells and MDCKII-
Bcrp1 transfected cells. The corrected flux ratio for vemurafenib in the MDR1 
transfected line was ~34, and that ratio in the BCRP transfected line was 150, 
indicating that vemurafenib subject to significant efflux by each transporter 
across the monolayers. The selective P-gp and BCRP inhibitors zosuquidar and 
Ko143 were able to restore the intracellular accumulation and bidirectional net 
flux of vemurafenib. These in vitro results conclusively show that vemurafenib is 
a substrate for these two efflux transporters.  
 
In vivo studies using FVB wild-type mice demonstrated that the CNS 
distribution of vemurafenib is significantly restricted across the blood-brain 
barrier. The brain concentrations of vemurafenib in FVB wild-type mice are 
significantly (~3 log units; Fig. 2.5) lower than the plasma concentrations. 
However, the brain concentrations were approximately ~8-30 fold higher in 
Mdr1a/b-/-Bcrp1-/- mice than in the wild-type mice (Fig. 2.7). Steady state brain to 
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plasma ratios increased from approximately 0.01 in the wild-type mice to 
approximately 1 in the triple knockout mice. This remarkable 80-fold increase in 
targeted brain distribution of vemurafenib in Mdr1a/b-/-Bcrp1-/- mice indicates the 
significant impact of P-gp and BCRP on CNS penetration of vemurafenib. It 
should be noted that the brain distribution of vemurafenib did not increase in 
Bcrp1-/- mice, it is increased by ~3-fold in Mdr1a/b-/- mice, indicating the 
“cooperative” role of these transporters at BBB.  This type of “synergistic” effect 
of P-gp and BCRP was seen with other drugs; such as topotecan (de Vries et al., 
2007), lapatinib (Polli et al., 2009), dasatinib (Chen et al., 2009), gefitinib 
(Agarwal et al., 2010) and sorafenib (Agarwal et al., 2011). One of the 
assumptions for this disproportional increase in brain distribution of the 
compounds is that the compensatory up- or down-regulation of active efflux and 
influx transporters in the single knockout (mice lacking either P-gp or BCRP) 
mice. However, in our previous study, using a quantitative proteomics approach, 
we have shown no compensatory changes in the BBB expression of relevant 
transporters in the single and combined knockout mice (Agarwal et al., 2012). 
The exact functional compensation between P-gp and BCRP at the BBB needs 
further investigation.  
Although vemurafenib shows high initial response rates in melanoma 
patients with BRAFV600E mutation, and has been shown to yield a durable 
response in a melanoma brain metastasis in one recent case study (Rochet, 
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2011), the development of resistance can occur quickly (Wagle et al., 2011). At 
the present time, several resistance mechanisms against BRAF inhibitors have 
been documented, some of which include the upregulation of NRAS, PDGFR, 
and IGFR-1/PI3K signaling (Johannessen et al., 2010; Nazarian et al., 2010; 
Villanueva et al., 2010). Therefore, the development of more effective 
combination therapies has been suggested (Vultur et al., 2011; Ji et al., 2012). In 
this context, the interaction of drugs such as vemurafenib with ABC transporters 
could be of great relevance for the rational design of therapeutic strategies in 
clinical setting. In the current study, we have shown that the brain distribution of 
vemurafenib is severely restricted at the blood-brain barrier due to active efflux 
by both P-gp and BCRP. This finding is clinically significant considering the 
ongoing trials on the efficacy of vemurafenib in brain metastases of melanoma. 
Given the remarkable success thus far with vemurafenib, it will be crucial 
to find both the drug resistance and drug delivery liabilities to further improve 
progression free survival rates through rational drug development and design. In 
this particular case, the lack of treatment options and the aggressive course of 
this malignancy suggest that adjuvant treatment to improve delivery to the CNS 
through efflux inhibition may be a viable option to improve survival.  
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Figures: 
Figure 2.1: Intracellular accumulation of vemurafenib in MDCKII cells 
Panel A shows that accumulation of vemurafenib is significantly lower in Bcrp 
transfected lines compared to its WT control. The difference in accumulation was 
abolished when a specific Bcrp inhibitor Ko143 was used. Panel B shows that the 
accumulation of vemurafenib is ~20% less in MDR1 transfected cells than the 
WT controls and difference was abolished when MDR1 specific inhibitor 
LY335979 was used. Data represent mean ± SD, n=3-6 for all data sets. 
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Figure 2.2: Competition assays for vemurafenib in MDCKII-MDR1 and 
MDCKII-Bcrp1 cells using [3H]-vinblastine and [3H]-prazosin as P-gp and 
Bcrp prototypical probe substrates respectively. 
 
The addition of increasing concentrations of vemurafenib resulted in an 
increased accumulation of [3H]-prazosin and [3H]-vinblastine in Bcrp1 (Panel A) 
and MDR1 (Panel B) cells respectively. The data represent mean ± SD, n = 3 for 
all data sets. A *, **, and *** indicates a p value of <0.05, <0.01, and <0.0001, 
respectively. 
  60
Figure 2.3: Directional flux of vemurafenib in MDCKII cell monolayers. 
 
Panel A and B show the transport of vemurafenib in wild-type and Bcrp1-
transfected cells. Panel C shows the apparent permeability of vemurafenib in 
wild-type and Bcrp1 cells in both A-to-B and B-to-A direction. In the Bcrp1 
transfected cells, the B-to-A permeability of vemurafenib was significantly greater 
than the A-to-B permeability (***, p < 0.05). The addition of 0.2 µM Ko143, a 
potent bcrp inhibitor, decreased this directionality in flux due to bcrp (#, p < 0.05). 
Panel D and E show the transport of vemurafenib in wild-type and MDR1-
transfected cells. Panel F shows the apparent permeability of vemurafenib in 
  61
wild-type and MDR1 cells in both A-to-B and B-to-A direction. In the MDR1 
transfected cells, the B-to-A permeability of vemurafenib was significantly greater 
than the A-to-B permeability (***, p < 0.05). The addition of 1 µM LY335979, a 
potent P-gp inhibitor, abolished this directionality in flux due to P-gp (#, p < 0.05), 
such that there was no significant difference between in the permeability of 
vemurafenib in both directions. Data represent mean ± SE, n = 3-9 for all data 
sets. 
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Figure 2.4: Brain and plasma concentrations of vemurafenib after an i.v. 
dose of 2.5mg/kg in FVB wild type mice. 
 
Whole brain and plasma were collected at 5, 30, 90, 180, 300, and 480minutes 
after dose and were analyzed using LC-MS/MS. The brain concentrations of 
vemurafenib were significantly lower than the plasma concentrations at all the 
time points. A *, **, and *** indicates a p value of <0.05, <0.01, and <0.0001 
respectively. Data are mean ± SD; n=3-4 for all data point. 
  
6
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Figure 2.5: Comparison of vemurafenib brain distribution in wild-type and Mdr1a/b-/-Bcrp1-/- mice 
 
Vemurafenib was given i.v. at 2.5mg/kg and the concentrations in brain and plasma were determined using LC-MS/MS. 
Panel A and Panel B shows the plasma and brain concentrations of vemurafenib in wild-type and Mdr1a/b-/-Bcrp1-/- mice 
respectively. The B/P ratio for vemurafenib in wild-type and Mdr1a/b-/-Bcrp1-/- mice was shown in Panel C. Data represent 
mean ± SD; n=3-4 for all data points.
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Figure 2.6: Brain to plasma ratios of vemurafenib after an oral dose of 
25mg/kg in FVB wild type, Mdr1a/b-/-, Bcrp1-/-, and Mdr1a/b-/-Bcrp1-/- mice. 
 
The mice were sacrificed after 1 (A) and 4hr (B) post dose of vemurafenib and 
the whole brain and plasma were analyzed using LC-MS/MS. The B/P ratios 
were significantly higher in Mdr1a/b-/-Bcrp1-/- mice than the wild type mice at both 
1 and 4hr post dose. A *** indicates a p value of <0.0001. Data are mean ± SD; 
n=3-4 for all data points.  
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Figure 2.7: Steady state brain distribution of vemurafenib in FVB wild type, 
Mdr1a/b-/- (P-gp knockout), Bcrp1-/- (BCRP knockout), and Mdr1a/b-/-Bcrp1-/- 
(triple knockout) mice. 
 
Vemurafenib was delivered at a constant infusion for 48 hrs at a rate of 25µg/hr, 
and the brain and plasma concentrations were determined thereafter. Panel A 
shows the steady state brain and plasma concentrations of vemurafenib, and 
panel B shows the B/P ratio in all four type mice. The B/P ratios were not 
significantly different in single knockout mice when compared to wild type mice. 
However the B/P ratio in triple knockout mice was significantly higher than the 
wild type mice, indicating the “cooperative” role of P-gp and Bcrp at the blood-
brain barrier. A *, and *** indicates a p value of <0.01 and <0.0001 respectively. 
Data are mean ± SD; n=3-4 for all data points. 
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Table 2.1: Vemurafenib Pharmacokinetic Parameters after an I.V. dose of 
2.5 mg/kg in FVB wild-type mice 
 
  Plasma Brain 
Terminal rate constant (min-1) 0.0051 0.0047 
Half-life ( min) 136 148 
Clearance (mL/min) 0.04  
Volume of Distribution (mL) 7.9  
AUC0 → t last (min · µg/mL) 1663 ± 140* 6.5 ± 0.9* 
AUCBrain/AUCPlasma         0.004 
 
Plasma and brain pharmacokinetic parameters were analyzed using non 
compartmental analysis after an i.v. dose of 2.5 mg/kg in FVB wild-type mice. 
The AUCbrain to AUCplasma ratio of 0.004 indicates the severely restricted brain 
distribution of vemurafenib.` 
* Mean ± SE (standard error of the estimate) 
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CHAPTER 3: MECHANISMS LIMITING DISTRIBUTION OF THE 
BRAFV600E INHIBITOR DABRAFENIB TO THE BRAIN: IMPLICATIONS 
FOR THE TREATMENT OF MELANOMA BRAIN METASTASES 
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Brain metastases are a common cause of death in stage IV metastatic melanoma. 
Dabrafenib is a BRAF inhibitor that has been developed to selectively target the valine 
600 to glutamic acid substitution (BRAFV600E) which is commonly found in metastatic 
melanoma. Clinical trials with dabrafenib are showing encouraging results, however the 
CNS distribution of dabrafenib remains unknown. Thus the objective of the current study 
was to evaluate the brain distribution of dabrafenib in mouse and to see whether active 
efflux by P-glycoprotein (P-gp) and Breast Cancer Resistance Protein (BCRP) restrict 
its delivery across blood-brain barrier (BBB). In vitro accumulation studies conducted in 
Madin-Darby canine kidney II (MDCKII) cells indicate that dabrafenib is an avid 
substrate for both P-gp and BCRP. Directional flux studies revealed greater transport in 
basolateral to apical direction with corrected efflux ratios of greater than 2 for both P-gp 
and Bcrp1 transfected cell lines. In vivo, the Kp (AUCbrain / AUCplasma) of dabrafenib after 
an iv dose (2.5 mg/kg) was 0.023, which increased by 18-fold in Mdr1 a/b-/-Bcrp1-/- mice 
to 0.42. Dabrafenib plasma exposure was ~2-fold greater in Mdr1 a/b-/-Bcrp1-/- mice as 
compared to wild-type with an oral dose (25 mg/kg), however the brain distribution was 
increased by ~10-fold with a resulting Kp of 0.25. Further, compared to vemurafenib, 
another BRAFV600E inhibitor, dabrafenib has greater brain penetration with a similar 
dose. In conclusion, the dabrafenib brain distribution is limited in an intact BBB model 
and the data presented herein may have clinical implications in the prevention and 
treatment of melanoma brain metastases.  
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3. 1 Introduction     
Melanoma is the most aggressive form of skin cancer as it accounts for more than 80% 
of deaths due to skin cancer. The incidence of melanoma has greatly increased over 
the past decade (Siegel et al., 2011). Extensive data in the literature point to the key 
role of mitogen-activated protein kinase (MAPK) pathway in melanoma pathogenesis. 
The MAPK pathway is involved in regulation of melanoma cell proliferation, growth, and 
survival. The downstream effectors of this signaling cascade include RAS-RAF-MEK-
ERK (McCubrey et al., 2008). BRAF is a commonly mutated protein in melanoma, with 
~80% carrying a V600E (BRAFV600E) mutation (Davies et al., 2002). Thus, targeting this 
pathway represents an attractive therapeutic approach for melanoma. 
Until recently, treatment options for melanoma were limited with no improvement 
in overall survival rates (Tsao et al., 2004; Garbe et al., 2011). However, in recent years 
there has been a tremendous improvement in the treatment of melanoma. Targeting 
BRAFV600E has proved to be a major advancement in the field of melanoma treatment 
(Flaherty et al., 2012; Sosman et al., 2012). For example, the recently US FDA 
approved drug, vemurafenib, a BRAFV600E inhibitor, showed remarkable efficacy against 
peripheral metastases (Chapman et al., 2011). However, brain metastases are 
prevalent in stage IV metastatic melanoma. This situation is alarming because ~50-75% 
of melanomas metastasize to the brain (Fife et al., 2004), and among those patients 
who have brain metastases, ~90% succumb to death (Skibber et al., 1996). The efficacy 
of vemurafenib in brain metastases of melanoma is under clinical investigation. Recent 
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preclinical studies have indicated that vemurafenib distribution is restricted at blood-
brain barrier (BBB) (Durmus et al., 2012; Mittapalli et al., 2012). 
Dabrafenib (GSK2118436A, Figure 3.1) targets both BRAFV600E and BRAFV600k. 
Dabrafenib showed very encouraging results in a phase 1 dose escalation study 
(Falchook et al., 2012; Hauschild et al., 2012). The safety and clinical response of 
dabrafenib against peripheral metastases is comparable with that of vemurafenib, with 
an objective response of ~56% (Gibney and Sondak, 2012; Hauschild et al., 2012). 
Further, ~90% (9 out of 10 patients) of the patients with melanoma brain metastases 
had a reduction in tumor size (Falchook et al., 2012). However, important questions 
remain about the effective delivery to all sites of brain metastases, especially to the 
micro metastases which are situated beyond an intact blood-brain barrier (BBB). In a 
recent study, using preclinical model of brain metastases from breast cancer, it was 
shown that the blood-tumor barrier remains a significant impediment to 
chemotherapeutic drugs (Lockman et al., 2010). However, to date there are no data 
available in terms of drug delivery to brain metastases of melanoma. Further, it was 
shown that treatment of peripheral disease with targeted therapy increases the 
incidence of brain metastases (Rochet et al., 2012). A phase 2 clinical trial evaluating 
the efficacy of dabrafenib in brain metastases of melanoma is underway (Long et al., 
2012) (clinicaltrials.gov identifier: NCT01266967). With this perspective, it is imperative 
to study the brain distribution of dabrafenib to provide a rationale to support clinical 
trials.  
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A critical challenge in treating brain metastases or in fact any neurological 
disorder is the delivery of drugs to the central nervous system. The BBB, an interface 
between blood and the brain, helps maintain homeostasis of the CNS and protects the 
brain from harmful toxins, metals and infectious agents (Deeken and Loscher, 2007). 
Together with capillary endothelial cells and tight junctions, it acts as a physical barrier 
(Hawkins and Davis, 2005). Further, with the expression of active efflux transporters 
such as P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP), it acts a 
functional barrier (Schinkel and Jonker, 2003). Several anticancer agents have been 
shown to be substrates for both P-gp and BCRP and as such the brain distribution of 
these molecules is limited because of active efflux at the BBB (de Vries et al., 2007; 
Polli et al., 2009; Agarwal et al., 2010; Agarwal et al., 2011; Mittapalli et al., 2012).  
In our previous study, we have shown that the brain distribution of vemurafenib is 
severely restricted at BBB due to active efflux by both P-gp and BCRP (Mittapalli et al., 
2012). Given the highly encouraging clinical results with dabrafenib, the aim of the 
present study was to evaluate the brain distribution of dabrafenib in mouse, with the 
hope that these preclinical data would help in further improvement of a durable 
response in melanoma brain metastases patients. Using both in vitro transport studies 
and in vivo pharmacokinetic studies, we show that dabrafenib is a substrate for both P-
gp and Bcrp and as such its brain distribution is limited in an intact BBB model. The 
data presented herein have clinical implications in the prevention or treatment of 
melanoma brain metastases because of concerns that sub-therapeutic concentrations 
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in the brain or at sites of micro metastases with an intact BBB would result in limited 
anti-tumor activity.  
3. 2 Materials and Methods 
3. 2. 1 Chemicals 
 Dabrafenib (GSK2118436A) was purchased from Chemietek (Indianapolis, IN). [3H]-
vinblastine and [3H]-mitoxantrone were purchased from Moravek Biochemicals (La 
Brea, CA). [3H]-prazosin was purchased from PerkinElmer Life and Analytical Sciences 
(Waltham, MA). [14C]-Inulin was purchased from American Radiolabeled Chemicals, Inc. 
(St. Louis, MO). Ko143 was purchased from Tocris Bioscience (MO, USA). Zosuquidar 
[LY335979, (R)-4-((1aR, 6R,10bS)-1,2-difluoro-1,1a,6,10b-tetrahydrodibenzo-(a,e) 
cyclopropa ( c)cycloheptan-6-yl)-((5-quinoloyloxy) methyl)-1-piperazine ethanol, 
trihydrochloride] was kindly provided Eli Lilly and Co.(Indianapolis, IN). All other 
chemicals used were of high performance liquid chromatography or reagent grade and 
were obtained from Sigma-Aldrich (St. Louis, MO).  
3. 2. 2 In vitro studies 
Polarized Madin-Darby canine kidney II (MDCKII) cells were used for all the in vitro 
studies. MDCKII-Wild-type (WT) and Bcrp1-transfected (MDCKII-Bcrp1) cells were a 
kind gift from Dr. Alfred Schinkel (The Netherlands Cancer Institute). MDCKII-WT and 
MDR1-transfected (MDCKII-MDR1) cell lines were kindly provided by Dr. Piet Borst 
(The Netherlands Cancer Institute). Cells were cultured in Dulbecco’s modified Eagle’s 
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medium supplemented with 10% (v/v) fetal bovine serum and antibiotics (penicillin, 100 
U/mL; streptomycin, 100 µg/mL; and amphotericin B, 250 ng/mL). Cells were grown in 
25 mL tissue culture treated flasks before seeding for the experiments and were 
maintained at 37º C in a humidified incubator with 5% CO2.  The growth media for 
MDCKII-MDR1 additionally contained 80 ng/ml of colchicine to maintain positive 
selection pressure of P-gp expression. 
3. 2. 2. 1 In vitro cellular accumulation 
 Cellular accumulation studies were performed in 12-well polystyrene plates with 
a seeding density of 2 x 105 cells per well, and media was changed every other day until 
confluent monolayers are formed. The cells were washed two times with warm cell 
assay buffer (122 mM NaCl, 25 mM NaHCO3, 10 mM glucose, 10 mM HEPES, 3 mM 
KCl, 2.5 mM MgSO4, 1.8 mM CaCl2, and 0.4 mM K2HPO4) on the day of the experiment, 
and preincubated with cell assay buffer for 30 min. The cell assay buffer was aspirated 
after pre-incubation period, and the experiment was initiated by adding one ml of 2 µM 
of dabrafenib to each well and further incubated for 60 min in an orbital shaker (60 rpm) 
that was maintained at 37º C. At the end of 60 min accumulation, the experiment was 
ended by aspirating the dabrafenib solution followed by washing twice with ice-cold 
PBS. Cell lysis was accomplished by adding 0.5 milliliters of 1 % Triton-X. When the 
inhibitor was present it was included in both pre-incubation and accumulation steps. The 
concentration of dabrafenib in solubilized cell fractions was analyzed using liquid 
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chromatography-tandem mass spectrometry (LC-MS/MS) as described below, and was 
normalized to the protein content. 
3. 2. 2. 2 Bcrp and P-gp inhibition studies 
Inhibition studies were performed using prototypical probe substrates, [3H]-prazosin or 
[3H]-mitoxantrone for Bcrp and [3H]-vinblastine for P-gp. The intracellular accumulation 
of these probe substrates was evaluated in presence of varying concentrations of 
dabrafenib ranging from 0.1 to 50 µM. Briefly, the cells were pre-incubated with 
increasing concentrations of dabrafenib for 30 min. After pre-incubation the cells were 
incubated with radiolabelled probe substrate along with increasing concentrations of 
dabrafenib for 60 min. At the end of the incubation period, the radiolabelled probe 
substrate was aspirated; cell lysis was accomplished using 1% Triton-X. The 
radioactivity in solubilized cell fractions was determined by liquid scintillation counting 
(LS-6500; Beckman Coulter, Fullerton, CA). The radioactivity in cell fractions was 
normalized to protein concentrations in each well. The increase in cellular accumulation 
of probe substrate as compared to control (no treatment with dabrafenib) was measured 
and reported as a function of dabrafenib concentration. 
3. 2. 2. 3 Directional flux studies 
The bidirectional transport assays were performed in 12-well Transwell® plates 
(polyester membrane, 0.4 µM pore size, 1.12 cm2 growth surface area; Corning Inc., 
USA). The cells were seeded at a density of 2 x105 cells per well and the media was 
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changed every other day until confluent monolayers were formed. The monolayer 
tightness was assessed by measurement of trans-epithelial electrical resistance 
(TEER). In parallel, the cell monolayer integrity was evaluated by analyzing the leakage 
of [14C]-Inulin using the same passage cells seeded on the same day and at the same 
density.  
On the day of the experiment, the cell monolayers were washed with pre-warmed 
cell assay buffer and preincubated for 30 minutes after which the experiment was 
initiated by adding 5 µM of dabrafenib solution in cell assay buffer to the donor 
compartment. Samples (100 µL) were collected from receiver compartment at 60, 120, 
and 180 min and replaced immediately with drug-free cell assay buffer. In addition, at 
the beginning of the experiment, 100 µL of sample was collected from donor 
compartment and replaced with 100 µL drug solution. The Transwell® assay plates were 
incubated in an orbital shaker (60 rpm) maintained at 37 °C for the duration of 
experiment except for the brief sampling times. In the inhibition experiments, either 0.2 
µM Ko143 (selective Bcrp inhibitor) or 1 µM of zosuquidar (selective P-gp inhibitor) was 
added to both apical (A) and basolateral (B) compartments. Dabrafenib concentration 
was measured by LC-MS/MS. The apparent permeability (Papp), in A-to-B and B-to-A 
directions, was calculated as follows: Papp = (dQ/dt) (1/A x C0), where dQ/dt is the slope 
obtained from the initial linear range from the amount transported versus time graph, A 
is the area of the Transwell® membrane, and C0 is the initial donor concentration. The 
efflux ratio (ER) and the corrected efflux ratio (CFR) were calculated as follows: Efflux 
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ratio = [Papp (B → A) / Papp (A → B)]; Corrected efflux ratio = (Efflux ratio in transfected 
cells) / (Efflux ratio in wild-type cells); where, A→B represents permeability in apical to 
basolateral and B→A represents permeability in basolateral to apical direction. 
3. 2. 2. 4 Equilibrium dialysis experiments 
Unbound fractions in mouse plasma and brain homogenates were determined using 
equilibrium dialysis cassettes (Fisher Scientific, Acrylic, 1mL) as described by Kalvass 
et.al. (Kalvass et al., 2007). For initial pilot studies commercial mouse plasma (Valley 
Biomedical, Winchester, VA) and pooled brain homogenates from wild-type and 
knockout mice were used to determine the time to reach the equilibrium (Supplemental 
Fig. 3.3). Once the time to reach equilibrium was determined, the free fraction 
experiments were performed in plasma and brains isolated freshly from either wild-type 
or Mdr1a/b-/-Bcrp1-/- mice. Spectra/por® dialysis membranes (MWCO: 12-14000 Da; 
Spectrum Laboratories, Inc. CA) were equilibrated in HPLC-water for 30 min followed by 
30 min in ECF buffer (pH 7.4). Three volumes of ECF buffer was added to the brain 
tissue and homogenized to get a uniform homogenate. Dabrafenib was added to 
plasma and brain homogenate to achieve a final concentration of 2 µM; 1 ml was (n =3) 
loaded into the equilibrium dialysis cassette and dialyzed against an equal volume of 
ECF buffer (pH 7.4) in an orbital shaker (200 rpm) maintained at 37 °C. Equilibrium was 
achieved in ~ 6 hrs in both plasma and brain homogenates (Supplemental Fig. 3.3). At 
the end of the experiment, matrix (plasma or brain homogenate) and buffer samples 
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were removed from dialysis cassette and the concentrations of dabrafenib were 
measured using LC-MS/MS. 
3. 2. 3 In vivo studies 
All of the in vivo studies were performed in FVB (wild-type) and Mdr1a/b-/-Bcrp1-/- 
(triple knockout) mice of either sex of a FVB genetic background (Taconic Farms, 
Germantown, NY). All animals were 8 to 10 weeks old at the time of experiment. 
Animals were maintained in a 12 hr light/dark cycle with an unlimited access to food and 
water. All studies were carried out in accordance with the guidelines set by the 
Principles of Laboratory Animal Care (National Institutes of Health, Bethesda, MD) and 
approved by the Institutional Animal Care and Use Committee of the University of 
Minnesota. 
3. 2. 3. 1 Plasma and brain pharmacokinetics of dabrafenib after intravenous and 
oral administration 
All dosing formulations of dabrafenib were prepared on the day of the experiment. 
Dabrafenib dosing formulations were prepared either as a solution in a vehicle 
containing DMSO, propylene glycol, and water (40:40:20; for i.v. dosing studies) or as a 
stable suspension in 1% carboxy methyl cellulose (for oral dosing studies). 
In the first study, FVB wild-type and Mdr1a/b-/-Bcrp1-/- mice were administered an 
i.v. dose of 2.5 mg/kg via the tail vein. Blood and brain samples were collected 5, 15, 
30, 60, and 120 min post dose (n =4 at each time point). Animals were euthanized using 
  78
a CO2 chamber at the desired time point. Blood was collected by cardiac puncture and 
plasma was harvested. Whole brain was removed from the skull and washed with ice-
cold PBS; superficial meninges were removed by blotting with tissue paper. Plasma and 
brain specimens were stored at -80° C until further analysis.  
In another study, FVB wild-type and Mdr1a/b-/-Bcrp1-/- mice were administered 25 
mg/kg dabrafenib via oral gavage. Blood and brain samples were harvested at 15, 30, 
60, 120, and 240 min post dose (n =4 at each time point) as described above. Brain 
concentrations were corrected for residual drug in brain vasculature assuming a 
vascular volume of 1.4% in mouse brain (Dai et al., 2003). 
3. 2. 4 LC-MS/MS Analysis 
The concentrations of dabrafenib from all in vitro and in vivo studies were determined 
using a specific and sensitive LC-MS/MS assay. Brain samples were thawed to room 
temperature and homogenized with three volumes of 5% bovine serum albumin in PBS. 
An aliquot of sample (cell lysate, cell assay buffer, plasma, or brain homogenate) was 
spiked with 10 ng of internal standard [AG1478; (4-(3-chloroanilino)-6,7-
dimethoxyquinazoline)] and liquid-liquid extraction was performed by addition of 10 
volumes of ethyl acetate. After extraction, the supernatant organic layer was transferred 
to a micro-centrifuge tube and dried under gentle stream of nitrogen. The dried sample 
was reconstituted in 100 µL of mobile phase, vortex-mixed, centrifuged, transferred to 
auto sampler vials, and a 5 µL sample was injected onto the column, a Zorbax Eclipse 
XDB-C18 column (4.6 x 50 mm, 1.8 µm particle size; Agilent Technologies, Santa Clara, 
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CA). The aqueous mobile phase (A) was 20 mM ammonium formate with 0.1% formic 
acid and the organic mobile phase (B) was acetonitrile. The gradient was as follows: 
50% B for the first 3 min, and increased to 90% B from 3 to 3.5 min and maintained at 
90% B for 3 min, and decreased to 50% B within 0.5 min. The total run time was 11 min 
with a flow rate of 0.35 mL/min. The ionization was conducted in positive mode and the 
m/z transitions were 520.122 → 307.007, and 316.068 → 299.993 for dabrafenib and 
AG1478, respectively. The retention time of dabrafenib was 6.8 min and that of AG1478 
was 2.8 min. The assay was sensitive and linear over a range of 2 ng/mL to 2 µg/mL, 
with the coefficient of variation being less than 20% over the entire range. 
3. 2. 5 Pharmacokinetic calculations 
Pharmacokinetic parameters and metrics from the concentration-time data in plasma 
and brain were obtained by non-compartmental analysis (NCA) performed using 
Phoenix WinNonlin 6.2 (Mountain View, CA). The area under the concentration-time 
profiles for plasma (AUCplasma) and brain (AUCbrain) were calculated using the linear 
trapezoidal method. The sparse sampling module in WinNonlin 6.2 (Pharsight, Mountain 
View, CA) was used to estimate the standard error around the mean of the AUCs 
(Bailer, 1988; Nedelman et al., 1995).  
3. 2. 6 Statistical Analysis  
Data in all experiments represent mean ± SD unless otherwise indicated. One way 
ANOVA, followed by Bonferonni’s multiple comparisons test, was utilized to compare 
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multiple groups. Comparisons between two groups were made using an unpaired t-test. 
A significance level of p <0.05 was used for all experiments. (Graph Pad Prism 5.01 
software, San Diego, CA, USA).  
3. 3 Results: 
3. 3. 1 In vitro accumulation of dabrafenib in MDCKII-Bcrp1 and MDCKII-MDR1 
cells 
The cellular accumulation of dabrafenib in MDCKII- wild-type, Bcrp1, and MDR1 
transfected cell lines is summarized in Fig. 3.2. [3H]-prazosin and [3H]-vinblastine were 
used as positive controls for Bcrp and MDR1, respectively, and as expected, the cellular 
accumulation of these probe substrates were significantly lower as compared to wild-
type controls [ WT: (100 ± 8); Bcrp1: (16.7 ± 1.4); MDR1: (11.6 ± 3.1);] confirming 
significant  transporter activity in these transfected cell lines. We choose a concentration 
of 2 µM for dabrafenib accumulation studies as the pilot studies revealed that no 
saturation of transporters occur up to 75 µM of dabrafenib (Supplemental Fig. 3.1). 
Dabrafenib accumulation was significantly lower in Bcrp1 cells [Fig. 3.2A, Bcrp: (11.3 ± 
1.4); WT: (100 ± 10); p < 0.001] when compared to corresponding wild-type controls. 
The addition of 0.2 µM of Ko143, a specific Bcrp1 inhibitor, increased dabrafenib 
accumulation, such that it was not significantly different than wild-type control. Likewise, 
dabrafenib accumulation in MDR1 transfected cell lines (Fig. 3.2B) was ~ 65% lower 
when compared wild-type control and the difference was abolished when 1 µM of 
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LY335979 was used. These data indicate that dabrafenib is a substrate for both P-gp 
and Bcrp1 and inhibition of these efflux transporters enhance the cellular delivery of 
dabrafenib. 
3. 3. 2 Competition assays using prototypical probe substrates 
The effect of increasing concentrations of dabrafenib on the cellular accumulation of 
prototypical probe substrates (prazosin or mitoxantrone for Bcrp, vinblastine for P-gp) 
was assessed in MDCKII-wild-type, Bcrp1 and MDR1 transfected cell lines. Increasing 
concentrations of dabrafenib did not increase the accumulation of [3H]-prazosin in both 
Bcrp cells as well as the respective wild-type control cells (Fig. 3.3A). Similarly, 
increasing dabrafenib concentrations did not increase the accumulation of [3H]-
vinblastine until 25 µM was reached, however at 50 µM of dabrafenib, there was ~1.5 
and 2.5 fold increase in vinblastine accumulation in wild-type and MDR1 cells, 
respectively (Fig. 3.3B). Furthermore, dabrafenib did not change the cellular 
accumulation of mitoxantrone in Bcrp1 cells (Supplemental Fig. 3.2).  
3. 3. 3 Directional transport studies 
The directional transport of dabrafenib was assessed using monolayers of MDCKII-wild-
type, Bcrp1, and MDR1 transfected lines grown on Transwell® permeable membranes. 
Confluent monolayers were formed in 3 to 4 days with intact tight junctions. Paracellular 
leakage was assessed by measuring the transport of [14C]-Inulin across the cell 
monolayers and the inulin transported in 60 min was found to be less than 1%. The 
  82
directional permeability of dabrafenib was very similar between A-to-B and B-to-A 
directions in the wild-type cells (11.5 ± 1.4 vs 14.1 ± 1.4 x 10-6 cm/s for A-to-B and B-to-
A, respectively; Table 3.1). However in the Bcrp1 transfected cell line, the apparent 
permeability of dabrafenib in B-to-A direction was significantly higher than the 
permeability in A-to-B direction [A-to-B: (1.3 ± 0.3); B-to-A: 27.3 ± 4.1), p < 0.05; Table 
3.1) with and efflux ratio of 21. Treatment with Ko143 significantly (p < 0.05) reduced 
the Bcrp1-mediated efflux of dabrafenib in B-to-A direction and increased the A-to-B 
permeability with a resulting efflux ratio of 0.7. The corrected efflux ratio was found to be 
~18 for Bcrp1 mediated transport. Similarly, in MDR1 cells the B-to-A permeability was 
significantly higher compared to A-to-B permeability with an efflux ratio of 11. Addition of 
LY335979, a specific P-gp inhibitor, abolished the difference in directional permeabilities 
with a resulting efflux ratio of 1 (Table 3.2). The corrected efflux ratio was ~4. These 
results conclusively indicate that dabrafenib is an avid substrate for both Bcrp1 and P-
gp. 
3. 3. 4 Plasma protein and brain tissue binding 
Since it is the unbound drug concentration that results in pharmacological action, we 
determined the free fraction (fu) in plasma and brain tissue homogenates. Dabrafenib is 
highly bound to plasma proteins as well as brain tissue. No significant difference was 
observed in free fraction in plasma and brain tissue homogenate when compared 
between wild-type and Mdr1a/b-/-Bcrp1-/- mice genotypes [Wild-type: (fu, plasma = 0.004 ± 
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0.001), (fu,brain homogenate = 0.02 ± 0.003); Mdr1a/b-/-Bcrp1-/-: (fu, plasma = 0.006 ± 0.004), 
(fu,brain homogenate = 0.02 ± 0.005)].  
3. 3. 5 Brain distribution of dabrafenib in FVB wild-type and Mdr1a/b-/-Bcrp1-/- mice 
 The brain and plasma dabrafenib concentration time profiles after an i.v. dose of 2.5 
mg/kg in FVB wild-type mice are summarized in Fig. 3.4. The brain concentrations of 
dabrafenib were significantly lower than the corresponding plasma concentrations at all 
measured time points. The pharmacokinetic parameters were summarized in Table 3.3. 
The brain-to-plasma partitioning (Kp, AUCbrain / AUCplasma) was found to be 0.023, 
indicating the limited distribution of dabrafenib to the brain. We also investigated the 
brain distribution of dabrafenib in Mdr1a/b-/-Bcrp1-/- mice after a 2.5 mg/kg i.v. dose of 
dabrafenib. The plasma concentrations were no different between wild-type and 
Mdr1a/b-/-Bcrp1-/- mice (Fig. 3.5A), however the brain concentrations of dabrafenib in 
Mdr1a/b-/-Bcrp1-/- mice (Fig. 3.5B) were significantly higher than the corresponding brain 
concentrations observed in wild-type mice. The Kp in Mdr1a/b-/-Bcrp1-/- mice increased 
to ~0.4 which was 18-fold greater than what was observed in wild-type mice indicating 
the influence of P-gp, Bcrp or both on the brain distribution of dabrafenib. 
 Dabrafenib is administered to patients orally (Falchook et al., 2012) and we 
sought to determine the brain and plasma pharmacokinetics after an oral dose. Hence, 
in a separate study, we investigated the brain distribution of dabrafenib after an oral 
dose of 25 mg/kg in wild-type and Mdr1a/b-/-Bcrp1-/- mice, and the results are 
summarized in Fig. 3.6 and Table 3.4. The AUCplasma in Mdr1a/b-/-Bcrp1-/- mice (31 ± 5 
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µg x min/mL) was ~2-fold higher as compared to the wild-type mice (16 ± 3 µg x 
min/mL). This indicates that P-gp and Bcrp may have some influence on the oral 
absorption or systemic clearance of dabrafenib at 25 mg/kg dose. Dabrafenib brain 
concentrations were significantly enhanced in Mdr1a/b-/-Bcrp1-/- mice compared with 
those in wild-type. The AUCbrain in wild-type mice was 0.69 µg x min/mL which 
increased approximately 10-fold in Mdr1a/b-/-Bcrp1-/- to 7.6 µg x min/mL. The Kp in wild-
type mice was 0.044, which increased by 6 fold in Mdr1a/b-/-Bcrp1-/- mice to 0.25. The 
aggregate of these data suggests that the brain distribution of dabrafenib is significantly 
limited at BBB due to active efflux by both P-gp and BCRP after either intravenous or 
oral administration. 
3. 3. 6 Comparison of brain distribution of dabrafenib with vemurafenib 
We compared the brain distribution of dabrafenib after single oral dose with our 
previously published results for vemurafenib (Mittapalli et al., 2012) and the data were 
shown in Fig. 3.7. The plasma concentrations, for both dabrafenib and vemurafenib, 
were higher in the Mdr1a/b-/-Bcrp1-/- mice as compared to wild-type mice (Fig. 3.7A). It 
should be noted that the plasma concentrations of dabrafenib were not significantly 
different as compared to vemurafenib in either type of the mice. Since the total brain 
distribution of vemurafenib was approximately equal to the brain vascular volume, for 
comparison purposes, the data shown in this particular case was not corrected for 
vascular content for both dabrafenib and vemurafenib. The brain concentrations of 
dabrafenib were significantly higher as compared to vemurafenib brain concentrations in 
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both wild-type and Mdr1a/b-/-Bcrp1-/- mice (Fig. 3.7B). The brain-to-plasma 
concentration ratio for dabrafenib is ~10, ~4 fold greater compared to vemurafenib brain 
to plasma ratio in wild-type and Mdr1a/b-/-Bcrp1-/- mice, respectively [Wild-type: 
dabrafenib: (0.1 ± 0.03); vemurafenib: (0.008 ± 0.001); Mdr1a/b-/-Bcrp1-/-: dabrafenib: 
(0.3 ± 0.04); vemurafenib: (0.07 ± 0.02);]. The aggregate of these data indicate that 
dabrafenib has greater brain penetration than vemurafenib. 
3. 4 Discussion 
Brain metastases are a common cause of death from stage IV metastatic 
melanoma (Skibber et al., 1996; Davies et al., 2011). Until 2011, the only FDA approved 
therapies for metastatic melanoma were dacarbazine and interleukin-2, which showed 
response rates of only 10-20% (Comis, 1976; Atkins et al., 1999; Garbe et al., 2011). 
However, therapies for metastatic melanoma have been changed dramatically with the 
development of highly selective inhibitors of BRAFV600E, the most commonly found 
mutation in melanoma patients. The first of these selective BRAFV600E inhibitors, 
vemurafenib was approved by US FDA in 2011, and showed remarkable efficacy in 
clinical trials (Chapman et al., 2011). A second BRAFV600E inhibitor, dabrafenib, showed 
similar results when compared to vemurafenib, with fewer adverse effects in clinical 
trials (Falchook et al., 2012; Hauschild et al., 2012). Further, dabrafenib showed 
remarkable efficacy in reducing the tumor size in brain of patients with brain metastases 
(Falchook et al., 2012). However, a durable response depends on effective delivery of 
therapies to all the sites of metastases in brain, especially to the micrometastases (less 
  86
than 1 mm in diameter) that have an intact BBB (Gibney and Sondak, 2012) with 
functional efflux transporters. Furthermore, in a recent study, Rochet and colleagues 
reported that treatment of melanoma patients with vemurafenib resulted in development 
of metastatic disease in the brain (Rochet et al., 2012). From these data, it appears that 
the brain remains at least in part a pharmacological sanctuary site due to the continued 
presence of an intact BBB where some metastatic sites reside. The efficacy of 
dabrafenib in brain metastases of melanoma is under investigation in a phase 2 clinical 
trial. With this perspective, it is critical to determine the mechanisms that limit the brain 
distribution of dabrafenib. In the current study, using both in vitro and in vivo models, we 
demonstrate that dabrafenib is a dual substrate for BCRP and P-gp and its brain 
distribution is limited due to active efflux at the BBB. Furthermore, our data indicate that 
dabrafenib has greater brain distribution when compared to vemurafenib and as such 
dabrafenib might have some advantages for treating patients with melanoma brain 
metastases. To the best of our knowledge, this is the first report to show the brain 
distribution of dabrafenib and its interactions with Bcrp and P-gp. 
The experiments performed in transfected MDCKII cells that overexpress either 
murine Bcrp or human P-gp revealed that dabrafenib is a dual substrate for both Bcrp 
and P-gp (Fig. 3.2, Tables 1 and 2). Interestingly, inhibition studies conducted using 
prototypical probe substrates (prazosin and mitoxantrone for Bcrp, and vinblastine for P-
gp) showed no increase in probe substrate accumulation with increasing concentrations 
of dabrafenib up to a concentration of 50 and 25 µM in Bcrp1 and MDR1 cells, 
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respectively. In both wild-type and MDR1 cells, using vinblastine as a probe substrate, 
dabrafenib showed significant increase in accumulation at 50 µM. However, it should be 
noted that this concentration is not pharmacologically relevant, as the clinically 
observed concentrations of dabrafenib (given 150 mg/kg twice daily) are ~ 2 µM 
(Falchook et al., 2012). 
It should be noted that specific Bcrp (Ko143) and P-gp (LY335979) inhibitors 
were able to increase cellular accumulation of dabrafenib (Fig. 3.2), as well as the 
probe substrates (Fig. 3.3), in both Bcrp1 and MDR1 cells, respectively, indicating that 
Ko143 and LY335979 bind to multiple binding sites on the transporter proteins. The fact 
that dabrafenib is a substrate for both Bcrp and P-gp, but does not inhibit these 
transporter proteins for some prototypical probe substrates, may indicate that 
dabrafenib is binding to a different site on the transporter protein as compared to the 
probe substrates tested. It is noteworthy to recognize how screening assays using 
specific binding site probe substrates can be misleading. In our previous studies, we 
have shown that differences exist in the inhibition of BCRP depending on both the 
inhibitor used and the substrate under evaluation (Giri et al., 2009).  
With this knowledge from in vitro data, we next investigated the in vivo brain 
distribution of dabrafenib in mouse. After an i.v. dose, the brain concentrations of 
dabrafenib in FVB wild-type mice were significantly lower than the corresponding 
plasma concentrations (Fig. 3.4), with a Kp of 0.023. However, the brain distribution of 
dabrafenib was significantly improved when the same dose was administered in 
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Mdr1a/b-/-Bcrp1-/- mice, with a resulting Kp of 0.42 (Table 3.3). It is worth noting that the 
unbound brain-to-plasma partition ratio (Kp,uu)  in wild-type and Mdr1a/b-/-Bcrp1-/- mice 
were ~0.1 and ~1.7, respectively. These data indicate that dabrafenib brain distribution 
is limited in an intact BBB model through the action of efflux transporter mediated 
clearance.  
Since the clinical use of dabrafenib utilizes chronic oral dosing, we next 
determined the brain distribution of dabrafenib after oral administration. The AUCplasma 
in Mdr1a/b-/-Bcrp1-/- mice is ~2-fold higher (Fig. 3.6A; Table 3.4) as compared to wild-
type mice after oral administration. As the systemic clearance is no different between 
the genotypes after an i.v. dose (see Fig. 3.5; Table 3.3), the observed higher plasma 
exposure in Mdr1a/b-/-Bcrp1-/- mice after oral dose indicate that BCRP and P-gp may 
have some influence on oral absorption of dabrafenib at 25 mg/kg dose. This 
phenomenon was observed with other drugs that are dual substrates of BCRP and P-
gp, such as dasatinib (Lagas et al., 2009) and vemurafenib (Durmus et al., 2012). 
However the brain concentrations are ~12-fold higher in Mdr1a/b-/-Bcrp1-/- mice resulting 
in a ~6-fold increase in B/P ratio as compared to wild-type mice. Taken together, all 
these data indicate that dabrafenib brain distribution is limited in an intact BBB model. In 
this regard, use of pharmacological inhibitors such as elacridar, a dual P-gp and Bcrp 
inhibitor, may have significant value in improving the CNS distribution of dabrafenib. 
Since both dabrafenib and vemurafenib are showing remarkable results in clinical 
trials, it is appropriate to compare these two molecules in terms of their brain 
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distribution. In our previous study, we have shown that both BCRP and P-gp have a 
significant impact on the brain distribution of vemurafenib (Mittapalli et al., 2012), which 
was further supported by a recently published report by another group (Durmus et al., 
2012). Compared to vemurafenib (Mittapalli et al., 2012) the B/P ratio of dabrafenib is 
significantly higher in both wild-type and Mdr1a/b-/-Bcrp1-/- mice (Fig. 3.7). While the B/P 
ratio in this case was measured only at one time point, we also observed a greater 
AUCbrain to AUCplasma of dabrafenib in wild-type mice after a similar i.v. dose as 
compared vemurafenib (Table 3.5). Given the in vitro potency of dabrafenib, which is at 
least 40 times higher than vemurafenib against BRAFV600E [vemurafenib IC50: 31 nM 
(Bollag et al., 2010); dabrafenib IC50: 0.8 nM (Laquerre et al., 2009)], and greater brain 
penetration than vemurafenib, dabrafenib might be beneficial in treating melanoma 
brain metastases, however this prediction warrants further preclinical and clinical 
investigation.  
Currently, the duration of response with single agent therapy has been limited 
because the development of resistance is inevitable, as reported in case of vemurafenib 
(Johannessen et al., 2010; Nazarian et al., 2010; Villanueva et al., 2010). Further, 
studies have shown that mutations in upstream signaling proteins such as RAS or 
compensatory signaling from other growth factor receptors such as PI3K/mTOR drive 
the reactivation of the MAPK signaling pathway and build up the resistance to BRAF 
therapy (Flaherty et al., 2012). Thus, understanding the key molecular aberrations 
associated with resistance will be crucial in designing the rational combinations using 
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two or more drugs to simultaneously block multiple pathways, such as the clinical trial 
evaluating the combination of dabrafenib with the MEK inhibitor trametinib 
(NCT01072175). Also, the evaluation of combinations of immune therapies such as 
ipilimumab (Margolin et al., 2012) and rational choices of molecularly-targeted agents 
would be valuable in overcoming the low response rates of immune therapy and short 
durations of response associated with targeted therapies. 
The development of BRAFV600E inhibitors has been a major breakthrough for the 
treatment of melanoma patients. However, challenges still remain in delivering these 
targeted therapies to melanoma micro metastases in brain that could be growing behind 
an intact BBB. Given the success rate so far with both dabrafenib and vemurafenib, it 
will be essential to determine the both the resistance mechanisms and CNS delivery 
issues that need to be addressed to achieve a durable response. Multiple drugs / 
cocktails need to be evaluated for rational combinations (e.g., a BRAF inhibitor and/or 
MEK inhibitor and/or PI3K/mTOR inhibitor) to decrease resistance in peripheral or 
systemic disease. At the same time, there is also a critical need to examine the CNS 
delivery of combinations to see if one agent influences the brain delivery of another, or 
one or more drug(s) in the combination does not reach the brain, leading to heightened 
resistance.  The successful and durable treatment of melanoma requires that the brain 
does not become a pharmacological sanctuary site for melanoma metastases. 
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Figures: 
 
Figure 3.1: Chemical structure of dabrafenib (GSK2118436A) 
 
 
 
  92
Figure 3.2: In vitro cellular accumulation of dabrafenib. 
 
Panel A shows the accumulation of prazosin (prototypical Bcrp probe substrate; positive 
control), and dabrafenib in MDCKII-wild-type and Bcrp1-transfected cell lines with and 
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without Bcrp inhibitor Ko143 (0.2 µM). The accumulation of dabrafenib and vinblastine 
(probe substrate for P-gp) in MDR1 cells with and without P-gp inhibitor LY335979 (1 
µM) is shown in Panel B. Data represent mean ± SD; n = 6 for all data points. ***, p < 
0.001 compared to respective wild-type control. #, p< 0.001 compared to untreated 
transfected cell line. 
 
  
9
4
 
 
Intracellular accumulation of [3H]-prazosin (Bcrp probe 
substrate), [3H]-vinblastine (P-gp probe substrate) in Bcrp1-
transfected (Panel A) and MDR1-transfected (Panel B) cell 
lines with increasing concentrations of dabrafenib from 0.1 µM 
to 50 µM. Ko: Bcrp inhibitor Ko143; LY: P-gp inhibitor 
LY335979. Data represent mean ± SD; n = 3 for all data points. 
**, p =0.0439 compared to untreated wild type cells. **, p 
=0.003 compared to untreated MDR1 cells.
Figure 3.3: Competition assays using prototypical probe substrate molecules 
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Figure 3.4: Brain and plasma concentration vs time profiles of dabrafenib 
 
Brain and plasma concentrations of dabrafenib after an i.v. dose of 2.5 mg/kg in 
FVB wild-type mice at 5, 15, 30, 60, and 120 minutes post dose. Brain 
concentrations of dabrafenib are significantly lower than plasma concentrations 
at all measured time points. Data represent mean ± SD, n = 3-4. *, **, ***, 
represent p< 0.05, p< 0.001, p<0.0001, respectively. 
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Figure 3.5: Brain distribution of dabrafenib in FVB wild-type and Mdr1a/b-/-Bcrp1-/- mice. 
 
Plasma concentration vs time (A), brain concentration vs time (B), and brain-to-plasma concentration ratios (C) of 
dabrafenib in wild-type and Mdr1a/b-/-Bcrp1-/- mice after an iv dose of 2.5 mg/kg. Plasma and brain concentrations were 
determined using LCMS/MS at 5, 15, 30, 60, and 120 minutes post dose of dabrafenib. Data represent mean ± SD, n = 3-
4. *, **, ***, represent p< 0.05, p< 0.001, p<0.0001, respectively. 
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Figure 3.6: Brain distribution of dabrafenib in FVB wild-type and Mdr1a/b-/-Bcrp1-/- mice after an oral dose. 
 
Plasma (A), brain (B) concentration vs. time profiles, and brain-to-plasma concentration ratios (C) of dabrafenib in wild-
type and Mdr1a/b-/-Bcrp1-/- mice after an oral dose of 25 mg/kg. Plasma and brain concentrations were determined using 
LCMS/MS at 15, 30, 60, 120, and 240 minutes postdose of dabrafenib. Data represent mean ± SD, n = 3-4. *, **, ***, 
represent p< 0.05, p< 0.001, p<0.0001, respectively. 
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Figure 3.7: Comparison of the brain distribution of dabrafenib and vemurafenib. 
 
Plasma (A), brain (B), and brain to plasma concentration ratios (C) of dabrafenib and vemurafenib in wild-type and 
Mdr1a/b-/-Bcrp1-/- mice after 1 hr postdose in separate animals (25 mg/kg, oral dose).  Vemurafenib data is from our 
previously published results (Mittapalli et al., 2012). Data represent mean ± SD, n = 3-4. A *, **, ***, represent p< 0.05, p< 
0.001, p<0.0001, respectively. 
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Table 3.1: Directional flux of dabrafenib in MDCKII-WT and MDCKII-Bcrp1 
transfected cell lines. 
A-to-B B-to-A
MDCKII-WT 11.5 ± 1.4 14.1 ± 1.4 1.2
MDCKII-WT + 0.2 µM Ko143 16.4 ± 0.9 15.3 ± 2.6 0.9
MDCKII-Bcrp1 1.3 ± 0.3* 27.3 ± 4.1* 21.0
MDCKII-Bcrp1 + 0.2 µM Ko143 13.2 ± 2.1
#
9.6 ± 0.33
# 0.7
CFR
-
17.5
Cell line
Papp (cm/s x10
-6
)
ER
 
Note:  
ER-Efflux ratio 
CFR: Corrected efflux ratio 
Papp: apparent permeability of dabrafenib 
*significantly different compared to respective wild-type control cells 
# significantly different compared to untreated Bcrp1 control cells 
Data represent mean ± SD; n = 3 
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Table 3.2: Directional flux of dabrafenib in MDCKII-WT and MDCKII-MDR1 
Cells. 
A-to-B B-to-A
MDCKII-WT 2.6 ± 1.0 7.7 ± 1.6 3.0
MDCKII-WT + 1 µM LY335979 5.5 ± 0.4 5.2 ± 0.7 0.90
MDCKII-MDR1 0.7 ± 0.3* 7.9 ± 1.9 11.4
MDCKII-MDR1 + 1 µM LY335979 4.9 ± 0.52
# 5.2 ± 1.4 1.1
CFR
-
3.8
Cell line
Papp (cm/s x10
-6
)
ER
 
 
Note:  
ER-Efflux ratio 
CFR: Corrected efflux ratio 
Papp: apparent permeability of dabrafenib 
*significantly different compared to respective wild-type control cells 
# significantly different compared to untreated MDR1 control cells 
Data represent mean ± SD; n = 3 
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Table 3.3: Comparison of Pharmacokinetic Parameters of Dabrafenib in 
FVB Wild-type and Mdr1a/b-/-Bcrp1-/-  Mice After an i.v. dose of 2.5 mg/kg. 
 
Wild-type Mdr1a/b-/-Bcrp1-/- Mice 
 
Plasma Brain Plasma Brain 
Terminal rate Constant (min-
1) 
0.03 0.036 0.024 0.026 
Half-life ( min) 23.7 19.1 28.3 26.6 
Clearance (mL/min/kg) 24.2 
 
28.4  
Volume of Distribution (L/kg) 0.83 
 
1.2  
AUC0 → t last (µg · min /mL)1 
120.9 ± 
15.8 
2.8 ± 0.4 101.4 ± 8.7 42.1 ± 3.4* 
Kp2 0.023 0.42 
Kp Ratio3 18.3 
   
 
1. Area under the curve from time zero to 2 hour post dose 
2. Kp = AUCbrain/AUCplasma 
3. Kp Ratio = (Kp in Mdr1a/b-/-Bcrp1-/- mice) / (Kp in wild-type mice) 
4.  *, p < 0.05 compared to wild-type AUCbrain 
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Table 3.4: Pharmacokinetic metrics in FVB wild-type and Mdr1a/b-/-Bcrp1-/- 
Mice after Oral Dosing with 25 mg/kg Dabrafenib (Data presented as Mean ± 
SEE) 
Mouse 
Genotype 
Tissue 
Cmax              
(µg/mL) 
AUClast1 
(µg.min/mL) 
Kp2 
Kp 
Ratio3 
Wild-type Plasma 0.143 ± 0.014 15.8 ± 3.0 
0.044 
5.7 
Wild-type Brain 0.007 ± 0.001 0.69 ± 0.22 
Mdr1a/b-/-
Bcrp1-/- 
Plasma 0.324 ± 0.085 31.1 ± 5.1# 
0.25 
Mdr1a/b-/-
Bcrp1-/- 
Brain 0.098 ± 0.022 7.6 ± 1.3* 
 
1. Area under the curve from time zero to 4 hour post dose 
2. Kp = AUCbrain/AUCplasma 
3. Kp Ratio = Kp in TKO Mice / Kp in WT Mice 
4. #, p = 0.0414 compared to WT plasma 
5. *, p = 0.002 compared to WT brain 
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Table 3.5: Comparison of brain distribution of vemurafenib and dabrafenib 
in FVB wild-type mice after an i.v. dose of 2.5 mg/kg. 
  Dabrafenib Vemurafenib# 
  Plasma Brain Plasma Brain 
Terminal rate Constant (min-
1) 
0.031 0.036 0.0051 0.0047 
Half-life ( min) 23.7 19.1 136 148 
Clearance (mL/min/kg) 24.2 
 
1.6 
 
Volume of Distribution (L/kg) 0.83 
 
0.316 
 
AUC0 → t last (min · µg/mL) 
120.9 ± 
15.8 
2.8 ± 
0.4 
1663 ± 140 6.5 ± 0.9 
Kp 0.023 0.004 
 # From previously published data (Mittapalli et al., 2012). 
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Supplemental Figure 3.1:  
Accumulation of different concentrations (0.5 to 75 µM) of dabrafenib in MDCKII- 
wild type and Bcrp1 transfected cell lines. The data show a linear correlation 
between concentration and cellular accumulation indicating that no saturation of 
efflux transporters. Data represent Mean ± SD; n= 3 for all data sets. 
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Supplemental Figure 3.2:  
Intracellular accumulation of [3H]-mitoxantrone (MTX; Bcrp probe substrate) in 
Bcrp1-transfected cell lines with increasing concentrations of dabrafenib from 0.1 
µM to 50 µM. Ko: Bcrp inhibitor Ko143; Data represent mean ± SD; n = 3 for all 
data points. 
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Supplemental Figure 3.3:  
Equilibrium dialysis in plasma and brain homogenate: The graph shows the free 
fraction of dabrafenib (fraction unbound, fub) in plasma and brain homogenate 
with respect to time. The data indicate that equilibrium is achieved in ~6hrs in 
both plasma and brain homogenate. 
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Chapter 4: Factors influencing the CNS distribution of a novel 
MEK 1/2 Inhibitor: Implications for combination therapy for 
melanoma brain metastases 
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Brain metastases are a major cause of mortality in patients with advanced 
melanoma.  Adequate brain distribution of targeted agents for melanoma will be 
critical for treatment success.  Recently, improvement in overall survival led to 
FDA-approval of the BRAF inhibitors, vemurafenib and dabrafenib, and the 
MEK1/2 inhibitor, trametinib.  However, brain metastases and emergence of 
resistance remain a significant problem.  MEK1/2 is downstream of BRAF in the 
MAPK signaling pathway, making it an attractive target to combat resistance.  
The recently approved combination of dabrafenib and trametinib has shown 
improvement in progression-free survival; however, adequate brain distribution of 
both compounds is required to effectively treat brain metastases.  In previous 
studies, we found limited brain distribution of dabrafenib, the purpose of the 
current study was to investigate factors influencing the brain distribution of 
trametinib.  In vitro studies indicated that trametinib is a substrate for both P-gp 
and Bcrp; efflux transporters found at the blood-brain barrier.  In vivo studies in 
transgenic mouse models confirmed that P-gp plays an important role in 
restricting brain distribution of trametinib. The brain-to-plasma partition coefficient 
(AUCBrain/AUCPlasma) was approximately 5-fold higher in Mdr1a/b(−/−) (P-gp knock-
out) and Mdr1a/b(−/−)Bcrp1(−/−) (triple knock-out) mice when compared with wild-
type and Bcrp1(−/−) (Bcrp knock-out) mice.  The brain distribution of trametinib 
was similar between the wild-type and Bcrp knock-out mice.  These results show 
that P-gp plays an important role in limiting brain distribution of trametinib and 
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may have important implications for use of trametinib as single agent or in 
combination therapy for treatment of melanoma brain metastases. 
4. 1 Introduction 
Melanoma is the deadliest skin cancer with a remarkably high propensity for 
brain metastasis. Approximately 94% of melanoma patients develop brain 
metastases within 3 years of diagnosis of primary melanoma, and more than 
90% of these patients die from progressive disease (Fife et al., 2004). Patients 
with 1 to 3 brain metastases are often treated with surgical resection or 
radiosurgery, while those with multiple brain metastases typically receive whole 
brain irradiation (Gibney et al., 2012). Unfortunately, melanoma is resistant to 
radiation and chemotherapy, and patients with brain metastases have a median 
survival of about four months despite aggressive therapy (Sampson et al., 1998; 
Fife et al., 2004). Thus, identifying therapies specifically effective for melanoma 
brain metastases could provide significant benefit for these patients. 
The recent discovery of activating mutations in the MAPK pathway in melanoma 
has led to significant advances in treatment options for metastatic melanoma. 
These activating mutations cause deregulated constitutive signaling via the 
MAPK pathway that stimulates nuclear translocation of phosphorylated ERK, 
subsequent gene transcription, and ultimately tumor growth and proliferation 
(McCubrey et al., 2008). BRAF is mutated in greater than 50% of patients with 
metastatic melanoma (Davies et al., 2002). A majority of patients with BRAF 
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mutations exhibit a valine to glutamic acid substitution at amino acid 600 (V600E; 
BRAF V600E) (Davies et al., 2002).  The FDA-approved BRAF inhibitors 
(vemurafenib and dabrafenib) and a MEK inhibitor, trametinib (GSK1120212; Fig. 
4.1), have shown remarkable initial efficacy against peripheral BRAFV600E 
mutant tumors (Flaherty et al., 2010; Johannessen et al., 2010; Kim et al., 2010; 
Nazarian et al., 2010; Villanueva et al., 2010; Chapman et al., 2011; 
Gowrishankar et al., 2012). Vemurafenib and dabrafenib were both approved 
after showing a significant improvement in progression-free survival and overall 
survival as compared to dacarbazine in phase 3 clinical trials (Chapman et al., 
2011; Hauschild et al., 2012). Similar to vemurafenib and dabrafenib, trametinib 
showed a 4.3 month progression-free survival as compared to 1.5 months in the 
chemotherapy group in phase 3 clinical trials in patients with V600 BRAF 
mutations (Flaherty et al., 2012).  Emergence of resistance to BRAF inhibitor 
therapy commonly occurs through hyperactivation of downstream MEK signaling, 
and concurrent therapy with the BRAF inhibitor dabrafenib and the MEK inhibitor 
trametinib significantly prolongs survival compared to single agent therapy.  
Other mechanisms of BRAF-inhibitor resistance also have been defined involving 
hyperactivation of receptor tyrosine kinases, NRAS, or PI3K/mTOR, and these 
discoveries suggest that various combinations of molecular targeted agents will 
become the standard of care for melanomas (Johannessen et al., 2010; 
Gowrishankar et al., 2012).  
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The efficacy of many molecularly targeted agents in central nervous system 
tumors is limited by penetration across the blood brain barrier.  The BBB is 
comprised of a monolayer of endothelial cells connected by tight junctions that 
serve as a physical barrier protecting the brain. In addition, these endothelial 
cells express multiple efflux transporters, including p-glycoprotein (P-gp) and 
breast cancer resistance protein (BCRP) that are known to exclude many 
anticancer agents from the brain.(Ohtsuki and Terasaki, 2007; Agarwal et al., 
2011) We have previously demonstrated that vemurafenib and dabrafenib are 
restricted in brain distribution due to their efflux by P-gp and BCRP in an intact 
BBB (Mittapalli et al., 2012; Mittapalli et al., 2013). Microscopic subclinical brain 
metastases likely have a relatively intact BBB, and the limited accumulation of 
these BRAF inhibitors in the brain suggest that they may not be particularly 
effective in preventing emergence of new brain metastases. Consistent with this 
observation, there are clinical data suggesting an increased incidence of brain 
metastases in patients in whom peripheral disease is effectively controlled with 
these BRAF inhibitors (Rochet et al., 2012). However, there are sparse data 
about the efficacy of trametinib in the treatment of brain metastases, and no 
reports on factors influencing its brain distribution.  
Effective combination therapy of melanoma brain metastases with targeted 
agents requires the sufficient delivery of all agents in the combination across the 
BBB to the target sites in melanoma brain metastases that may reside behind an 
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intact BBB. The latency time from the initial seeding of undetectable micro-
metastatic melanoma in the brain to the first detection by MRI, and the 
subsequent poor survival after detection, suggests the deadly nature of occult 
disease and the importance of prevention of clinically-detectable brain 
metastases. Since trametinib is a highly efficacious combination partner for 
treatment of melanoma, the purpose of this study was to evaluate the factors 
limiting the brain distribution of trametinib in mice with the goal that this 
information will inform development of effective combination therapies that might 
include trametinib for patients with melanoma brain metastases.  
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4. 2 Materials and Methods 
4. 2. 1 Chemicals  
Trametinib and dabrafenib (GSK2118436A) were purchased from Chemietek 
(Indianapolis, IN). [3H]-Prazosin and [3H]-digoxin were purchased from Perkin 
Elmer Life and Analytical Sciences (Waltham, MA). [3H]-Vinblastine and [3H]-
mitoxantrone were purchased from Moravek Biochemicals (La Brea, CA). [14C] 
dasatinib was kindly provided by Bristol-Myers Squibb Co. (Princeton, NJ) and 
[14C]-inulin was purchased from American Radiolabeled Chemicals, Inc. (St. 
Louis, MO).  Ko143 [(3S,6S,12aS)-1,2,3,4,6,7,12,12aoctahydro-9-methoxy-6-(2-
methylpropyl)-1,4-dioxopyrazino(1’,2’:1,6) pyrido(3,4-b)indole-3-propanoic acid 
1,1-dimethylethyl ester] was purchased from Tocris Bioscience (Ellisville, MO) 
and zosuquidar [LY335979, (R)-4-((1aR, 6R,10bS)-1,2-difluoro-1,1a,6,10b-
tetrahydrodibenzo-(a,e) cyclopropa(c)cycloheptan-6-yl)-α-((5-quinoloyloxy) 
methyl)-1-piperazine ethanol, trihydrochloride] was kindly provided Eli Lilly and 
Co.(Indianapolis, IN). Cell culture reagents were purchased from Invitrogen 
(Carlsbad, CA). All other chemicals used were of high performance liquid 
chromatography or reagent grade and were obtained from Sigma-Aldrich (St. 
Louis, MO).  
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4. 2. 2 In vitro studies 
In vitro studies were performed using polarized Madin-Darby canine kidney-II 
(MDCK-II) cells.  MDCKII-WT and Bcrp1-transfected (MDCKII-Bcrp1) cell lines 
were gifts from Dr. Alfred Schinkel (The Netherlands Cancer Institute). MDCKII-
wild type (WT) and MDR1-transfected (MDCKII-MDR1) cell lines were kindly 
provided by Dr. Piet Borst (The Netherlands Cancer Institute). Cells were 
cultured in Dulbecco’s modified Eagle’s medium supplemented with 10% (v/v) 
fetal bovine serum and antibiotics (penicillin, 100 U/mL; streptomycin, 100 μg/mL; 
and amphotericin B, 250 ng/mL). Cells were grown in 25 mL tissue culture 
treated flasks before seeding for the experiments and were maintained at 37º C 
in a humidified incubator with 5% CO2. The growth media for MDCKII-MDR1 
additionally contained 80 ng/ml of colchicine to maintain positive selection 
pressure of P-gp expression  
4. 2. 2. 1 In vitro accumulation studies 
 The intracellular accumulation of trametinib was performed in 12-well 
polystyrene plates (Corning Inc. Corning, NY). Briefly, cells were seeded at a 
density of 2 x 105 cells per well and were grown until the cells were ~80% 
confluent. On the day of experiment the culture media was aspirated and the 
cells were washed two times with cell assay buffer (122 mM NaCl, 25 mM 
NaHCO3, 10 mM glucose, 10 mM HEPES, 3 mM KCl, 2.5 mM MgSO4, 1.8 mM 
CaCl2, and 0.4 mM K2HPO4). Then the cells were preincubated with assay buffer 
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for 30 min, after which the buffer was aspirated and the experiment was initiated 
by adding 1 mL of trametinib (2 µM) to each well and further incubated for 60 
min. The assay plates were incubated at 37º C on an orbital shaker (60 rpm) for 
the entire duration of the experiment. When the inhibitor was present, it was 
included in both pre-incubation and accumulation steps. After the incubation 
period, the drug solution was aspirated and the cells were washed twice with ice 
cold PBS. Then the cells were lysed by adding 500 µL of 1% Triton X to each 
well. The solubilized cell fraction was sampled from each well and the 
concentration of trametinib was determined using liquid chromatography-tandem 
mass spectrometry (LC-MS/MS) and normalized to protein content (BCA protein 
assay). 
4. 2. 2. 2 Bcrp and P-gp inhibition studies 
Inhibition assays were performed using radiolabeled prototypical probe 
substrates [3H]-prazosin for Bcrp, [3H]-digoxin for P-gp and [14C] dasatinib or 
dabrafenib (2 µM) as dual substrates. The intracellular accumulation of these 
probe substrates was evaluated in the presence of varying concentrations of 
trametinib ranging from 0.1 to 25 μM. Briefly, the cells were pre-incubated with 
increasing concentrations of trametinib for 30 min. After pre-incubation the cells 
were incubated with substrate along with increasing concentrations of trametinib 
for 60 min. At the end of the incubation period, the buffer was aspirated and cells 
were lysed using 1% Triton-X. The radioactivity in solubilized cell fractions was 
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determined by liquid scintillation counting (LS-6500; Beckman Coulter, Fullerton, 
CA). The concentration of dabrafenib in the solubilized cell fraction was 
determined using liquid chromatography-tandem mass spectrometry (LC-
MS/MS) by a method previously described by Mittapalli et.al (Mittapalli et al., 
2013). The concentration of dabrafenib and radioactivity of probe substrates in 
cell fractions was also normalized to protein content in each well. The increase in 
cellular accumulation of substrate as compared to control (no treatment with 
trametinib) was measured and reported as a function of trametinib concentration. 
4. 2. 2. 3 Directional transport across MDCKII monolayers 
The bidirectional flux studies were performed using twelve well Transwell® plates 
(polyester membrane, 0.4 μM pore size, 1.12 cm2 growth surface area); (Corning 
Inc., Lowell, MA). The cells were seeded at a density of 2 x105 cells per well and 
the media was changed every other day until confluent monolayers were formed.  
On the day of experiment, the culture medium was aspirated and the cells were 
washed twice with cell assay buffer. After a 30 min pre-incubation, the 
experiment was initiated by adding the trametinib solution (5 µM) in assay buffer 
to the donor compartment. Samples (100 µL) were collected from the receiver 
compartment at 0, 60, 120, and 180 minutes and replaced with drug-free assay 
buffer. Similarly, at the beginning of the experiment, a 100 µL sample was drawn 
from the donor compartment and replaced with 100 µL drug solution. The 
Transwell® plates were incubated at 37ºC on an orbital shaker for the duration of 
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experiment except for the brief sampling times. In the inhibition experiments, 
either 0.2 μM Ko143 (selective Bcrp inhibitor) or 1 μM of zosuquidar (selective P-
gp inhibitor) was added to both apical (A) and basolateral (B) compartments; the 
inhibitor was present in both compartments during the pre- and post-incubation 
period.  
The apparent permeability (Papp) was calculated using the following 
equation 
 
 
(1) 
Where, (dQ/dt) is the slope obtained from the initial linear range from the amount 
transported versus time plot, A is the area of the Transwell® membrane, and C0 is 
the initial donor concentration. The efflux ratio and corrected flux ratio were 
calculated using equations 2 and 3, respectively.  
 
 
(2) 
 
 
 
(3) 
 
Where, A→B represents permeability in apical to basolateral and B→A 
represents permeability in basolateral to apical direction. 
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4. 2. 3 In vivo Studies 
4. 2. 3. 1 Animals  
All of the in vivo studies were performed in FVB (wild type), Mdr1a/b-/- (P-gp 
knockout), Bcrp1-/- (Bcrp knockout), and Mdr1a/b-/-Bcrp1-/- (triple knockout) mice 
of either sex from an FVB genetic background (Taconic Farms, Germantown, 
NY). All animals were 8 to 10 weeks old at the time of experiment. Animals were 
maintained in a 12 hr light/dark cycle with unlimited access to food and water. All 
studies were carried out in accordance with the guidelines set by the Principles of 
Laboratory Animal Care (National Institutes of Health, Bethesda, MD) and 
approved by the Institutional Animal Care and Use Committee (IACUC) of the 
University of Minnesota. 
4. 2. 3. 2 Brain distribution of trametinib in FVB mice 
The trametinib i.v. dosing formulation was prepared in a vehicle containing 40% 
DMSO, 40% propylene glycol and 20% saline.  All trametinib dosing solutions 
were freshly prepared on the day of the experiment. Wild type, Mdr1a/b-/- , Bcrp1-
/- , and Mdr1a/b-/-Bcrp1-/- mice received an i.v. dose of 5 mg/kg trametinib via the 
tail vein, and blood and brain samples were collected after 1, 4, 8, 16 and 24 
hours post dose. At the end of the desired time point, the animals were 
euthanized using a CO2 chamber. Blood was collected via cardiac puncture in 
heparinized tubes. Plasma was separated by centrifuging whole blood at 3500 
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rpm for 10 min at 4ºC. The whole brain was removed from the skull and washed 
with ice-cold PBS and superficial meninges were then removed by blotting with 
tissue paper. Both brain and plasma samples were stored at -80ºC until further 
analysis.  
4. 2. 3. 3 Steady-state brain distribution of trametinib and combination of 
dabrafenib-trametinib 
To determine the steady state brain and plasma concentrations of trametinib, 
Alzet osmotic mini pumps (Durect Corporation, Cupertino, CA) were loaded with 
trametinib (2 mg/mL dissolved in DMSO) to be released for 48 hrs at a rate of 
1µL/hr. After initial trametinib loading, mini pumps were primed overnight in 
sterile saline at 37º C. Pumps were implanted in the peritoneal cavity of wild type, 
Mdr1a/b-/- , Bcrp1-/- , and Mdr1a/b-/-Bcrp1-/- mice as described previously 
(Mittapalli et al., 2012).  Briefly, mice were anesthetized using isofluorane and the 
abdominal cavity was shaved. A small midline incision was made in the lower 
abdominal wall under the rib cage. Then a small incision was made directly in the 
peritoneal membrane and the primed pump was inserted in the cavity. The 
incision was sutured and the skin was closed using surgical clips. The animals 
were allowed to recover on a heating pad and once recovered they were moved 
to their original cages. The animals were sacrificed 48 hrs after the implantation 
of the pumps, and brain and plasma samples were processed as described 
above.  
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Similarly, in another study, Alzet mini-pumps were loaded with trametinib and 
dabrafenib (2 mg/mL trametinib and 10 mg/mL dabrafenib dissolved in DMSO) to 
be released for 48 hours at the rate of 1 µL/hr. Pumps were primed overnight and 
implanted in the peritoneal cavity of wild type and Mdr1a/b-/-Bcrp1-/- mice. These 
animals were also sacrificed 48 hrs after the implantation of the pumps, and brain 
and plasma samples were processed as described previously. 
4. 2. 4 Analysis of trametinib concentrations using LC-MS/MS 
 The concentrations of trametinib in cell lysates, assay buffer, plasma and brain 
homogenate were determined using a sensitive and specific liquid 
chromatography coupled with tandem mass spectrometry (LC-MS/MS) assay. 
For brains, three volumes of 5% bovine serum albumin were added and 
homogenized to get a uniform homogenate. For analysis of unknowns, an aliquot 
of cell lysate, cell assay buffer, brain homogenate or plasma was spiked with 50 
ng of vemurafenib as an internal standard. The samples were then extracted by 
addition of 10 volumes of ethyl acetate followed by vigorous shaking for 5 min 
and centrifuged at 7500 rpm for 5 min at 4ºC to separate the organic layer. The 
organic layer was transferred to microcentrifuge tubes and dried under nitrogen. 
Samples were reconstituted in 100 µL of mobile phase and transferred into HPLC 
glass vials. Chromatographic analysis was performed using an AQUITY UPLC® 
system (Milford, MA, USA). The chromatographic separation was achieved using 
an Agilent Technologies Eclipse XDB-C18 column (4.6 x 50 mm) with 1.8 µm 
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Zobrax Rx-SIL as the stationary phase. The mobile phase consisted of 20 mM 
ammonium formate with 0.1% formic acid and acetonitrile (35:65 v/v), and was 
delivered at a flow rate of 0.25 mL/min.  
The column effluent was monitored using a Waters/Micromass QuattroTM 
Ultima mass spectrometer (Waters, Milford, MA). The instrument was equipped 
with an electrospray interface, and controlled by the Masslynx (Version 4.1) data 
system. The samples were analyzed using an electrospray probe in the negative 
ionization mode operating at a spray voltage of 2.96 kV for both trametinib and 
vemurafenib (internal standard). Samples were introduced into the interface 
through a heated nebulized probe where the source temperature and desolvation 
temperature was set at 100 ºC and 275 ºC, respectively. The spectrometer was 
programmed to allow the [MH]- ion of trametinib at m/z 613.93 and that of 
internal standard at m/z 488.23 to pass through the first quadrupole (Q1) and into 
the collision cell (Q2). The collision energy was set at 27V both for trametinib and 
vemurafenib. The product ions for trametinib (m/z 530.79) and vemurafenib (m/z 
380.89) were monitored through the third quadrupole (Q3). The retention times 
for trametinib and the internal standard (vemurafenib) were 4.5 and 5.7 minutes, 
respectively. The assay was sensitive and linear over a range of 1.26 ng/mL to 
1500 ng/mL with the coefficient of variation less than 15% over the entire range. 
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4. 2. 5 Pharmacokinetic Calculations 
Pharmacokinetic parameters and metrics from the concentration-time data in 
plasma and brain were obtained by non-compartmental analysis (NCA) 
performed using Phoenix WinNonlin 6.2 (Pharsight, Mountain View, CA). The 
area under the concentration-time profiles for plasma (AUCplasma) and brain 
(AUCbrain) were calculated using the linear trapezoidal method. The sparse 
sampling module in WinNonlin was used to estimate the standard error around 
the mean of the AUCs.  
4. 2. 6 Statistical Analysis 
Data in all experiments represent mean ± SD unless otherwise indicated. 
Comparisons between two groups were made using an unpaired t-test. One way 
ANOVA, followed by Bonferonni’s multiple comparisons test, was utilized to 
compare multiple groups.  A significance level of p <0.05 was used for all 
experiments. (GraphPad Prism 5.01 software, GraphPad, San Diego, CA, USA). 
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4. 3 Results 
4. 3. 1 Intracellular accumulation of trametinib 
The intracellular accumulation of trametinib was studied in MDCKII WT and P-gp 
or Bcrp overexpressing cell lines. The cellular accumulation of [3H]-prazosin and 
[3H]-vinblastine were used as positive controls for Bcrp and P-gp mediated efflux 
transport, respectively. The accumulation of [3H]-prazosin (Fig. 4.2A) was 87% 
lower in Bcrp overexpressing cells (WT: 100 ± 9.2%; Bcrp: 12.7 ± 1.7%, p< 
0.0001). Similarly, the accumulation of [3H]-vinblastine (Fig. 4.2B) in P-gp 
overexpressing cells was ~77% lower compared to WT cells (WT: 100.0 ± 6.8%; 
MDR1: 22.85 ± 0.7%, p< 0.0001). Trametinib accumulation was approximately 
81% lower in Bcrp overexpressing cells compared to WT cells (WT: 100 ± 2.95%; 
Bcrp: 18.8 ± 1.4%, p<0.0001). The difference in accumulation was abolished 
when the specific Bcrp inhibitor Ko143 was added (Bcrp: 18.8 ± 1.4%; Bcrp with 
Ko143: 103.6 ± 1.1%, p<0.0001). Similarly, the accumulation of trametinib was 
~45% lower in P-gp overexpressing line compared to its WT control (WT: 100.0 ± 
3.5%; MDR1: 55.0 ± 4.2%, p< 0.0001), and the difference in accumulation was 
abolished (Fig. 4.2B) when a specific P-gp inhibitor LY335979 was added 
(MDR1: 55.0 ± 4.2%; MDR1 with LY: 97.0 ± 2.7%, p< 0.0001).  These cellular 
accumulation data indicate that trametinib is a substrate for both P-gp and Bcrp 
in vitro. 
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4. 3. 2 Competition assays using prototypical probe substrates 
The effect of increasing concentrations of trametinib on probe substrate 
accumulation was assessed in Bcrp-transfected and MDR1-transfected MDCKII 
cells. Increasing concentrations of trametinib did not significantly increase the 
accumulation of prazosin in the Bcrp1-transfected cells (Fig. 4.3A). However, 
increasing concentrations of trametinib significantly increased (~ 3 fold at 5 µM 
trametinib) the accumulation of dasatinib in the Bcrp cells (Fig. 4.3B). The 
addition of increasing concentrations of trametinib resulted in an increase in the 
accumulation of digoxin (~ 4 fold increase at 5 µM trametinib) in the MDCKII-
MDR1 cells (Fig. 4.3C). The fold increase in digoxin accumulation in MDCKII-
MDR1 cells at 5 µM of trametinib was no different than the effect seen with 1 µM 
LY335959. These competitive inhibition results suggest that trametinib possibly 
shares the same binding site on Bcrp as dasatinib and on P-gp as digoxin. Given 
that dabrafenib and trametinib will be administered as combination therapy, it is 
important to note that increasing concentrations of trametinib did not significantly 
increase the intracellular accumulation of dabrafenib in the range from 0.1 to 10 
µM in the Bcrp1 (Fig. 4.4A) and MDR1 (Fig. 4.4B) transfected cells, suggesting 
no competing interaction between trametinib and dabrafenib in this concentration 
range. 
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4. 3. 3 Directional transport studies 
The directional flux of trametinib was assessed in MDCKII- wild-type, Bcrp1-
transfected, and MDR1-transfected monolayers grown on Transwell membranes. 
Confluent monolayers with intact tight junctions were formed in 3-4 days. 
Paracellular leakage was assessed by measuring the transport of [14C]-inulin 
across the cell monolayers and the % of inulin transported in 120 min was found 
to be less than 1% in all cell lines. The directional permeability of trametinib was 
similar in the apical to basal (A-to-B) and B-to-A directions in the wild-type cells 
(12.8 ± 2.5 versus 12.3 ± 4.7 × 10^-6 cm/sec, respectively; Table 4.1). However, 
in the Bcrp1-transfected cells, the apparent permeability of trametinib in the B-to-
A direction was significantly higher than the apparent permeability in the A-to-B 
direction (19.3 ± 1.96 versus 5.17 ± 2.1 × 10^-6 cm/sec, respectively; p < 0.05; 
Table 4.1) with an efflux ratio of 3.7 (Table 4.1). Treatment with the Bcrp inhibitor 
Ko143 significantly (p < 0.05) decreased the Bcrp1-mediated efflux of trametinib 
in the B-to-A direction and increased the A-to-B permeability with a resulting 
efflux ratio of 1.04. The corrected efflux ratio was found to be 3.85 for Bcrp1 
mediated bidirectional transport. Similarly, in MDR1-transfected cells, the B-to-A 
permeability was significantly higher compared to A-to-B permeability, with an 
efflux ratio of 2.55 (Table 4.1). The presence of LY335979 significantly abolished 
the difference in directional permeabilities with a resulting efflux ratio of 1.23. The 
corrected efflux ratio in the MDR1 cells was found to be 2.45. These data further 
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confirm that trametinib is a substrate for Bcrp1 and MDR1 in vitro and suggests 
that these transporters may be an important factor in the brain distribution of 
trametinib. 
4. 3. 4 Brain distribution of trametinib in different genotypes 
The brain distribution of trametinib was studied in FVB wild type, Bcrp1-/-, 
Mdr1a/b-/- and Mdr1a/b-/-Bcrp1-/- mice after intravenous administration of 5 mg/kg 
of trametinib via the tail vein. Fig. 4.5 shows the plasma and brain concentrations 
of trametinib in all 4 genotypes at 1, 4, 8, 16, and 24 hours after a single IV dose. 
The plasma concentrations (Fig. 4.5A) were no different between the four 
genotypes at any given time point. The plasma concentrations of trametinib were 
2-30 fold higher than the brain concentrations (Fig. 4.5B) in the wild-type and 
Bcrp1-/- mice. The brain concentrations in the Mdr1a/b-/- and Mdr1a/b-/-Bcrp1-/- 
were 4-20 fold higher than the brain concentrations in the wild-type and the 
Bcrp1-/- mice. The brain to plasma AUC ratios (Fig. 4.5C) in the wild type, Bcrp1-/-
, Mdr1a/b-/- and Mdr1a/b-/-Bcrp1-/- were: 0.148, 0.136, 0.733, 0.675, respectively, 
resulting in a drug targeting index 
(AUCbrain/AUCplasma)knockout/(AUCbrain/AUCplasma)wild-type of ~ 5 in both 
Mdr1a/b-/- and Mdr1a/b-/-Bcrp1-/- mice (Table 4.2), but there was no significant 
brain targeting in the Bcrp1-/- mice. These data suggest that P-gp plays a major 
role, greater than Bcrp, in significantly limiting the brain distribution of trametinib.   
 
  
 
127
4. 3. 5 Steady-state brain distribution of trametinib 
The steady state brain distribution of trametinib was examined after a continuous 
intraperitoneal infusion using AlzetTM osmotic pumps for 48 hrs at 2 µg/hr. As 
shown in Fig. 4.6, the steady-state brain to plasma ratios were 0.28 ± 0.09, 0.14 
± 0.13, 1.53 ± 0.57, 2.45 ± 1.3 in the FVB wild type, Bcrp1-/-, Mdr1a/b-/- and 
Mdr1a/b-/-Bcrp1-/- mice, respectively. The B/P ratios at steady state were ~ 5 fold 
higher in the Mdr1a/b-/- and ~ 9 fold higher in the Mdr1a/b-/-Bcrp1-/- mice when 
compared to wild-type mice. These data indicate that the brain distribution of 
trametinib is significantly limited due to active efflux at the BBB with P-gp playing 
a greater role than Bcrp in the mouse, and the steady-state data correspond well 
with the AUC ratios following a single i.v. dose.  
4. 3. 6 Steady state brain distribution of dabrafenib and trametinib in 
combination 
We then examined the steady-state brain distribution of dabrafenib (10 µg/hr) 
and trametinib (2 µg/hr) when dosed simultaneously as a 48 hours constant 
intraperitoneal infusion for 48 hours in wild type and Mdr1a/b-/-Bcrp1-/-. The 
steady-state brain to plasma concentration ratios of dabrafenib in the wild type 
and Mdr1a/b-/-Bcrp1-/- mice were 0.019 ± 0.02 and 1.09 ± 0.85, respectively (Fig. 
4.7). The steady-state brain to plasma concentration ratios of trametinib in the 
wild type and Mdr1a/b-/-Bcrp1-/- mice were 0.03 ± 0.01 and 0.85 ± 0.38, 
respectively (Fig. 4.7). The aggregate of these data suggests that both drugs in 
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the combination of dabrafenib and trametinib suffer from limited brain distribution 
due to active efflux at the BBB. 
4. 4 Discussion 
Brain metastases are a significant cause of morbidity and mortality among 
patients with advanced melanoma (Skibber et al., 1996; Fife et al., 2004; Davies 
et al., 2011). The last decade has seen remarkable improvements in the 
treatment of metastatic melanoma. Earlier, dacarbazine and interleukin-2 were 
the only two systemic agents that were approved for the treatment of metastatic 
melanoma. The response rates with these two agents were ~10-20% (Comis, 
1976; Atkins et al., 1999; Garbe et al., 2011). The discovery of oncogenic 
mutations in BRAF and its high prevalence in melanoma tumors made it an 
excellent molecular target. The approval of BRAF inhibitors, vemurafenib and 
dabrafenib, as well as the MEK inhibitor, trametinib, has tremendously changed 
the landscape of treatment options for advanced melanoma. Vemurafenib and 
dabrafenib were approved by the FDA after they showed improved efficacy when 
compared to dacarbazine in clinical trials (Chapman et al., 2011; Hauschild et al., 
2012). Also, in a phase 1 dose escalation clinical trial in melanoma patients with 
untreated brain metastases, dabrafenib showed a promising reduction in brain 
tumor size in 90% of the patients (Falchook et al., 2012).  Despite the initial 
success of these two agents, most patients with metastatic melanoma relapse 
within a year due to the emergence of resistance (Johannessen et al., 2010; 
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Nazarian et al., 2010; Gowrishankar et al., 2012).  The improved duration of 
response from the combination of BRAF and MEK inhibitors, dabrafenib and 
trametinib, provides new hope for delaying resistance and improving response. 
The success of combination therapies in treating brain metastases depends on 
all agents being effectively delivered to all metastatic sites, including 
micrometastases that reside behind an intact BBB with functional efflux 
transporters. In our previous studies, we have shown that both vemurafenib and 
dabrafenib are substrates for P-gp and BCRP, and their brain distribution is 
significantly limited due to their interaction with these two important efflux 
transporters (Mittapalli et al., 2012; Mittapalli et al., 2013). We also observed that 
dabrafenib has a greater brain distribution when compared to vemurafenib, with 
the B/P ratio of dabrafenib being greater than that of vemurafenib in both wild-
type and Mdr1a/b-/-Bcrp-/- mice. These data suggest that dabrafenib may be a 
better option than vemurafenib in the treatment of brain metastases.  However, 
for the success of the dabrafenib and trametinib combination in the treatment of 
brain metastases, it is important to investigate the mechanisms influencing the 
brain distribution of trametinib, both alone and in combination with dabrafenib.  
In the current study, we demonstrate that trametinib is a substrate for P-gp and 
BCRP in vitro. In vivo, we observe that P-gp plays a greater role than BCRP in 
limiting trametinib brain distribution. This is the first report of the interaction of 
trametinib with BCRP and P-gp. 
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The experiments performed in vitro in MDCKII cells that overexpress either 
murine Bcrp or human MDR1 revealed that trametinib is a substrate for both Bcrp 
and P-gp (Fig. 4.2; Table 4.1).  We observed a significantly lower accumulation 
of trametinib in the P-gp and Bcrp transfected cells as compared to wild-type 
(Fig. 4.2). In the presence of specific P-gp and Bcrp inhibitors (LY335979 and 
Ko-143, respectively) this difference in intracellular accumulation was abolished 
(Fig. 4.2). The percent accumulation of vinblastine in the presence of LY335979 
in the wild-type and MDR1-transfected cells was significantly greater than 100 %, 
this may be due to the fact that vinblastine was used at a tracer concentration 
(positive control for functional cells). In comparison, trametinib accumulation at 
an incubating trametinib concentration of 2 µM was not greatly affected by 
LY335979, presumably because the higher trametinib concentration (substrate) 
may be saturating transport, leading to less influence of LY335979 (inhibitor) on 
the efflux transport clearance.  
In P-gp transfected cells, using a prototypical probe substrate, digoxin, for P-gp, 
we observed a significant increase in intracellular accumulation with increasing 
concentrations of trametinib starting at 5 µM (Fig. 4.3C). Interestingly, we did not 
observe a significant increase in intracellular accumulation of BCRP substrate, 
prazosin, up to a concentration of 25 µM (Fig. 4.3A). In Bcrp cells, we observed a 
significant increase in accumulation of dual substrate dasatinib, starting at 5 µM 
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trametinib (Fig. 4.3B). In both, Bcrp and MDR1 cells, we did not observe a 
significant increase in intracellular dabrafenib with increasing concentrations of 
trametinib up to 10 µM (Fig. 4.4). It is noteworthy here that this is not a 
pharmacologically relevant concentration, the average peak concentration 
observed when patients received 2 mg of trametinib once daily was ~ 0.035 µM 
(Kim et al., 2013). Using a specific Bcrp inhibitor Ko143 and P-gp inhibitor 
LY335979, we observed an increase in the intracellular accumulation of 
trametinib in both Bcrp1 and MDR1 cells. From accumulation studies, we 
conclude that trametinib is a substrate for both BCRP and P-gp. At 5 µM, 
trametinib inhibits the active efflux of P-gp probe substrate digoxin and dual 
substrate dasatinib. This suggests the possibility of trametinib sharing similar 
binding sites as digoxin and dasatinib on P-gp and BCRP, respectively. 
Trametinib however, did not inhibit these two transporters in the case of Bcrp 
probe substrate, prazosin and the dual substrate dabrafenib. This may suggest 
the interaction of trametinib on a different binding site as compared to these two 
substrates on the efflux transporters. Importantly, the fact that trametinib (0.1 – 
10 µM) does not inhibit Bcrp and P-gp mediated efflux of dabrafenib suggests 
that at the studied concentrations, the combination of dabrafenib and trametinib 
may not have any transporter mediated drug-drug interaction in treating brain 
metastases. From our bidirectional flux studies of trametinib across monolayers 
of MDCKII wild-type, Bcrp1 transfected and MDR1 transfected cells, we 
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observed a corrected flux ratio of 3.85 in the Bcrp1 cells and 2.45 in the MDR1 
cells (Table 4.1), indicating the involvement of these two efflux transporters in the 
active efflux of trametinib. The specific inhibitors of Bcrp and P-gp were able to 
restore the net bidirectional flux of trametinib. All these in vitro experimental 
results, put together, conclusively show that trametinib is a substrate for these 
two efflux transporters. Based on our current in vitro and in vivo findings, we 
have noted a disparity with the current findings and the trametinib product label, 
which states that trametinib is not a substrate for, or inhibitor of, P-gp or Bcrp. 
We attribute these differences to be due to the trametinib concentration at which 
in vitro inhibition studies were conducted (0.04 µM).  In our studies, we observe 
trametinib to be a substrate of P-gp and Bcrp. More importantly, we observe that 
the in vitro findings translate in vivo with changes in brain distribution in both the 
P-gp knock-out and triple knock-out mice.  
With these results from in vitro experiments, we then investigated the brain 
distribution of trametinib in mice. After an i.v. dose of trametinib, we observed 
that the brain concentrations in the wild type and Bcrp-/- mice were ~ 1 log unit 
lower than the plasma concentrations at all measured time points (Fig. 4.5B). 
However, the brain distribution of trametinib was significantly improved in the 
Mdr1a/b-/- and Mdr1a/b-/-Bcrp-/- mice (Fig. 4.5B). The plasma concentrations were 
not different in all 4 genotypes at all measured time points (Fig. 4.5A). The 
AUCbrain to AUCplasma ratio (KP) in the wild-type and Bcrp-/- mice were 0.148 and 
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0.136, respectively while they were 0.733 and 0.675 in the Mdr1a/b-/- and 
Mdr1a/b-/-Bcrp-/- mice (Table 4.2). The remarkable increase in the targeted brain 
distribution led to a Kp ratio (Kp knockout/Kp wild-type) of ~ 5 in the Mdr1a/b-/- 
and Mdr1a/b-/-Bcrp-/- mice. An important consideration here is the plasma and 
tissue binding of trametinib. As per the product label, trametinib is 97.4% bound 
to human plasma proteins. KP,uu would provide useful information regarding brain 
partitioning and the role of efflux transporters, however, it should be noted here 
that the magnitude of difference, i.e., fold increase in brain-to-plasma ratio 
observed between wild-type and knockout mice would not change with correction 
for free fraction since protein binding is no different between wild-type and 
knockout mice (Mittapalli et al., 2013). Keeping this in mind, our overall 
conclusions with regards to the brain penetration of trametinib remain valid. 
Also, at steady state, the B/P ratios in the wild-type and Bcrp-/- mice were 
significantly lower (5-9 fold) than in the Mdr1a/b-/- and Mdr1a/b-/-Bcrp-/- mice (Fig. 
4.6). From simultaneous infusion of dabrafenib and trametinib to steady-state, we 
observed a significant increase in the B/P ratio in the Mdr1a/b-/-Bcrp-/- mice as 
compared to wild-type (Fig. 4.7). Also, when infused simultaneously, we 
observed a decrease in the B/P ratio of trametinib in the wild-type as compared 
to single agent infusion. A possible explanation for this could be the saturation of 
influx transporters during co-dosing. It is interesting to note that even though the 
in vitro cell accumulation and directional flux studies show that trametinib is a 
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substrate for Bcrp-mediated transport, that fact did not translate into significant 
effects of Bcrp-mediated transport at the BBB in these mouse models. Here, it is 
important to think about species differences in the expression of efflux 
transporters. For example, the expression of BCRP at the human BBB is ~3-
times greater as compared to the expression at the mouse BBB, and the 
expression of P-gp is ~2.5 fold lower at the human BBB as compared to mouse 
BBB (Uchida et al., 2011). Also, FVB mice express ~ 4 times more P-gp as 
compared to Bcrp (Agarwal et al., 2012). However, in spite of various differences 
in transporter expression, rodent models have been widely used to study the 
brain distribution of drugs. From this study, keeping in mind known differences in 
transporter expression at the brain capillary endothelium, it may be possible to 
make correlations to predict potential human exposure related to these two 
transporters. Also, it should be noted that the findings from this study may be 
able to guide/explain future clinical results. In the current study, we have 
observed that active efflux by P-gp plays a major role in keeping trametinib out of 
the mouse brain.  This interpretation of rodent data has to be kept in mind for 
assessing potential human exposure. In the case of trametinib, it is likely that, 
together, P-gp and Bcrp will affect its brain distribution in humans. This result is 
similar to previous findings with another molecularly targeted agent, cediranib 
(Wang et al., 2012).  It is well understood that P-gp and Bcrp may compensate 
for each other at the BBB in active efflux of dual substrates, i.e., with genetic 
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knock-out of one transporter (single knock-outs); another transporter can limit 
substrate brain distribution while in triple knock-outs, there can potentially be a 
greater than additive effect in the enhancement of brain distribution of dual 
substrates (Enokizono et al., 2008; Kodaira et al., 2010). Also, given the higher 
expression of P-gp at the mouse BBB, with substrates of similar affinities, it is 
common to observe a greater P-gp effect on brain penetration (Agarwal et al., 
2011; Agarwal et al., 2012). Taken together, these data clearly indicate that the 
brain distribution of trametinib is limited by active efflux in an intact BBB model, 
primarily mediated by P-gp.   
The duration of response of single agent BRAF inhibitors is limited by the 
eventual development of resistance. An understanding of the underlying 
mechanism of resistance in patients will enable the development of rational 
combinations. Blocking multiple signaling mechanisms has been shown to 
overcome resistance to BRAF inhibitors (Villanueva et al., 2010). However, for 
treatment of brain metastases, combination agents have to be delivered to all 
metastases in the brain. With the clinical development of a combination of 
dabrafenib and trametinib, and the fact that both these agents are individually 
substrates for active efflux, we were interested in understanding the factors that 
affect the brain distribution of the combination in vivo. When dabrafenib and 
trametinib were dosed to steady state, we observed a remarkable (> 10 fold) 
increase in the brain to plasma concentration ratios in the Mdr1a/b-/-Bcrp-/- as 
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compared to wild-type. These data indicate that the brain distribution of both 
drugs in the combination is restricted by active efflux at the BBB.  
The development of BRAF inhibitors has truly been a breakthrough for the 
treatment of metastatic melanoma. The addition of combination agents to BRAF 
inhibitor therapy is a rational method for overcoming resistance. However, given 
the deadly nature of brain metastases, there is a critical need to address CNS 
delivery issues of these combinations to achieve a durable response. With the 
limited delivery of combination agents to the brain, the brain may become a 
sanctuary site with greater resistance. These findings are clinically relevant as a 
means to choose rational combinations to ensure the effective treatment of brain 
metastases.  
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Figures 
 
Figure 4.1: Chemical structure of trametinib 
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Figure 4.2: In vitro cellular accumulation of trametinib. 
 
(A) The accumulation of prazosin (prototypical Bcrp probe substrate; positive control) and trametinib in MDCKII-wild-type 
and Bcrp1-transfected cells with and without specific Bcrp inhibitor Ko-143 (0.2 µM). The accumulation of trametinib and 
vinblastine (probe substrate for P-gp) in MDR1 cells with and without specific P-gp inhibitor LY335979 (1 µM) is shown in 
(B). Data represent the mean ± SD.; n=3 for all data points. ***p < 0.0001 compared with respective wild-type controls; #p 
< 0.001 compared with the untreated transfected cell line.  
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Figure 4.3: Competition assays using prototypical probe substrate molecules. 
 
Intracellular accumulation of [3H]-prazosin (Bcrp probe substrate) (A) and [14C]-dasatinib (dual substrate) (B) in Bcrp-1 
transfected cells, and [3H]-digoxin (P-gp probe substrate) (C) in MDR1 transfected cells with increasing concentrations of 
trametinib from 0.1 µM to 25 µM. Ko143: Bcrp inhibitor; LY335979: P-gp inhibitor. Data represent the mean ± SD.; n=3 for 
all data points. ***p < 0.0001, **p = 0.003 compared with untreated transfected cells.  
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Figure 4.4: Intracellular accumulation of dabrafenib in the presence of increasing concentrations of trametinib. 
(A) Intracellular accumulation of dabrafenib in Bcrp1 transfected cells in the presence of increasing concentrations of 
trametinib (0.1-10 µM). The accumulation of dabrafenib in MDR1 cells with increasing concentrations of trametinib from 
0.1 µM to 10 µM is shown in (B). Ko-143: Bcrp inhibitor Ko143; LY: P-gp inhibitor LY335979. Data represent the mean ± 
SD.; n=3 for all data points. ***p < 0.0001, *p = 0.0031 compared with untreated transfected cells. 
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Figure 4.5: Brain distribution of trametinib in FVB wild-type, Bcrp1-/-, Mdr1a/b-/- and Mdr1a/b-/-Bcrp1-/- mice. 
 
Plasma (A), brain (B), and brain to plasma concentration ratios (C) of trametinib in wild- type, Bcrp1-/- , Mdr1a/b-/-   and 
Mdr1a/b-/-Bcrp1-/- mice after an i.v. dose of 5 mg/kg. Plasma and brain concentrations of trametinib at 1, 4, 8, 16, and 24 
hours post dose were determined using LC-MS/MS. Data represent mean ± SD, n = 3-4. *p<0.05, **p<0.001, ***p<0.0001 
compared to wild-type. 
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Figure 4.6: Steady State distribution of trametinib at 2 µg/hr for 48hr. 
 
Steady state brain to plasma ratio of trametinib in wild-type, Bcrp1-/- , Mdr1a/b-/- , 
and Mdr1a/b-/-Bcrp1-/- mice. Trametinib was delivered at a constant infusion rate 
of 2 µg/hr for 48 hrs using Alzet osmotic pumps. Data represent mean ± SD, n = 
4-7. **p = 0.004, *p = 0.01 compared to wild-type. 
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Figure 4.7: Steady State distribution of dabrafenib and trametinib after 
simultaneous infusion for 48 hours. 
 
Steady state brain to plasma ratios of dabrafenib and trametinib in wild-type and 
Mdr1a/b-/-Bcrp1-/- mice. Dabrafenib and trametinib were simultaneously delivered 
at a constant rate of 10µg/hr and 2µg/hr respectively for 48 hrs using Alzet 
osmotic pumps.  Data represent mean ± SD, n = 4-9. **p = 0.002 compared to 
dabrafenib B/P ratio in wild-type, *p = 0.05 compared to trametinib B/P ratio in 
wild-type 
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Table 4.1: Bidirectional flux of Trametinib in MDCKII-WT, MDCKII-Bcrp1, and MDCKII-WT and MDCKII-MDR1 
transfected cells. 
Cell line (MDCKII) 
Papp (*10^-6 cm/sec)  
Efflux Ratio  
Corrected  
Flux Ratio  
A-to-B  B-to-A  
WT (Bcrp) 12.8 ±  2.5  12.3 ± 4.7  0.96 
 
WT (Bcrp) +0.2 µM Ko-143  12.5 ± 0.9  12.6 ± 1.0 1 
Inulin 0.93 ± 0.38 0.37 ± 0.26 0.4 
Bcrp   5.17 ± 2.1 a    19.3 ± 1.9 a 3.7 3.85 
Bcrp + 0.2 µM Ko-143  11.7 ± 2.6  12.2 ± 1.6  1.04 
  
Inulin 0.9 ± 0.32 0.93 ± 0.21 1.03 
          
WT (MDR1) 17.8 ± 1.8 18.6 ± 4.3  1.04 
 
WT (MDR1) + 1 µM LY335979  8.6 ± 4.9  11.3 ± 1.2  1.3 
Inulin 0.12 ± 0.12 0.24 ± 0.14 2 
MDR1   13.8 ± 8 a  35.2 ± 1.7 a 2.55 2.45 
MDR1 + 1 µM LY335979  9.3 ± 1.7 11.4 ± 2.9  1.23 
  
Inulin 0.5 ± 0.26 0.62 ± 0.19 1.24 
 
Papp: Apparent Permeability of trametinib; A, apical; B, basolateral; ER, efflux ratio; MDCKII, Madin-Darby canine 
kidney II; Papp, apparent permeability of trametinib; WT, wild type. a Represent significantly different compared 
with respective wild-type controls, ♦ Percent transported at 120 minutes was less than 1%. 
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Table 4.2: Trametinib PK parameters in FVBn wild-type (WT), Mdr1a/b-/-  (P-gp knockout), Bcrp1-/-   (Bcrp 
knockout) and Mdr1a/b-/- Bcrp1-/- (Triple knockout) after 5 mg/kg i.v. dose (AUC, area under the 
concentration-time curve; FVB, Friend leukemia virus strain B). 
 
 
 
 
 
 
 
 
 
Trametinib i.v. 5 
mg/kg 
PK Parameters 
Wild Type Bcrp1-/- Mdr1a/b-/- Mdr1a/b-/-Bcrp1-/- 
Plasma Brain Plasma Brain Plasma Brain Plasma Brain 
Terminal rate 
constant (hr-1) 0.15 0.12 0.11 0.15 
 
Half life (hr) 4.7 5.6 6.3 4.8 
Clearance (mL/hr) 5.1 6.1 4.7 5.2 
Volume (mL) 37.3 49.6 42.9 36.1 
AUC (0-tlast) µg-
hr/mL 
26.8 ± 
2.8 
4.0 ± 
0.43 
23.0 ± 
0.11 
3.1 ± 
0.30 
29.2 ± 
1.7 
21.4 ± 
0.93 
27.8 ± 
1.6 
18.8 ± 
0.87 
Kp (AUC Brain/ AUC 
Plasma) 0.15 0.14 0.73 0.68 
Kp ratio (Kp Knock 
out/Kp wild-type) 0.92 4.9 4.6 
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CHAPTER 5: FACTORS INFLUENCING THE CNS DISTRIBUTION 
OF A NOVEL PI3K/MTOR INHIBITOR GSK2126458: 
IMPLICATIONS FOR OVERCOMING RESISTANCE TO 
COMBINATION THERAPY FOR MELANOMA BRAIN 
METASTASES 
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Melanoma brain metastases are a major cause of mortality in patients with 
metastatic melanoma. The presence of brain metastases in a large percentage of 
patient autopsies suggests a unmet medical need. More recently, a better 
understanding of the key molecular drivers of melanoma and progression of the 
disease led to the development of drugs that inhibit specific signaling proteins in 
the mitogen-activated protein kinase (MAPK) pathway. The significant 
improvement in overall survival led FDA-approval of BRAF-inhibitors, 
vemurafenib and dabrafenib, and MEK 1/2 inhibitor, trametinib.  However, the 
emergence of brain metastases and acquired resistance are a huge problem. 
The combination of dabrafenib and trametinib was FDA-approved after the two-
drug combination showed a significant increase in progression-free survival as 
compared to the single agent arms. Unfortunately, patients acquire resistance to 
this combination. A promising approach to overcome resistance to acquired 
resistance to mutations in the MAPK signaling pathway is by simultaneously 
targeting the phosphoinositide 3-kinase (PI3K/mTOR) signaling pathway, which 
is deregulated in metastatic melanoma. In vitro, GSK2126458, a potent small 
molecule inhibitor of the PI3 kinase family and mTOR kinase has shown to 
overcome acquired resistance to dabrafenib and trametinib. In previous studies, 
we found that vemurafenib, dabrafenib, and trametinib are limited in brain 
distribution. The purpose of this study was to investigate factors that influence 
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the brain distribution of GSK2126458, alone and in combination with dabrafenib 
and trametinib. In vitro studies indicate that GSK212658 is a substrate for both P-
gp and Bcrp. The brain distribution of GSK2126458 was significantly greater in 
the Mdr1a/b-/-Bcrp1-/- (triple knockout) mice as compared to wild-type.  At steady-
state, the B/P ratio of GSK2126458 was approximately seven-fold higher in triple 
knockout mice as compared to wild-type. Also, on simultaneous infusion to 
steady state, we observed that all three drugs, GSK212658, dabrafenib and 
trametinib were limited in brain distribution due to active efflux by P-gp and Bcrp. 
Together, these in vivo studies in transgenic mouse models confirmed that active 
efflux by both P-gp and Bcrp play a significant role in restricting the brain 
distribution of GSK212658. These results have important implication to the use of 
GSK212658 as a single agent or in combination with other molecularly-targeted 
agents for the treatment of melanoma brain metastases.  
5. 1 Introduction 
Melanoma is a highly aggressive skin cancer with a great propensity for brain 
metastasis. Currently, melanoma brain metastases are a untreatable and lethal 
condition in most patients with advanced stages of melanoma. The incidence of 
melanoma has been steadily escalating over the years and approximately 76000 
new cases and ~ 10000 deaths are expected due to this disease in 2014 (Siegel 
et al., 2014).  In early stages of the disease, localized melanoma is curable with a 
5-year survival of greater than 90% while disseminated disease (metastatic 
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melanoma) has an extremely poor prognosis with a 5-year survival of less than 
15% (Balch et al., 2009). After lung and breast cancer, melanoma is the third 
most common cancer to metastasize to the brain (Johnson and Young, 1996).  
Patients with one to three brain metastases are often treated with surgical 
resection or stereotactic radiosurgery, while those with several brain metastases 
typically receive whole brain radiation (Gibney et al., 2012). Unfortunately, 
melanomas are highly resistant to radiation and chemotherapy, and patients with 
brain metastases have a dismal survival of the order of 4 months from first 
detection despite aggressive therapy (Sampson et al., 1998; Fife et al., 2004). 
Melanoma brain metastases are the cause of death in nearly 95 % of patients 
(Sampson et al., 1998).  
Patients with multiple brain metastases and extensive peripheral disease can 
have particularly poor survival, which can be as short as 1-2 months (Gupta et 
al., 1997; Fife et al., 2004). Incidentally, 50 to 70% of melanoma patients have 
brain metastases at autopsy (Fife et al., 2004).  The presence of brain 
metastases in such a large proportion of melanoma patients at autopsy is 
suggestive of a unmet medical need.  
There has been significant advancement over the last decade in the treatment of 
peripheral melanoma metastases based on the discovery and understanding of 
hallmark molecular events and oncogenic driver mutations that cause disease 
progression. In melanoma, oncogenic driver mutations in BRAF (v-raf murine 
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sarcoma viral oncogene homolog) and NRAS (neuroblastoma ras viral oncogene 
homolog) in the MAPK (mitogen-activated protein kinase) signaling pathway, p53 
mutations, and PTEN (phosphatase and tensin homolog) mutations have been 
identified to play an important role in the progression of the disease (Hodis et al., 
2012). The MAPK signaling pathway is known to be highly deregulated in about 
80% of melanomas as well as in a wide range of other human cancers (Davies et 
al., 2002). The discovery of activating mutations in the MAPK pathway, 
particularly the high prevalence of the valine to glutamic acid substitution 
mutation at amino acid 600 (V600E; BRAF V600E) in the BRAF protein, led to 
the development and FDA approval of two BRAF inhibitors, vemurafenib and 
dabrafenib. This mutation increases BRAF protein catalytic activity by 
approximately 50-200 fold as compared to wild-type resulting in constitutive 
activation of the MEK and ERK downstream proteins (Davies et al., 2002; 
Karasarides et al., 2004; Wan et al., 2004). These two drugs were approved after 
they showed a remarkable initial efficacy against peripheral tumors (Chapman et 
al., 2011; Bollag et al., 2012; Falchook et al., 2012). Similarly, trametinib, a 
mitogen-activated protein kinase kinase (MEK) inhibitor was approved after it 
showed a 4.8-month progression-free-survival (PFS) compared with 1.5 months 
in the chemotherapy group in phase 3 clinical trials in patients with BRAF V600E 
mutation (Flaherty et al., 2012b). However, the emergence of resistance to 
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MAPK pathway inhibitors is a huge problem and needs to be addressed 
immediately. 
Much of the current clinical data suggests that patients on BRAF inhibitors slowly 
stop responding to therapy due to the eventual development of resistance and 
relapse of disease (Puzanov et al., 2011).  Several mechanisms may be 
responsible for this resistance. Mutations in upstream signaling proteins such as 
RAS or compensatory signaling from other growth factor receptors such as 
PI3K/mTOR (phosphoinositide 3-kinase/ mammalian target of rapamycin), loss of 
PTEN, upregulation of cyclinD1 and downregulation of p27Kip1 may be driving the 
reactivation of the MAPK signaling pathway and strengthening the resistance to 
BRAF inhibitor therapy (Johannessen et al., 2010; Aplin et al., 2011; 
Gowrishankar et al., 2012). Combination therapy with multiple molecularly- 
targeted agents is a promising approach that has been pursued to overcome 
resistance and prolong survival. In this context, the combination of dabrafenib 
and trametinib was FDA approved after the two drug combination showed a 9.8-
month PFS as compared to 5.8 months in the dabrafenib monotherapy arm 
(Flaherty et al., 2012a). Unfortunately, resistance to BRAF and MEK inhibition 
occurs eventually via acquired MEK mutations (Wagle et al., 2014).  A 
combination of BRAF or MEK inhibitors with PI3K/mTOR inhibitors is known to 
overcome acquired resistance in vitro (Greger et al., 2012). GSK2126458, a 
potent ATP competitive inhibitor of the PI3 kinase family and the mTOR kinase is 
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a promising candidate for combinations (Knight et al., 2010). GSK2126458 was 
found to be highly specific, orally available and showed a low picomolar inhibitory 
activity against PI3 kinases and mTOR (Knight et al., 2010).  
The efficacy of molecularly-targeted agents and combinations for the successful 
treatment of melanoma brain metastases requires the sufficient delivery of all 
agents in the combination across the blood-brain-barrier (BBB) to all target sites 
in the brain, including those residing behind an intact BBB and are almost always 
clinically undetectable. The BBB is composed of a monolayer of endothelial cells 
connected by tight junction proteins and expressing multiple efflux transporter 
proteins including P-glycoprotein (P-gp) and breast cancer resistance protein 
(BCRP) that are known to exclude several anticancer drugs from the brain 
(Ohtsuki and Terasaki, 2007; Agarwal et al., 2011).  We have previously 
demonstrated that vemurafenib, dabrafenib and trametinib are restricted in brain 
distribution owing to active efflux by P-gp and Bcrp in an intact BBB model 
(Mittapalli et al., 2012; Mittapalli et al., 2013; Vaidhyanathan et al., 2014). Since 
GSK2126458 is a promising drug for combination therapy, the purpose of this 
study was to examine its potential for use in the treatment of melanoma brain 
metastases. We have evaluated some of the critical factors influencing its brain 
distribution as a single agent and in combination with dabrafenib and trametinib, 
with the goal that information from this work will guide the development of 
effective combinations for melanoma brain metastases. 
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5. 2 Materials and Methods 
5. 2. 1 Chemicals 
GSK2126458 [2,4-difluoro-N-(2-methoxy-5-(4-(pyridazin-4-yl)quinolin-6-
yl)pyridin-3-yl) benzenesulfonamide], Trametinib [N-[3-[3-cyclopropyl-5-(2-fluoro-
4-iodoanilino)-6,8-dimethyl-2,4,7- trioxopyrido[4,3-d]pyrimidin-1-
yl]phenyl]acetamide] and dabrafenib (GSK2118436A, N-[3-[5-(2-aminopyrimidin-
4-yl)-2-tert-butyl-1,3-thiazol-4-yl]-2-fluorophenyl]- 2,6-
difluorobenzenesulfonamide) were purchased from Chemietek (Indianapolis, IN). 
[3H]-Prazosin was purchased from Perkin Elmer Life and Analytical Sciences 
(Waltham, MA). [3H]-Vinblastine was purchased from Moravek Biochemicals (La 
Brea, CA). Ko143 [(3S,6S,12aS)-1,2,3,4,6,7,12,12aoctahydro-9-methoxy-6-(2-
methylpropyl)-1,4-dioxopyrazino(1’,2’:1,6) pyrido(3,4-b)indole-3-propanoic acid 
1,1-dimethylethyl ester] was purchased from Tocris Bioscience (Ellisville, MO) 
and zosuquidar [LY335979, (R)-4-((1aR, 6R,10bS)-1,2-difluoro-1,1a,6,10b-
tetrahydrodibenzo-(a,e) cyclopropa                ( c)cycloheptan-6-yl)-((5-
quinoloyloxy) methyl)-1-piperazine ethanol, trihydrochloride] was kindly provided 
Eli Lilly and Co.(Indianapolis, IN). Cell culture reagents were purchased from 
Invitrogen (Carlsbad, CA). All other chemicals used were of high performance 
liquid chromatography or reagent grade and were obtained from Sigma-Aldrich 
(St. Louis, MO). 
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5. 2. 2 In vitro studies  
In vitro studies were performed using polarized Madin-Darby canine kidney-II 
(MDCK-II) cells.  MDCKII-WT and Bcrp1-transfected (MDCKII-Bcrp1) cell lines 
were gifts from Dr. Alfred Schinkel (The Netherlands Cancer Institute). MDCKII-
wild type (WT) and MDR1-transfected (MDCKII-MDR1) cell lines were kindly 
provided by Dr. Piet Borst (The Netherlands Cancer Institute). Cells were 
cultured in Dulbecco’s modified Eagle’s medium supplemented with 10% (v/v) 
fetal bovine serum and antibiotics (penicillin, 100 U/mL; streptomycin, 100 μg/mL; 
and amphotericin B, 250 ng/mL). Cells were grown in 25 mL tissue culture 
treated flasks before seeding for the experiments and were maintained at 37º C 
in a humidified incubator with 5% CO2. The growth media for MDCKII-MDR1 
additionally contained 80 ng/ml of colchicine to maintain positive selection 
pressure of P-gp expression. 
5. 2. 2. 1 In vitro accumulation studies 
 The intracellular accumulation of GSK2126458 was performed in 12-well 
polystyrene plates (Corning Inc. Corning, NY). Briefly, cells were seeded at a 
density of 2 x 105 cells per well and were grown until the cells were ~80% 
confluent. On the day of experiment the culture media was aspirated and the 
cells were washed two times with cell assay buffer (122 mM NaCl, 25 mM 
NaHCO3, 10 mM glucose, 10 mM HEPES, 3 mM KCl, 2.5 mM MgSO4, 1.8 mM 
CaCl2, and 0.4 mM K2HPO4). Then the cells were preincubated with assay buffer 
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for 30 min, after which the buffer was aspirated and the experiment was initiated 
by adding 1 mL of GSK2126458 (2 µM) to each well and further incubated for 60 
min. The assay plates were incubated at 37º C on an orbital shaker (60 rpm) for 
the entire duration of the experiment. When the inhibitor was present, it was 
included in both pre-incubation and accumulation steps. After the incubation 
period, the drug solution was aspirated and the cells were washed twice with ice 
cold PBS. Then the cells were lysed by adding 500 µL of 1% Triton X to each 
well. The solubilized cell fraction was sampled from each well and the 
concentration of GSK2126458 was determined using liquid chromatography-
tandem mass spectrometry (LC-MS/MS) and normalized to protein content (BCA 
protein assay). 
5. 2. 2. 2 Bcrp and P-gp inhibition studies 
Inhibition assays were performed using radiolabeled prototypical probe 
substrates [3H]-prazosin for Bcrp and [3H]-vinblastine for P-gp. The intracellular 
accumulation of these probe substrates was evaluated in the presence of varying 
concentrations of GSK2126458 ranging from 0.1 to 50 μM. Briefly, the cells were 
pre-incubated with increasing concentrations of GSK2126458 for 30 min. After 
pre-incubation the cells were incubated with substrates along with increasing 
concentrations of GSK2126458 for 60 min. At the end of the incubation period, 
the buffer was aspirated and cells were lysed using 1% Triton-X. The 
radioactivity in solubilized cell fractions was determined by liquid scintillation 
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counting (LS-6500; Beckman Coulter, Fullerton, CA). The increase in cellular 
accumulation of substrate as compared to control (no treatment) was measured 
and reported as a function of GSK2126458 concentration. 
5. 2. 3 In vivo Studies 
5. 2. 3. 1 Animals 
All of the in vivo studies were performed in Friend leukemia virus strain B (FVB) 
(wild type), Mdr1a/b-/- (P-gp knockout), Bcrp1-/- (Bcrp knockout), and Mdr1a/b-/-
Bcrp1-/- (triple knockout) mice of either sex from an FVB genetic background 
(Taconic Farms, Germantown, NY). All animals were 8 to 12 weeks old at the 
time of experiment. Animals were maintained in a 12 hr light/dark cycle with 
unlimited access to food and water. All studies were carried out in accordance 
with the guidelines set by the Principles of Laboratory Animal Care (National 
Institutes of Health, Bethesda, MD) and approved by the Institutional Animal 
Care and Use Committee (IACUC) of the University of Minnesota. 
5. 2. 3. 2 Brain distribution of GSK2126458 after an oral dose in FVB mice 
Wild type and Mdr1a/b-/-Bcrp1-/- mice received an oral dose of 10 mg/kg 
GSK2126458, blood and brain samples were collected after 0.5, 1, 2, 4, 6, and 8 
hours post dose. The GSK2126458 p.o. dosing formulation was prepared in a 
vehicle containing 1% methocel, and 5% DMSO.  All GSK2126458 dosing 
suspensions were freshly prepared on the day of the experiment. At the end of 
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the desired time point, the animals were euthanized using a CO2 chamber. Blood 
was collected via cardiac puncture in heparinized tubes. Plasma was separated 
by centrifuging whole blood at 3500 rpm for 15 min at 4ºC. The whole brain was 
removed from the skull and washed with ice-cold PBS and superficial meninges 
were then removed by blotting with tissue paper. Both brain and plasma samples 
were stored at -80ºC until further analysis.  
5. 2. 3. 3 Steady-state brain distribution of GSK2126458 and a combination 
of dabrafenib, trametinib, and GSK2126458 
To determine the steady state brain and plasma concentrations of GSK2126458, 
Alzet osmotic mini pumps (Durect Corporation, Cupertino, CA) were loaded with 
GSK2126458 (2 mg/mL dissolved in DMSO) to be released for 48 hrs at a rate of 
1µL/hr. After initial GSK2126458 loading, mini pumps were primed overnight in 
sterile saline at 37º C. Pumps were implanted in the peritoneal cavity of wild type, 
Mdr1a/b-/- , Bcrp1-/- , and Mdr1a/b-/-Bcrp1-/- mice as described previously 
(Vaidhyanathan et al., 2014) . Briefly, mice were anesthetized using isofluorane 
and the abdominal cavity was shaved. A small midline incision was made in the 
lower abdominal wall under the rib cage. Then a small incision was made directly 
in the peritoneal membrane and the primed pump was inserted in the cavity. The 
incision was sutured and the skin was closed using surgical clips. The animals 
were allowed to recover on a heating pad and once recovered they were moved 
to their original cages. The animals were sacrificed 48 hrs after the implantation 
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of the pumps, and brain and plasma samples were processed as described 
above.  
Similarly, in another study, Alzet mini-pumps were loaded with GSK2126458, 
trametinib and dabrafenib (1 mg/ml GSK2126458, 0.5 mg/mL trametinib and 2.5 
mg/mL dabrafenib dissolved in DMSO) to be released for 48 hours at the rate of 
1 µL/hr. Pumps were primed overnight and implanted in the peritoneal cavity of 
wild type, Mdr1a/b-/-, Bcrp1-/-, and Mdr1a/b-/-Bcrp1-/- mice. These animals were 
also sacrificed 48 hrs after the implantation of the pumps, and brain and plasma 
samples were processed as described previously. 
5. 2. 3. 4 Influence of elacridar on the brain distribution of GSK2126458 
Elacridar microemulsion was made by preparing a 3 mg/mL solution of elacridar 
in Cremaphor EL, Carbitol and Captex 355 in a 6:3:1 ratio. This solution was 
diluted with saline prior to injection. Wild-type mice received vehicle or 10 mg/kg 
elacridar via an intraperitoneal injection. 1 hour after pretreatment, all mice 
received 10 mg/kg GSK2126458 orally and were sacrificed 1 hour after the oral 
dose. Plasma and brains were collected and processed as described earlier. 
5. 2. 4 Analysis of GSK2126458, dabrafenib, and trametinib using LC-
MS/MS 
The concentration of GSK2126458, dabrafenib and trametinib in cell lysates, 
plasma and brain homogenate were determined using a sensitive and specific 
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liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS) 
assay. For brains, three volumes of 5% bovine serum albumin were added and 
homogenized to get a uniform homogenate. For analysis of unknowns, an aliquot 
of cell lysate, brain homogenate or plasma was spiked with 10 ng PLX4720 and 
10 ng AG1478 as internal standards. The samples were then extracted by 
addition of 10 volumes of ethyl acetate followed by vigorous shaking for 5 min 
and centrifuged at 7500 rpm for 5 min at 4ºC to separate the organic layer. The 
organic layer was transferred to microcentrifuge tubes and dried under a gentle 
stream of nitrogen. Samples were reconstituted in 100 µL of mobile phase and 
transferred into HPLC glass vials. Chromatographic analysis was performed 
using an AQUITY UPLC® system (Milford, MA, USA). The chromatographic 
separation was achieved using an Agilent Technologies Eclipse XDB-C18 
column (4.6 x 50 mm) with 1.8 µm Zobrax Rx-SIL as the stationary phase. The 
aqueous component (A) of the mobile phase consisted of 20 mM ammonium 
formate with 0.1% formic acid and the organic mobile phase (B) was acetonitrile 
and was delivered at a flow rate of 0.25 mL/min. The gradient was as follows, 
45% B for the first 3.0 minutes, increased to 70% B minutes in the next 0.5 
minutes and maintained at 70% B for next 2.5 minutes, decreased to 45% B 
within the next 0.5 minutes and maintained at 45%B until 11.0 minutes. The total 
run time was 11 minutes with a flow rate of 0.25 mL/min. The cassette method 
involved detection of dabrafenib in the positive ionization mode, and the m/z 
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transitions were 520.1 →307.1 and 316.1 → 299.9 for dabrafenib and AG1478, 
respectively.  The detection of GSK2126458 and trametinib were in the negative 
ionization mode with m/z transitions of 412.3 →304.8, 504.0 → 176.9, 613.9 → 
530.8 for PLX4720, GSK2126458, trametinib, respectively. The retention times 
for dabrafenib, AG1478, PLX4720, GSK2126458, and trametinib were 7.26, 4.82, 
6.11, 5.25, and 6.96 minutes, respectively.  
5. 2. 5 Pharmacokinetic Calculations  
Pharmacokinetic parameters and metrics from the concentration-time data in 
plasma and brain were obtained by non-compartmental analysis (NCA) 
performed using Phoenix WinNonlin 6.2 (Pharsight, Mountain View, CA). The 
area under the concentration-time profiles for plasma (AUCplasma) and brain 
(AUCbrain) were calculated using the linear trapezoidal method. The sparse 
sampling module in WinNonlin was used to estimate the standard error around 
the mean of the AUCs.  
5. 2. 6 Statistical Analysis 
Data in all experiments represent mean ± SD unless otherwise indicated. 
Comparisons between two groups were made using an unpaired t-test. One way 
ANOVA, followed by Bonferonni’s multiple comparisons test; Dunnet’s test for 
comparing versus control was utilized to compare multiple groups.  A significance 
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level of p <0.05 was used for all experiments. (GraphPad Prism 5.01 software, 
GraphPad, San Diego, CA, USA).  
5. 3 Results 
5. 3. 1 Intracellular accumulation of GSK2126458 
The intracellular accumulation of GSK2126458 was studied in MDCKII WT and 
P-gp or Bcrp overexpressing cell lines. The cellular accumulation of [3H]-prazosin 
and [3H]-vinblastine was used as positive controls for Bcrp and P-gp mediated 
efflux transport, respectively. The accumulation of [3H]-prazosin (Fig. 5.2A) was 
~70% lower in Bcrp overexpressing cells (WT: 100 ± 3.96%; Bcrp: 29.87 ± 
7.72%, p< 0.0001). Similarly, the accumulation of [3H]-vinblastine (Fig. 5.2B) in 
P-gp overexpressing cells was ~41% lower compared to WT cells (WT: 100.0 ± 
11.21%; MDR1: 38.63 ± 5.90%, p< 0.0001). GSK2126458 accumulation was 
approximately 84% lower in Bcrp overexpressing cells compared to WT cells 
(WT: 100 ± 13.41%; Bcrp: 15.65 ± 7.97%, p<0.0001). Addition of specific Bcrp 
inhibitor Ko143 significantly increased the accumulation of GSK2126458 in the 
Bcrp transfected cells (Bcrp: 15.65 ± 7.97%; Bcrp with Ko143: 65.32 ± 12.23%). 
Similarly, the accumulation of GSK2126458 was ~84% lower in P-gp 
overexpressing line compared to its WT control (WT: 100.0 ± 5.31%; MDR1: 
16.25 ± 1.46%, p< 0.0001). When a specific P-gp inhibitor LY335979 was added 
(Fig. 5.2B), there was a significant increase in the accumulation of GSK2126458 
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in the MDR1 transfected cells (MDR1: 16.25 ± 1.46%; MDR1 with LY: 213.7 ± 
12.05%). These cellular accumulation data indicate that GSK2126458 is a 
substrate for both P-gp and Bcrp in vitro. 
5. 3. 2 Competition assays using prototypical probe substrates 
The effect of increasing concentrations of GSK2126458 on probe substrate 
accumulation was assessed in Bcrp-transfected and MDR1-transfected MDCKII 
cells. Increasing concentrations of GSK2126458 did not significantly increase the 
accumulation of prazosin in the Bcrp1-transfected cells until a concentration of 25 
µM (Fig. 5.3A). We observed a ~ 3-fold and ~ 4-fold increase in prazosin 
accumulation at 25 µM and 50 µM GSK2126458. Similarly, increasing 
concentrations of GSK2126458 significantly increased (~ 3 fold at 10 µM 
GSK2126458) the accumulation of vinblastine in the MDR1 cells (Fig. 5.3B). The 
results of these competitive inhibition studies suggest that GSK2126458 possibly 
shares the same binding site on Bcrp as prazosin and on P-gp as vinblastine.  
5. 3. 3 Plasma and brain pharmacokinetics of GSK2126458 
The plasma and brain pharmacokinetics of GSK2126458 was studied in FVB 
wild-type and Mdr1a/b-/-Bcrp1-/- mice after oral administration of 10 mg/kg. Fig. 
5.4 shows the plasma and brain concentrations of GSK2126458 in the two 
genotypes at 0.5,1,2,4,6, and 8 hours after a single oral dose. The plasma 
concentrations (Fig. 5.4A) were not significantly different between wild-type and 
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Mdr1a/b-/-Bcrp1-/- mice. In the wild-type mice the plasma concentrations were 
approximately 2 log units higher than the corresponding brain concentrations, 
indicating the severely restricted brain distribution of GSK2126458. The brain 
concentrations of GSK2126458 were 3-to 30-fold higher in the Mdr1a/b-/-Bcrp1-/- 
mice as compared to wild-type (Fig. 5.4B). These data show the significant role 
played by P-gp and Bcrp in restricting the brain distribution of GSK212648.  
5. 3. 4 Steady-state brain distribution of GSK2126458 
The steady state brain distribution of GSK2126458 was examined after a 
continuous intraperitoneal infusion using AlzetTM osmotic pumps for 48 hrs at 2 
µg/hr (Fig. 5.5). The brain concentrations were ~ 5-fold higher in the Mdr1a/b-/-
Bcrp1-/- mice as compared to wild-type (Fig. 5.5A). The brain concentrations 
were not significantly different in the Mdr1a/b-/- and Bcrp1-/- as compared to wild-
type and were significantly lower than their corresponding plasma concentrations 
(Fig. 5.5A). As shown in Fig. 5.5B, the steady-state brains to plasma ratios were 
0.07 ± 0.01, 0.06 ± 0.03, 0.02 ± 0.0.01, 0.47 ± 0.23 in the FVB wild type, 
Mdr1a/b-/- , Bcrp1-/- and Mdr1a/b-/-Bcrp1-/- mice, respectively. The B/P ratios at 
steady state were ~ 7 fold higher in the Mdr1a/b-/-Bcrp1-/- mice when compared to 
wild-type mice. These data further confirm that the brain distribution of 
GSK2126458 is significantly impaired due to active efflux at the BBB. 
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5. 3. 5 Steady state brain distribution of GSK2126458, dabrafenib and 
trametinib in combination  
We then examined the steady-state brain distribution of GSK2126458 (1 µg/hr) 
dabrafenib (2.5 µg/hr) and trametinib (0.5 µg/hr) when infused simultaneously to 
steady-state as a 48 hours constant intraperitoneal infusion for 48 hours in wild 
type, Mdr1a/b-/- , Bcrp1-/-and Mdr1a/b-/-Bcrp1-/- mice. The steady-state brain-to-
plasma concentration ratios of GSK2126458, dabrafenib and trametinib were 
significantly higher in the Mdr1a/b-/-Bcrp1-/- mice as compared to wild-type (Fig. 
5.6). In addition, the steady-state brain-to-plasma concentration ratios of 
dabrafenib and trametinib were significantly higher in the Mdr1a/b-/- mice as 
compared to wild-type (Fig. 5.6). The aggregate of these data suggests that all 
three drugs in the combination suffer from limited brain distribution due to active 
efflux at the BBB. 
 
5. 3. 6 Influence of elacridar microemulsion on the brain distribution of 
GSK2126458 
Next, we examined the influence of elacridar on the brain distribution of 
GSK2126458. Wild-type FVBs were pretreated with vehicle or elacridar (10 
mg/kg) via an intraperitoneal injection one hour before an oral dose of 
GSK2126458 (10 mg/kg). The brain-to-plasma concentration ratio of 
GSK2126458 was ~ 6 fold higher in the elacridar pretreated group as compared 
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to the vehicle treated group (Fig. 5.7). These results demonstrate that the 
administration of elacridar as a microemulsion formulation improves the brain 
distribution of GSK2126458 across the BBB. 
5. 4 Discussion 
Brain metastases from melanoma are a significant cause of mortality in patients 
with metastatic melanoma (Fife et al., 2004; Davies et al., 2011). The FDA-
approval of BRAF inhibitors, vemurafenib and dabrafenib, MEK inhibitor, 
trametinib, and dabrafenib-trametinib combination has tremendously changed the 
treatment options for advanced melanoma. However, the remarkable initial 
efficacy of these drugs is eventually followed by relapse owing to the 
development of resistance to therapy (Nazarian et al., 2010a; Nazarian et al., 
2010b; Gowrishankar et al., 2012).  A combination of agents co-targeting multiple 
signaling pathways is the approach of choice for delaying/overcoming acquired 
resistance. It has been previously suggested that targeting MEK, which is 
downstream of BRAF in the MAPK signaling pathway or PI3K is a valid 
therapeutic approach to overcome resistance to chronic BRAF inhibition 
(Villanueva et al., 2010). In this context, the combination of dabrafenib and 
trametinib proves to be a step in the right direction. However, concomitant MEK 
mutations observed with the dabrafenib plus trametinib combination suggests 
that melanomas are capable of switching to alternate signaling pathways. 
Chronic BRAF inhibition has been known to enhance PI3K/AKT activity via IGF-
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1R signaling (Villanueva et al., 2010). GSK2126458 in combination has shown to 
overcome acquired resistance to dabrafenib in vitro (Greger et al., 2012). The 
efficacy of a combination of agents in treating melanoma brain metastases will 
require that all agents in the combination be delivered to all metastatic sites, 
especially those that reside behind an intact BBB. These metastatic cells that are 
behind an intact BBB are protected by functional efflux transporters which 
exclude several anti-cancer drugs. We have previously shown that vemurafenib, 
dabrafenib, and trametinib are significantly limited in brain distribution due to their 
interaction with P-gp and BCRP (Mittapalli et al., 2012; Mittapalli et al., 2013; 
Vaidhyanathan et al., 2014) .  We have also shown that the brain distribution of 
the dabrafenib-trametinib combination is significantly higher in the Mdr1a/b-/-Bcrp-
/- mice as compared to wild-type, suggesting that this combination suffers from 
limited brain distribution due to active efflux at the BBB (Vaidhyanathan et al., 
2014) .  
In the current study, using in vitro and in vivo models, we demonstrate that 
GSK2126458 is a substrate for BCRP and P-gp in vitro and in vivo.  Also, we 
demonstrate that the combination of GSK2126458 with dabrafenib and trametinib 
suffers from active efflux at the BBB. This is the first report investigating the 
interaction of GSK2126458 with P-gp and BCRP.  
The experiments performed in vitro in MDCKII cells that overexpress either 
murine Bcrp or human MDR1 confirm that GSK2126458 is a substrate for both 
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Bcrp and P-gp (Fig. 2). We observed a significantly lower accumulation of 
GK2126458 in P-gp- and Bcrp transfected cells as compared to wild-type (Fig. 
2). In the presence of specific inhibitors of P-gp and Bcrp (LY335979 and Ko-
143, respectively), this difference in intracellular accumulation was significantly 
decreased (Fig. 2).   
In P-gp transfected cells, using a prototypical probe substrate, vinblastine for P-
gp, we observed a significant increase in intracellular accumulation with 
increasing concentrations of GSK2126458 starting at 10 µM (Fig. 3B). In Bcrp 
transfected cells, we observed a significant increase in probe substrate prazosin 
starting at 25 µM (Fig. 3A). At 10 µM and 25 µM, GSK2126458 inhibits the active 
efflux of vinblastine by P-gp and prazosin by BCRP. It is likely that such high 
concentrations of GSK2126458 may not be pharmacologically relevant. These 
data suggest the possibility of GSK2126458 sharing similar binding sites as 
vinblastine and prazosin on P-gp and BCRP, respectively. All these in vitro 
results put together, conclusively show that GSK2126458 is a substrate for P-gp 
and Bcrp. These in vitro findings translate in vivo with changes in brain 
distribution in the triple knockout mice as compared to wild-type.  
Based on our findings from in vitro studies, we went on to investigate the role of 
P-gp and BCRP in the brain distribution of GSK2126458. After an oral dose of 
GSK2126458, we observed that the brain concentrations were ~three-twenty-fold 
higher in Mdr1a/b-/-Bcrp-/- mice as compared to wild-type (Fig. 4.). The plasma 
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concentrations were not significantly different between wild-type and Mdr1a/b-/-
Bcrp-/-.  
At steady-state, the brain concentrations in wild-type, Mdr1a/b-/-, and Bcrp-/- were 
significantly lower than in Mdr1a/b-/-Bcrp-/-. The steady-state B/P ratio increased 
from approximately 0.07 in the wild-types to 0.47 in the triple knockout mice (Fig. 
5.). This ~ seven-fold increase in the targeted brain distribution of GSK2126458 
further confirms the impact of P-gp and BCRP on the CNS penetration of 
GSK2126458. Importantly, we did not observe a significant change in the brain 
distribution of GSK2126458 in the Mdr1a/b-/-, or Bcrp-/- mice as compared to wild-
type. This suggests the cooperative role of these two transporters in excluding 
GSK2126458 from the CNS. Such compensation is well understood, whereby, in 
the absence of one transporter (single knockout); another transporter can limit 
substrate brain distribution, while in triple knockouts, there can potentially be a 
disproportionate enhancement in brain distribution of dual substrates (Kodaira et 
al., 2010).  
When simultaneously infused with dabrafenib and trametinib, we observed a 
significantly higher B/P ratio for all three drugs in the Mdr1a/b-/-Bcrp-/- as 
compared to wild-type (Fig. 6.). Also, the brain distribution of dabrafenib and 
trametinib were significantly higher in the Mdr1a/b-/- mice. In the case of 
trametinib, we had previously observed that its brain distribution was limited 
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primarily by P-gp (Vaidhyanathan et al., 2014). These data confirm that the brain 
distribution of all three drugs in combination is limited by active efflux.  
Given the poor brain distribution of GSK2126458 and its potential use in 
combination therapy for the treatment of melanoma brain metastases, we 
investigated the influence of elacridar on its brain distribution. Pretreatment with 
elacridar in a microemulsion formulation led to a remarkable six-fold increase in 
the brain-to-plasma ratio of GSK2126458 in the elacridar pretreatment group as 
compared to vehicle treated mice (Fig. 7.). The result from this study suggests 
that the inhibition of P-gp and BCRP with elacridar could be a potential strategy 
for improving the brain distribution of GSK2126458. This finding is of clinical 
relevance and the enhancement in brain distribution is a likely strategy for 
enhancing the efficacy of combination therapies that suffer from active efflux. 
With the duration of response of BRAF inhibitors being limited by the 
development of acquired resistance, delaying resistance for ensuring durable 
response requires the development of rational combinations. An understanding 
of the mechanisms of resistance led provided the rationale for combining 
GSK2126458 with either dabrafenib or trametinib (Greger et al., 2012). However, 
for success in the treatment of brain metastases, all agents in the combination 
have to be delivered across the BBB. From our experiments, we observe that all 
three drugs in the combination are restricted by active efflux at the BBB.  
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The addition of agents to combinations for success in treating brain metastases 
has to take into account the potential for active efflux at the BBB. If all drugs in 
the combination do not reach the brain, there is an increased potential for 
resistance, possibly making the brain a sanctuary site for further metastases. It is 
imperative that in addition to the understanding of resistance mechanisms, the 
potential for active efflux be considered prior to the further development of 
combination therapies. Our findings are clinically relevant for the choice of 
rational combinations to ensure effective treatment of melanoma brain 
metastases.  
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Figure 5.1: Chemical structure of GSK2126458 
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Figure 5.2: In vitro cellular accumulation of GSK2126458 
 
(A) The accumulation of prazosin (prototypical Bcrp probe substrate; positive 
control) and GSK2126458 in MDCKII-wild-type and Bcrp1-transfected cells with 
and without specific Bcrp inhibitor Ko-143 (0.2 µM). The accumulation of 
GSK2126458 and vinblastine (probe substrate for P-gp) in MDR1 cells with and 
without specific P-gp inhibitor LY335979 (1 µM) is shown in (B). Data represent 
the mean ± SD.; n=3-6 for all data points. ***p < 0.0001, and **p < 0.05 
compared with respective wild-type controls. 
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Figure 5.3: Competition assays using prototypical probe substrate 
molecules 
 Intracellular accumulation of [3H]-prazosin (Bcrp probe substrate) (A) and [3H]-
vinblastine (B) in MDR1 transfected cells with increasing concentrations of 
GSK2126458 from 0.1 µM to 50 µM. Ko143: Bcrp inhibitor; LY335979: P-gp 
inhibitor. Data represent the mean ± SD.; n=3 for all data points. ***p  <0.0001 
compared to respective untreated transfected cells.
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Figure 5.4: Brain distribution of GSK2126458 in FVB wild-type, and Mdr1a/b-/-Bcrp1-/- mice. 
 
Plasma (A), brain (B), and brain-to-plasma concentration ratios (C) of GSK2126458 in wild- type, and Mdr1a/b-/-
Bcrp1-/- mice after an oral dose of 10 mg/kg.  
Plasma and brain concentrations of GSK2126458 at 0.5,1,2, 4, 6, and 8 hours post dose were determined using 
LC-MS/MS. Data represent mean ± SD, n = 3-4. **p<0.05, ***p≤0.0001 compared to wild-type. 
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Figure 5.5: Steady State distribution of GSK2126458 at 2 µg/hr for 48hr. 
 
Steady state brain-to-plasma ratio of GSK2126458 in wild-type, Bcrp1-/- , 
Mdr1a/b-/- , and Mdr1a/b-/-Bcrp1-/- mice. GSK2126458 was delivered at a constant 
infusion rate of 2 µg/hr for 48 hrs using Alzet osmotic pumps. Data represent 
mean ± SD, n = 3-5. **p < 0.05, ***p < 0.001 compared to wild-type. 
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Figure 5.6: Steady State distribution of GSK2126458, dabrafenib and 
trametinib after simultaneous infusion for 48 hours. 
  
Steady state brain-to-plasma ratios of GSK2126458, dabrafenib and trametinib in 
wild-type, Bcrp1-/- , Mdr1a/b-/- , and Mdr1a/b-/-Bcrp1-/- mice. GSK2126458, 
dabrafenib and trametinib were simultaneously delivered at a constant rate of 1 
µg/hr, 2.5 µg/hr and 0.5 µg/hr respectively for 48 hrs using Alzet osmotic pumps.  
Data represent mean ± SD, n = 3-4. ***p< 0.05 compared to corresponding B/P 
ratio in wild-type. 
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Figure 5.7: Influence of elacridar in a microemulsion formulation on the 
brain distribution of GSK2126458. 
 
Brain-to-plasma ratio of GSK212658 1 hr post dose after pretreatment with 
vehicle or elacridar microemulsion (administered 10 mg/kg i.p, 1 hour before oral 
administration of GSK2126458) in wild-type. Data represent mean ± SD, n = 3-4. 
*** p = 0.0045 compared to corresponding B/P ratio in vehicle treated wild-type 
mice.  
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CHAPTER 6: IMPROVED BIOAVAILABILITY OF ZELBORAF IN A 
STABLE AMORPHOUS SOLID DISPERSION LEADS TO 
IMPROVED ANTI-TUMOR RESPONSE IN A NOVEL MELANOMA 
MOUSE MODEL 
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The present work indicates the importance of using the most relevant pharmacy-
grade formulation of drugs to conduct pre-clinical studies in order to make 
pertinent conclusions and recommendations for further pre-clinical or clinical 
investigations. A large proportion of drugs are orally administered and methods 
to improve oral absorption are critical to the clinical use of low solubility drugs 
(BCS class II and IV). Vemurafenib (BCS class IV) is a potent FDA-approved 
BRAF inhibitor that is clinically used to treat metastatic melanoma. During its 
development, crystalline vemurafenib was reformulated into an amorphous-solid 
dispersion, termed as “microprecipitated bulk powder (MBP)” before being 
approved as pharmacy-grade vemurafenib (Zelboraf). From our oral 
pharmacokinetic studies in mice, we observe that Zelboraf has a ~ 2.5 fold 
higher oral bioavailability as compared to crystalline vemurafenib (non-pharmacy 
grade). Also, upon oral administration of Zelborafand non-pharmacy grade 
vemurafenib at the same dose, we observed that there was a significantly better 
anti-tumor response in a flank tumor melanoma model. We also go on to 
describe the mechanism by which the improved solubility of Zelboraf in 
comparison to non-pharmacy grade vemurafenib leads to a significant 
improvement in plasma exposure and bioavailability. 
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6. 1 Introduction   
Vemurafenib is a BCS class IV (low solubility, low permeability) drug that was 
reformulated into a amorphous solid dispersion stabilized with a polymer by a 
solvent-controlled coprecipitation method in order to increase its solubility and 
oral bioavailability before its FDA approval (Zelboraf)(Shah et al., 2013).  
Zelboraf was shown to provide a significantly higher rate and extent of 
dissolution than crystalline vemurafenib (Shah et al., 2013). Improving solubility 
through formulation approaches such as preparing stabilized solid dispersions in 
polymeric systems have been explored as an option for the improvement of 
solubility of poorly soluble drugs (Leuner and Dressman, 2000). This method 
exploits the stabilization of a high energy state (amorphous) of the poorly soluble 
drug in order to translate the solubility advantage into enhanced absorption and 
improved bioavailability (Brouwers et al., 2009).  
In the case of vemurafenib, the amorphous solid dispersion was prepared using 
a solvent controlled coprecipitation method using hypromellose acetate succinate 
(HPMCAS) as the stabilizing enteric polymer (Shah et al., 2013). The formulation 
of Zelboraf into a MPB led to achieving efficacious systemic concentrations, 
which was extremely critical to the clinical success of this drug product. The 
saturation solubility of the drug formulation also affects the rate of dissolution 
(Noyes, 1897). Amorphous solids have a higher solubility than crystalline solids, 
  
 181
which has led to an increased focus on the development of amorphous 
formulations, especially for BCS class II and IV drugs. In the case of 
vemurafenib, the apparent solubility of the MBP was ~ 30 fold higher than its 
crystalline counterparts, and this supersaturation was maintained for a sustained 
period of 4 hours (Shah et al., 2013). 
Vemurafenib specifically inhibits the mutant form of the BRAF (v-raf murine 
sarcoma viral oncogene homolog B) protein that is found to be mutated in a 
majority of melanoma patients (Davies et al., 2002). BRAF V600 mutations were 
found to be responsible for the constitutive activation of the MAP kinase signaling 
pathway leading to uncontrolled cell proliferation and tumor growth. Vemurafenib, 
approved in August 2011 for the treatment of metastatic melanoma was a 
remarkable progress in melanoma therapy. Vemurafenib received FDA-approval 
after showing a substantial improvement in progression-free survival and overall-
survival in comparison to dacarbazine in phase 3 clinical trials (Chapman et al., 
2011).   
Currently, there is a paucity of clinically relevant melanoma mouse models that 
can be used to understand the progression of the disease and improve treatment 
options. For our studies, we use a novel patient derived xenograft model, where 
patient tumor tissue is directly implanted into nude mice, followed by serial 
passage and expansion. This method is known to preserve the genetic and 
phenotypic characteristics of the primary patient tumor (Renfrow and Lesser, 
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2013). In this current study, patient derived M12 BRAF V600E mutant melanoma 
cells are implanted subcutaneously to represent a flank tumor. 
The purpose of this study was to compare the pharmacokinetics and 
pharmacodynamics (efficacy) of pharmacy-grade Zelboraf against a non-
pharmacy grade vemurafenib in order to understand and delineate the impact of 
formulation differences on the design and meaningful interpretation of pre-clinical 
studies. Information from this work will provide a strong basis for making the right 
choice of formulation to conduct studies in pre-clinical models. 
6. 2 Materials and Methods 
6. 2. 1 Chemicals 
Zelboraf  was purchased from the pharmacy. Non-pharmacy grade vemurafenib 
was purchased from LC laboratories (Woburn, MA). All other chemicals used 
were of high-performance liquid chromatography or reagent grade. 
6. 2. 2 Animals 
Pharmacokinetic studies were performed in Friend leukemia virus strain B (FVB) 
wild-type mice. Efficacy studies were performed in nude mice implanted with M12 
BRAF V600E flank tumors. All animals were 8-12 weeks old at the time of 
starting the experiment. Animals were maintained in a 12-hour light/dark cycle 
with unlimited access to food and water. All studies were carried out in 
accordance with the National Institutes of Health’s Guide for the Care and Use of 
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Laboratory Animals (Institute of Laboratory Animal Resources, 1996) and 
approved by the Institutional Animal Care and Use Committee (IACUC) of the 
University of Minnesota. 
 
6. 2. 3 Pharmacokinetic Studies 
The oral dosing vehicle for non-pharmacy grade vemurafenib was 1% methocel, 
5% DMSO and 1% methocel for Zelboraf . All dosing suspensions were 
prepared on the day of the experiment. Zelboraf  oral dosing suspension was 
prepared by gently triturating the Zelboraf  tablet in a mortar-pestle and 
suspending the powder in 1% methocel. FVBn wild-type mice received 75 mg/kg 
single oral dose of vemurafenib or Zelboraf and blood samples were collected 
after 1, 2, 4,8,12, 16 and 24 hours post-oral dose. At the end of the desired time 
point, the animals were euthanized using a CO2 chamber. Blood was collected 
via cardiac puncture in heparinized tubes. Plasma was separated by centrifuging 
whole blood at 3500 rpm for 10 minutes at 4 degree C.  Vemurafenib plasma 
concentrations were measured using a specific liquid-chromatography- tandem 
mass spectrometry (LC-MS/MS) method that has been described in detail in our 
previously published work (Mittapalli et al., 2012). 
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6. 2. 4 Efficacy studies in a flank melanoma tumor model 
M12 cells were obtained from the tumor tissue of a patient diagnosed with 
melanoma carrying the BRAF V600E mutation. Nude mice were implanted with 
M12 flank tumors (100,000 cells injected subcutaneously). Once tumors reached 
a size of 250-300 mm3, they received vehicle or 75 mg/kg b.i.d of non-pharmacy 
vemurafenib or Zelboraf until tumors reach a size of 2000 mm3 or mice became 
moribund. During the course of the study, the size of the flank tumor was 
measured using calipers.  
 
6. 2. 5 Modeling the case of solubility limited absorption and bioavailability  
STELLA 9.0.1 was used to develop a model that describes the impact of 
improving the solubility of a drug on oral bioavailability. We describe a 2-
compartment model with a drug administered orally with first-order absorption 
from the gut-compartment and first-order elimination from the central 
compartment (Fig. 6.3). The rate of absorption is directly proportional to the 
concentration gradient, which in turn increases with an increase in the solubility 
of the drug or upon achieving its saturation solubility in the gut compartment. A 
case that involves affecting the concentration achieved in the gut due to 
formulation differences is simulated and the corresponding changes in plasma 
pharmacokinetics are observed. The model assumes that the rate of dissolution 
is a function of the concentration gradient. All rate constants, initial amount in the 
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gut, and maximum achievable concentration or saturation concentration 
achievable (Csat) have been arbitrarily assumed in this model. The equations 
describing the model are listed in Table 6.2.  
6. 2. 6 The Noyes-Whitney model and the relationship between saturation 
solubility and dissolution kinetics:  
The Noyes-Whitney model relates surface area, and degree of unsaturation of 
the solution to the dissolution rate of a drug. For the purpose of this study, we 
assume that the solubility enhancement of the amorphous formulation far 
exceeds any differences in surface characteristics of individual nuclei between 
the amorphous and crystalline formulations. So, the rate of dissolution of the drug 
molecule can be written as  
 
(1) 
 
where a dissolution rate is constant,  is the saturation solubility of the 
drug formulation, and Csolution  is the instantaneous concentration of the drug in 
the gut compartment. Therefore, increasing  increases the dissolution rate of 
the drug. 
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6. 3 Results and Discussion 
6. 3. 1 Improved bioavailability of Zelboraf in comparison to non-pharmacy 
grade vemurafenib 
Zelboraf and non-pharmacy grade vemurafenib were given orally to wild-type 
FVB mice as a suspension. We observed that the plasma concentrations were 
higher in mice dosed with Zelboraf as compared to non-pharmacy grade 
vemurafenib at all measured time points (Fig. 6.1.), possibly an effect of the 
sustained supersaturation observed for the Zelboraf® formulation. 
 
The area under the curve (AUC) in the Zelboraf treated mice was ~2.5 fold 
higher in the Zelboraf treated mice as compared to non-pharmacy grade 
vemurafenib (Table 1). The oral bioavailability of Zelboraf  was ~ 100% as 
compared to 48% for non-pharmacy grade vemurafenib (Table 1). These data 
confirm that the suspension prepared from pharmacy-grade Zelboraf  has 
improved oral bioavailability as compared to its crystalline non-pharmacy grade 
vemurafenib.  
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6. 3. 2 Improved anti-tumor response of Zelboraf  in the M12 melanoma 
model  
In an efficacy study in M12 flank tumor bearing nude mice that were dosed 75 
mg/kg b.i.d Zelboraf , non-pharmacy grade vemurafenib or vehicle control, we 
observed that the anti-tumor response measured by tumor volume was 
significantly better in the Zelboraf  treated group as compared to non-pharmacy 
grade vemurafenib or vehicle control (Fig. 6.2). Interestingly, we observed that 
the tumor volumes in the non-pharmacy vemurafenib treated group were similar 
to the vehicle treated group. This study confirms that the efficacy of vemurafenib 
is dependent on the formulation and the lower exposure of vemurafenib from the 
non-pharmacy grade formulation did not lead to a significant response, while the 
improved bioavailability from the Zelboraf  MBP led to correspondingly higher 
vemurafenib exposure which translated into significantly higher reduction in flank 
tumor volume.  
6. 3. 3 Modeling the case of solubility limited absorption and bioavailability  
In our model, the dissolution rate is proportional to the concentration gradient or 
the difference between Csat and Csolution in the gut (Fig. 6.3). So, an increase in 
the saturation solubility leads to an increase in the rate of dissolution. This leads 
to improved exposure and bioavailability of vemurafenib in the MBP (Zelboraf). 
On changing the drug from its highly insoluble crystalline form to a stabilized 
amorphous solid dispersion, a significant increase in the maximum achievable 
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concentration in the gut is observed.  This increase in gut concentration leads to 
a higher rate of dissolution followed by a higher rate of absorption and improved 
exposure. We observe that with an increase in Csat, a higher concentration is 
achieved in the gut, which correspondingly leads to an increase in plasma 
concentrations (Fig. 6.4).   
6. 4 Summary and Conclusions 
Our pharmacokinetic studies in mice confirm that the suspension prepared from 
Zelboraf (MBP) has a higher overall exposure and oral bioavailability as 
compared to non-pharmacy grade vemurafenib. The MBP provided a ~ 2.5 fold 
increase in overall plasma exposure as compared to non-pharmacy grade 
vemurafenib. From the efficacy studies in the M12 flank melanoma model, we 
observe that the reduction in tumor volume (efficacy of vemurafenib) is 
significantly higher when mice receive Zelboraf as compared to non-pharmacy 
grade vemurafenib or placebo. These data could indicate that the concentrations 
achieved from the non-pharmacy grade vemurafenib in the flank tumor are 
insufficient to block BRAF signaling as compared to Zelboraf. This is most likely 
a direct effect of the improved pharmacokinetics of Zelboraf  as compared to the 
non-pharmacy grade vemurafenib. 
From the model describing solubility limited oral bioavailability, we observe that 
increasing the saturation solubility leads to a greater concentration gradient and 
improved plasma exposure. Taken together, we conclude that the sustained 
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increase in solubility of the MBP leads to improved bioavailability and this has to 
be taken into account in planning studies in pre-clinical models. The choice of 
formulation has a direct impact on the observed pharmacokinetics and 
pharmacodynamics and an incorrect choice of formulation could lead to 
potentially inaccurate conclusions regarding the activity of the drug.  
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Figures 
Figure 6.1: Plasma concentrations of vemurafenib in FVB wild-type at 1, 
2,4,8,12,16 and 24 hours after an oral dose of 75 mg/kg Zelboraf (red) or 
non-pharmacy grade vemurafenib (black). Data represent mean ± SD., n = 
3-4. 
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Figure 6.2: Comparison of efficacy of Zelboraf , non-pharmacy grade 
vemurafenib, and placebo (vehicle control). 
 
Nude mice bearing flank melanoma tumors (M12) were treated with 75 mg/kg 
p.o. b.i.d of Zelboraf , non-pharmacy grade vemurafenib or placebo until 
placebo treated tumors reached 2000 mm3 (n=10 per group). At day 72, drug 
  
 192
treatments were stopped, when the placebo treated group reached a tumor size 
of 1500 mm3. 
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Figure 6.3: Model describing a case of solubility limited oral absorption. 
 
Model assumes that the rate of dissolution is proportional to the concentration 
gradient, first order absorption and first order elimination. The equations 
describing this model are listed in Table 6.2. 
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Figure 6.4: Increase in saturation solubility (similar to the increase between 
Zelboraf  and non-pharmacy grade vemurafenib) leads to an increase in 
exposure.  
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This is seen by the increase in area under the curve, and is also confirmed by the 
higher concentration of drug in solution (Csolution) in the gut on increasing the 
saturation solubility of the drug. 
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Table 6.1: Area under the curve (AUC) and bioavailability of Zelboraf and 
non-pharmacy grade vemurafenib. Vemurafenib i.v. AUC is from our 
previously published work (Mittapalli et al., 2012). 
 
Non-pharmacy grade vemurafenib 
    hr*µg/mL F (%) 
Dpo=75mpk 
Mean 
AUC p.o. 393.03 
47.24 
Div = 2.5 mpk 
  
Mean 
AUC i.v. 1663 
AUC iv (min*µg/mL)   
AUC iv( hr.µg/mL)   27.73 
Zelboraf 
    hr*µg/mL F (%) 
Dpo=75mpk 
Mean 
AUC p.o. 1003.89 
120.67 
      
Div = 2.5 mpk 
Mean 
AUC i.v. 1663 
AUC iv (min*µg/mL)   
AUC iv( hr.µg/mL)   27.73 
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Table 6.2: Equations describing the model shown in Fig. 6.3.  
Drug(t) = Drug(t - dt) + (- Rate_of_diss - rate_unabs) * dt 
INIT Drug = 1.5 
 
OUTFLOWS: 
Rate_of_diss = CLdis*CDiff 
rate_unabs = Drug*kexit_unabsorbed 
Plasma(t) = Plasma(t - dt) + (Rate_of_abs - Rate_of_elim) * 
dt 
INIT Plasma = 0 
 
INFLOWS: 
Rate_of_abs = Csolution*PS 
OUTFLOWS: 
Rate_of_elim = Plasma*Kel 
Solution(t) = Solution(t - dt) + (Rate_of_diss - 
Rate_of_abs) * dt 
INIT Solution = 0 
 
INFLOWS: 
  
 198
Rate_of_diss = CLdis*CDiff 
OUTFLOWS: 
Rate_of_abs = Csolution*PS 
CDiff = Csat-Csolution 
CLdis = 10 
Cpl = Plasma/Vpl 
Csat = 0.25 
Csolution = Solution/Vgut 
Kel = 0.1 
kexit_unabsorbed = 0.5 
PS = 0.2 
Vgut = 3 
Vpl = 0.2 
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CHAPTER 7: RECAPITULATION 
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Melanoma is a highly aggressive skin cancer with a great propensity for brain 
metastasis. Currently, brain metastases from melanoma are untreatable and 
lethal in most patients with advanced disease. The presence of brain metastases 
in a large proportion of patients at autopsy confirms an unmet medical need. 
Patients with multiple brain metastases and extensive peripheral disease can 
have a particularly poor survival; which can be as short as 1-2 months.  
Recently, there has been significant advancement in the treatment of peripheral 
melanoma. With the discovery and better understanding of hallmark molecular 
events and oncogenic mutations that cause disease progression, there has been 
a steady increase in the development of molecularly targeted drugs for the 
treatment of melanoma. In particular, in melanoma, oncogenic driver mutations in 
BRAF have been known to play an important role in the disease. Vemurafenib 
and dabrafenib are two BRAF inhibitors that were FDA approved after they 
showed significant improvement in survival in melanoma patients as compared to 
conventional therapies. However, the improvement in patient outcomes with 
BRAF inhibition is short-lived as patients tend to develop resistance to BRAF 
inhibition. Addition of a MEK inhibitor, trametinib to BRAF inhibition with 
dabrafenib was also approved as a single agent and in combination for clinical 
use due to the significant improvement in patient outcomes.  Unfortunately, 
patients on this combination have also shown to develop resistance eventually 
and relapse with aggressive disease.  The emergence of resistance to MAPK 
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pathway inhibition is a significant problem and needs to be addressed 
immediately. 
A combination of BRAF and MEK inhibitors with PI3K/mTOR inhibition is known 
to overcome acquired resistance in vitro. GSK2126458 is a potent ATP 
competitive inhibitor of PI3K/mTOR which is a promising candidate for 
combination therapy.  
The efficacy of these molecularly targeted agents and combinations is the 
sufficient delivery of all agents in the combination across the BBB, also to target 
sites in the brain that are residing behind an intact BBB, that are almost always  
undetectable. The BBB is composed of a monolayer of endothelial cells that are 
connected by tight junction proteins and expressing several efflux transporters. 
Of particular interest are two important efflux transporter proteins  P-glycoprotein 
(P-gp) and breast cancer resistance protein (Bcrp) that have been previously 
known to play an important role in excluding several anti-cancer drugs from the 
brain; limiting the efficacy of chemotherapeutics. The central goal of this 
dissertation was to understand the influence of active efflux on the brain 
distribution of these molecularly targeted agents.  
The influence of active efflux on the first approved BRAF inhibitor, vemurafenib, 
was thoroughly studied in the first project using elegant in vitro studies in MDCK 
II cells and in vivo pharmacokinetic studies in wild-type, P-gp knockout, Bcrp 
knockout and triple knockout mice (Chapter 2). From our in vitro studies, we were 
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able to conclude that vemurafenib was a substrate for both P-gp and Bcrp. Also, 
from our pharmacokinetic studies in mice, we observed that the brain distribution 
of vemurafenib was severely restricted at the BBB by a cooperative role of both 
P-gp and Bcrp. At steady-state, the brain-to-plasma ratio increased ~ 80 fold; 
from 0.01 in the wild-type mice to 1 in the triple knock-out mice (lacking both P-
gp and Bcrp).However, the brain distribution of vemurafenib was restricted in the 
single knockouts; confirming the cooperation of the two transporters. 
In continuation of our research plan, we then examined the influence of P-gp and 
Bcrp on the brain distribution of a second FDA-approved, highly promising BRAF 
inhibitor, dabrafenib   (Chapter 3). From our studies, we were able to conclude 
that dabrafenib was also restricted in brain distribution by P-gp and Bcrp. The Kp 
(AUCbrain/ AUCplasma) of dabrafenib was ~ 18 fold higher in the triple knockouts 
(0.42) as compared to wild-type mice (0.023). We also observed that dabrafenib 
had a higher brain penetration as compared to vemurafenib, suggesting that 
dabrafenib may be a better choice for the treatment of melanoma brain 
metastases.  
Despite the initial success with vemurafenib and dabrafenib in treating peripheral 
disease, most patients with metastatic melanoma relapse within one year due to 
the emergence of resistance to BRAF inhibition. The development of resistance 
to MAPK signaling blockage by BRAF inhibition is a serious problem that has to 
be factored in while designing combination therapies. The improved duration of 
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response from the combination of BRAF and MEK (downstream of BRAF in the 
MAPK signaling pathway) inhibition (dabrafenib and trametinib) provides new 
hope for delaying resistance and improving response.  However, the success of 
combination therapies in treating brain metastases depends on all agents being 
effectively delivered t0 all metastatic sites, including micrometastases that reside 
behind an intact blood  brain barrier. In the light of this problem, we then 
examined the influence of active efflux of MEK inhibitor, trametinib which was 
approved for use as a single agent and in combination with dabrafenib for the 
treatment of metastatic melanoma (Chapter 4). In the case of trametinib, we 
observed that P-gp played a greater role than Bcrp in restricting its brain 
distribution in the mouse, while we observed that trametinib was a substrate for 
both P-gp and Bcrp in vitro. The Kp ratio of trametinib in the wild-type and Bcrp 
knockout mice were 0.148 and 0.136, respectively while they were 0.733 and 
0.675 in the P-gp knockout and triple knockout mice. Upon simultaneously 
infusing dabrafenib and trametinib, we observed that both drugs were restricted 
in brain distribution in wild-type mice with a significantly higher brain penetration 
in triple knockouts.   
Simultaneous inhibition of multiple signaling pathways is a possible approach for 
delaying/overcoming acquired resistance. Simultaneously targeting the MAPK 
and PI3K signaling pathway is a valid therapeutic approach to overcome 
resistance to chronic MAPK inhibition (BRAF alone, MEK alone or BRAF + MEK 
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inhibition). In the final chapter (chapter 5), we studied the influence of active 
efflux on the brain distribution of PI3K/mTOR inhibitor GSK2126458. Using in 
vitro studies in MDCK II cells, we observed that GSK212658 is a substrate for 
both P-gp and Bcrp. From pharmacokinetic studies in mice, we observed that 
GSK2126458 has a severely limited brain distribution in wild-type mice as 
compared to triple-knockouts. The steady-state B/P ratio increases ~ 7 fold from 
0.07 in the wild-type mice to 0.47 in triple knockout mice. Also, we did not 
observe a significant change in the brain distribution in the P-gp knockout and 
Bcrp knockout mice as compared to wild-type. The aggregate of these studies 
confirm the cooperative role of P-gp and Bcrp in restricting the brain distribution 
of GSK2126458. If all drugs in a combination do not reach the brain, there is an 
increased potential for resistance, making the brain a sanctuary site for further 
metastases. 
In chapter 6, we investigate the influence of the pharmacy-grade formulation of 
vemurafenib (Zelboraf) on the oral bioavailability of vemurafenib in comparison 
to its non-pharmacy grade counterpart. We observe that the conversion of 
crystalline drug into an amorphous solid-dispersion leads to a significant increase 
in bioavailability and efficacy in a melanoma mouse model. The findings of this 
chapter are critical to the appropriate selection of drug formulations at any stage 
of pre-clinical or clinical investigation.   
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Future work on this project will require the study of several different combinations 
of molecularly targeted agents in a relevant mouse model of melanoma brain 
metastasis. This will enable a better rational choice of combinations in treating 
melanoma brain metastases and potentially lead to durable treatment outcomes 
and lead to substantial delay in resistance. 
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